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1Marginal organ donors can be arbitrarily defined as patients of advanced age and/or those 
donors who have above-average concomitant morbidity such as impaired renal function, 
cardiovascular disease, hypertension, or diabetes mellitus. In addition, organs recovered after 
cardiocirculatory death are also usually considered marginal donor grafts.1 Kidneys derived 
from marginal donors may have an impaired posttransplant organ function, with an elevated 
risk of developing delayed graft function. Also, the risk of primary non-function will be 
increased. Although many marginal organs will eventually show acceptable function, long-
term graft survival can be sub-standard as well.2-4 In the early days of deceased donor kidney 
transplantation (1960s through 1980s), donor selection was such that only high-quality 
organs were considered for transplantation. Not only were waiting lists significantly shorter 
due to fewer medical indications for a renal transplant, but also were the typical donors young 
men in their early twenties who had suffered serious cerebral injury after a traffic accident. 
As a result of increased traffic safety, this category of ICU patients has become relatively 
rare in the last few decades.5,6 Aditionally, the practise of early neurosurgical decrompressive 
craniectomy after traumatic cerebral injury has recently become more common, which is 
likely to result in a lower number of ICU patients who will eventually meet legal criteria for 
brain stem death.7 Lengthening waiting lists in combination with a quickly decreasing pool 
of “optimal” deceased donors after brain death have urged the transplantation community 
to accept more kidneys which only a couple of decades ago would not have been considered 
suitable grafts, such as renal transplants from expanded criteria donors and donors after 
cardiac death. The various types of organ donors are briefly described in the section below.
Living donors were the first patients from whom kidneys were successfully transplanted, 
starting with the famous Boston twins in the 1950s.8 A kidney donated by an identical twin 
will not require any immunosuppressive therapy in the recipient sibling, and as a result such 
rare cases in which only one half of a pair of indentical twins developed end-stage renal failure 
comprised the first serious and often successful attempts at renal transplantation in humans. 
In the decades that followed, methods were developed to partially suppress the immune 
response, first by means of total body irradiation, and later by increasingly refined and specific 
pharmacological agents. This has made tissue-type incompatible kidney allotransplantation 
possible from living-related and living-unrelated donors.9 Also, the advent of adequate 
immunosuppression quickly paved the way for transplantation of kidneys recovered from 
deceased donors, which can be categorized as follows:
Donors after brain death, also known as heart beating donors, are those ICU patients who 
have sustained irreversible cerebral injury and meet the legal criteria for brain stem death, which 
were first described by the Harvard ad hoc committee on brain stem death in 1968 in Boston, 
MA, USA.10 Brain death can be the end result of either traumatic injury, or a cerebrovascular 
event that led to cerebral ischemia and/or compression due to bleeding. Organs recovered 
from donors after brain death are perfused with the donor’s own oxygenated circulation until 
the moment of aortic clamping in the operating room and systemic cold perfusion with one 
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of several cold preservation solutions. Although the pro-inflammatory and pro-coagulatory 
state of brain death itself has a well-documented detrimental influence on donor grafts,11 
organs that are recovered from donors after brain death sustain only minimal amounts of 
warm ischemic injury. Donors after brain death can be further sub-divided into standard 
criteria donors and expanded criteria donors. The latter category is usually defined as donor 
age ≥60, or donor age between 50 and 60, with at least two of the following additional donor 
characteristics: (1) history of hypertension, (2) cerebrovascular cause of death, (3) pre-retrieval 
serum creatinine >132 μmol/l.12 In the original publication by Metzger et al, who developed 
this definition, the authors do not mention whether their definition also applies to donors 
after cardiac death. In subsequent publications by the same and other groups, no uniform 
choice is made as to whether all donors in the latter category are to be considered expanded 
criteria donors, or only those that meet the definition should be included. Alternatively, many 
groups implicitly assume that expanded criteria donors can only be donors after brain death.
Donors after cardiac death, also called donors after cardiocirculatory death or non-heart 
beating donors, are a heterogenous group of deceased donors who have one characteristic 
in common: Organs are recovered after cessation of spontaneous circulation due to cardiac 
death. Therefore, death is declared on classic cardiocirculatory instead of neurologic criteria 
and, as a result, most donors after cardiac death were either not legally brain dead, or their 
neurologic status was unknown at the moment of cardiac death. Donors after cardiac death 
can be further sub-divided into four categories, which were defined at the first meeting on 
non-heart beating donation in 1995 in Maastricht, The Netherlands.13 Chapter 2 discusses 
those four different types and their individual characteristics in detail.
This thesis comprises clinical and pre-clinical studies that aim to quantify the impact 
that donor characteristics have on posttransplant outcome, and to investigate the effect 
of interventions before or during organ preservation which might better conserve organ 
quality prior to transplantation. In addition, two studies aim to predict aspects of transplant 
outcome by measuring biomarkers in donor plasma and in machine preservation solution, or 
by assessing machine perfusion characteristics. Although the findings of these studies may 
pertain to all types of donor kidneys, they are particularly applicable to renal grafts recovered 
from marginal donors. As outcome of such transplants is often sub-standard, any additional 
information on organ quality, as well as measures that will better preserve graft function are 
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ABSTRACT
With increasing numbers of patients on the waiting list for organ transplantation, many centers 
are revisiting donation after cardiac death (DCD) as a tool to enlarge the deceased donor pool. 
Early scepticism has changed to careful enthusiasm, as first long term results after DCD kidney 
transplantation are promising. To date, extrarenal DCD organs are also considered a serious 
option to close the gap between organ supply and demand. However, warm ischemic injury 
leads to potentially more organ dysfunction compared with grafts derived from brain dead 
donors. Minimizing graft damage is one of today’s challenges in DCD donor management and 
organ preservation. This review discusses mechanisms of warm ischemic injury, potential new 
approaches to improve posttransplant results, and several persistently controversial issues in 
DCD. In addition, we provide an overview of current DCD protocols and up-to-date evidence 
on selection criteria, organ preservation, and clinical outcome after transplantation of various 
types of DCD organs.
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INTRODUCTION
The concept of donation after cardiac death (DCD) is not new. In the early days of organ 
transplantation, all deceased donor grafts were retrieved from donors who had suffered 
cardiac death.14-16 When legal definitions for brain death became available in the 1960s of the 
last century,10 most centers established transplant programs based on organ retrieval from 
donation after brain dead (DBD), thus avoiding the warm ischemic damage that DCD donor 
organs by definition have sustained.17
Organ donation, however, has become a victim of its own success. In the last decades, 
indications for transplantation have become broader, whereas donor organ availability did 
not increase substantially. Partially due to improved traffic safety regulations, the number of 
DBD organ donors has dropped: In the Eurotransplant region the relative amount of donors 
with cerebral trauma decreased from 43% in 1990 to 35% in 2005.18,19 Attempts to improve 
the willingness of the public to donate their organs after death have been only marginally 
successful. All these factors contribute to an ever increasing number of patients on the 
waiting list. Within Eurotransplant alone, on December 31, 2005, more than 15,000 patients 
were waiting for an organ. Less than 6,000 transplants were performed in that same year and 
almost 1,400 patients died while on the waiting list.19 
In an effort to enlarge the donor pool, living donation has made a valuable contribution 
to kidney transplantation programs, and living split-liver donation is a promising method for 
the future in liver transplantation.20,21 However, such programs will never yield sufficient new 
donor organs to bridge the gap between supply and demand.
To date, many centers are revisiting DCD in order to enlarge the deceased donor pool. 
This is a logical step, for the potential pool of these donors is many times larger than the 
amount of available DBD donors.17,22,23 In the late 1980s and early 1990s, a few hospitals 
had already re-introduced DCD protocols. The group from Maastricht, led by Kootstra, was 
one of the pioneering centers.24 In 1995, at the first international workshop on DCD donors 
in Maastricht, consensus was reached about donor management protocols and four different 
categories of DCD donors were defined (Table 1).13 Ever since, the practice of DCD donation 
has increasingly become a part of transplant programs all over the world.
Category Description Organ recovery
 I Dead on arrival Uncontrolled 
 II Unsuccessful resuscitation Uncontrolled 
 III Awaiting cardiac arrest (withdrawal of treatment) Controlled
 IV Cardiac arrest while brain dead Uncontrolled
Table 1: Maastricht classification of donors after cardiac death
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With increasing numbers of grafts that have suffered from prolonged warm ischemia, 
maintenance of organ viability has once again become an important factor to preserve 
current high standards for functional outcome and long term survival after transplantation. 
The amount of injury differs for the various DCD donor categories.13 Category III donors are 
most widely used, since the duration of warm ischemia (WI) is known and usually short. In 
addition, organ recovery can be planned in advance. Nevertheless, the time interval between 
withdrawal of treatment and cardiac arrest in the potential donor may account for additional 
WI injury due to low oxygenation and organ hypoperfusion. This period is usually not included 
in calculations of total WI time, but it is likely to be relevant to appreciate the real ischemic 
insult that a particular organ has sustained. The length of this so-called agonal phase varies 
widely between individual donors, and many different upper limits for acceptable donation are 
in use, depending on which organs are to be procured. While for example in The Netherlands 
a maximum period of two hours is considered acceptable for kidney donation,25 US guidelines 
recommend no more than 60 minutes.26 Since ischemic injury accumulates as a continuum, 
influenced by a multitude of factors, setting an evidence based cut-off value for the maximum 
length of the agonal phase remains difficult. Suntharalingam et al. have recently conducted a 
comprehensive multicenter study to identify clinical parameters that independently predict 
the timing of death following treatment withdrawal. Their data show that younger age, higher 
FiO2, and the mode of ventilation (no pressure support vs. pressure support) are independently 
associated with a shorter agonal phase before cardiocirculatory death.27 These are imprortant 
findings, as they may allow better identification of patients suitable for DCD and facilitate 
timing of organ retrieval. Various guidelines are in use for the maximum acceptable duration of 
true warm ischemia (commonly defined as the interval between a mean arterial pressure below 
60 mmHg and initiation of organ perfusion). Most up-to-date evidence shows that for the liver, 
a WI time above 20-30 minutes, and for the kidney a WI time longer than 45-60 minutes is 
associated with increased complications posttransplant.28
In some countries donation after withdrawal of treatment is illegal. As a result, transplant 
programs have to rely solely on uncontrolled DCD, in which the average WI time is considerably 
longer. However, uncontrolled DCD may have one advantage over category III donors: Serious 
brain injury is associated with a significant pro-inflammatory and pro-coagulatory response in 
the donor, which has a negative effect on organ quality and increases the risk of immunological 
complications posttransplant.11 Most controlled DCD donors have sustained irreversible cerebral 
injury. As a result, their organs may suffer more from negative immunological and coagulatory 
effects than grafts derived from uncontrolled DCD donors, whose primary medical condition is 
usually not neurologic. In renal transplantation, the detrimental effect of delayed graft function 
(DGF) on graft survival appears to be more pronounced in kidneys derived from brain injured 
donors, versus organs coming from uncontrolled DCD donors.29 These data suggest that WI 
plus profound cerebral injury could account for a different, more detrimental form of DGF than 
observed in uncontrolled DCD kidneys that have sustained only WI.
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Mechanism of warm ischemic injury
Tissue ischemia leads to a cascade of cellular injury and repair responses. Lowering organ 
temperature to 0–4ºC will slow down such responses, although accumulation of injury will 
continue at a rate of ~10% from normal.30 For this reason, hypothermic organ preservation 
cannot be extended beyond certain time constraints, since cold ischemia will keep the graft 
in an acceptable condition for only a limited period.
The onset of ischemia immediately impairs oxidative metabolism. This leads to depletion of 
ATP, an increase in anaerobic glycolysis, and inhibition of Na+/K+ ATPase. Membrane transport 
mechanisms will slow down, causing intracellular accumulation of water and ions which 
results in cell edema and dysruption of the cytoskeleton. Impaired oxidative metabolism 
triggers formation of radical oxygen species (ROS) that have a direct detrimental effect on 
the cell. ROS will also facilitate production of other free radicals such as nitric oxide (NO), 
further disrupting the cytoskeleton. Anaerobic glycolysis lowers the intracellular pH due to 
synthesis of lactic acid, which negatively influences cellular homeostasis. In addition, hypoxia 
will inhibit cytoprotective mechanisms, such as upregulation of heme oxygenase-1 (HO-1) 
and heat shock protein-70. Impaired cytoprotection will render the graft more susceptible 
to further ischemic injury.31 At reperfusion, more injury ensues when damaged endothelial 
cells express intercellular adhesion molecule 1 and vascular cell adhesion molecule 1, which 
attract host leukocytes. These leukocytes release more ROS and inflammatory mediators, 
aggravating cellular injury. Ischemia-reperfusion injury also stimulates antigen-independent, 
innate immunity via complement activation and Toll-like receptor(TLR)-mediated pathways. 
Innate immune activation in turn triggers the adaptive immune response, in part through 
TLR-induced surface expression of CD80 and CD86 on dendritic cells. This will cause early 
T-cell regulated inflammatory damage to the graft. Adaptive immune activation will also 
increase the risk of acute rejection. Both, innate and adaptive immune responses eventually 
contribute to the development of chronic allograft pathology.32 Recent evidence suggests 
that ischemia-reperfusion injury is a highly coordinated and specific process mediated by 
components of both innate and adaptive arms of immunity.33 
After reperfusion, energy levels in the graft are rapidly restored. This fuels cytoprotective 
processes, such as formation of HO-1 and vascular endothelial growth factor expression, 
which protect cells from the host immune attack.34 A sequence of events follows, initiating 
repair of endothelial, epithelial, and parenchymal cells. Although mechanisms and rates differ 
between various cell types, cell differentiation, migration, and proliferation directed by growth 
factors and molecular signalling pathways play an important role in the repair response.35
Novel approaches
DCD grafts are exposed to significantly more ischemia-reperfusion injury than organs derived 
from donation after brain death (DBD). In general, the most obvious and economic approach 
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to minimize injury would be to keep WI time as short as possible, and to limit cold ischemic 
time. Reducing ischemic times by just a few percent is likely to have a much larger impact 
on outcome than the application of novel technical or pharmacological interventions.36 
Normothermic recirculation and normothermic machine perfusion are sophisticated 
novel organ preservation techniques, which aim at providing oxygen and nutrients to the 
graft during organ preservation to better maintain viability and perhaps fuel cellular repair 
mechanisms.37,38 In the Hospital Clínic in Barcelona, Spain, a protocol for normothermic 
recirculation of uncontrolled DCD donors is in use: Before cold storage is initiated, the donor 
is rewarmed and recirculated for a brief period with normothermic extracorporeal membrane 
oxygenation via the femoral vessels. The group reports resuscitation of otherwise non-
transplantable liver grafts.39 Donor pretreatment with anti-inflammatory, anti-coagulatory, 
and other agents, as well as addition of thrombolytic agents to the systemic flush solution 
could mitigate the initial ischemic insult.40 However, treatment of a donor-to-be before the 
legal determination of death is associated with serious ethical concerns. For the near future, 
finding agents that are beneficial for both, the critically ill ICU patient and his or her potential 
donor organs may be the most pragmatic approach.
Controversial issues
Apart from ethical concerns about donor pretreatment, one of the largest other controversies 
in DCD to date surrounds the issue of donor type substitution. A most striking example is the 
recent situation in The Netherlands (Fig. 1): In a short time period, controlled DCD has become 
very popular, with exceptional rates approaching 50% of all deceased donor procedures. 
Surprisingly, this did not result in enlargement of the donor pool. The absolute number of 
kidney donations and transplants remained approximately the same, whereas the number 
of procured thoracic organs decreased (source: Eurotransplant annual report 2008). It is very 
difficult and politically sensitive to pinpoint a single cause for this alarming phenomenon, but 
it seems plausible that some form of substitution could be involved.2 A possible mechanism 
might be that donor families are given a choice between a controlled DCD or a DBD procedure. 
For the family, the timely withdrawal of treatment followed by cardiocirculatory arrest may 
be perceived as a more emotionally acceptable way to cope with the loss of a beloved one, 
even if the patient meets legal brain death criteria or progression to brain stem death is 
imminent. In addition, current high pressure on ICU beds may add to an eagerness to initiate 
donation procedures as soon as possible, rather than to wait up to a few days for brain stem 
death. Also, a lower treshold to perform early decompressive neurosurgical interventions in 
patients with cerebral injury could have resulted in an absolute decrease in the number of ICU 
patients who eventually progressed to brain stem death. All these factors together could lead 
to relatively more DCD procedures, and hence fewer available hearts, livers and pancreata.
Another persistent concern in DCD is the question when exactly a patient may be 
declared dead from a cardiocirculatory point of view. In order to maintain societial support 
for DCD it is essential to have transparent policies for the indication to initiate withdrawal of 
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treatment, and a well defined no-touch period afterwards. Common consensus requires that 
the physicians who are involved in the cessation of life support and the declaration of death 
are always strictly separated from the organ procurement team. In addition, the most up-to-
date evidence suggests that the declaration of cardiocirculatory death should be no earlier 
than two minutes after asystole, since autoresuscitation has never been reported after this 
period.41 Most protocols to date dictate a no-touch period of 3–5 minutes, although some 
centers use a 10 minutes interval.28,42
Figure 1:  The annual number of DCD and DBD procedures in The Netherlands leading to at least one 
transplant. Above each bar, the percentage of DCD versus total deceased donor procedures is indicated. 
From 1997 through 2008, the relative contribution of DCD to the deceased donor pool increased from 
7% to more than 40%, whereas the total annual number of deceased donors did not rise. These figures 
could indicate substitution of DBD for DCD procedures. Source: Dutch Transplantation Foundation annual 
reports 1997–2008.
The use of extracorporeal membrane oxygenator support after cardiac arrest, as practiced by 
some centers, may raise paradoxal ethical concerns. If the heart is reperfused with oxygenated 
blood it will likely resume a normal rhythm, thus potentially affecting the “state of death” 
that had been declared a few minutes earlier based on cardiocirculatory criteria. Hence, 
physicians often choose to inflate a thoracic aortic balloon, or administer lidocaine to prevent 
the heart from resuming activity. Nevertheless, it may be argued that irreversible brain injury 
has already taken place when cardiac reanimation occurs, provided that a reasonable 2–5 
minutes no-touch period was observed after cardiac arrest.43 
22  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
CLINICAL EVIDENCE
The kidney
For kidney recipients, dialysis is always available as a backup in the case of insufficient immediate 
graft function. Therefore, kidneys were the first organs to be transplanted from DCD donors. 
Renal grafts comprise by far the largest group of DCD organs actually used for transplantation 
(Fig. 2a). To date, DCD kidneys of all Maastricht categories are used worldwide, but categories 
III and II are predominant. Many centers use rapid in situ cooling techniques for category II 
kidney-only donor management. After unsuccessful resuscitation, both kidneys are perfused 
with cold preservation solution following insertion of a double-balloon-triple-lumen (DBTL) 
catheter via the femoral artery. Various protocols are in use for category III donor management. 
Although DBTL catheter in situ cooling can also be utilized when extrarenal organs are to be 
procured, rapid laparatomy with aortic cannulation and systemic cold perfusion is nowadays 
the most widely used technique for the DCD multi-organ donation scenario. Some centers 
do use DBTL catheter cooling for category III kidney-only donors, however, evidence suggests 
that rapid laparatomy with aortic cannulation leads to comparable results and fewer technical 
complications.44 Category I donors are used to some extent by a few centers, e.g. by the Madrid 
group in Spain. This center employs strict emergency service protocols to minimize WI time 
and has a high organ discard rate (57%) due to stringent donor selection criteria. In a country 
where category III DCD is illegal, this pragmatic approach provides an alternative source of 
donors to bridge the gap beween organ supply and demand. The group reports 68% delayed 
graft function (DGF), 6% primary non-function (PNF) and a similar 5 year graft survival (GS) 
as achieved with DBD kidneys (~75%).45 However, when interpreting these numbers it should 
be kept in mind that kidneys have been subjected to an exceptionally strict selection process 
with a considerable discard rate: The group uses only those donors with a known time between 
cardiac arrest and initiation of adequate cardiopulmonary resuscitation under 15 minutes, 
no violence as cause of death, no thoracic or abdominal bleeding injuries, no more than 120 
minutes between start of resuscitation and initiation of organ preservation, and the availability 
of a next of kin within four hours. DCD cat. IV donors including sudden cardiac death after 
declaration of brain death are a very rare group, for which hardly any isolated data are available.
The question of how to best preserve DCD kidneys has remained unresolved until recently. Many 
centers embarked on static cold storage (CS), whereas others strongly advocate hypothermic 
machine perfusion (MP), especially for category II grafts. Retrospective studies suggest a short 
and long term outcome benefit of MP versus CS.46 A prospective study conducted in the United 
Kingdom on MP versus CS for DCD kidneys was terminated early as the investigators expected 
that it would not show any difference in outcome after transplantation.47,47 However, the recent 
large European prospective randomized controlled trial comparing MP with CS preservation 
showed that MP indeed reduced the risk of DGF with an adjusted odds ratio of 0.57 for all 
common types of deceased donor kidneys, regardless of whether the graft came from a DCD, 
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DBD, or expanded criteria donor. In addition, MP reduced the risk of graft failure in the first 
year posttransplant with an adjusted hazard ratio of 0.52 versus CS.48 Hence, with this level 
of evidence and since the incidence of DGF is particularly high in DCD kidneys, MP appears to 
be the best choice to preserve a DCD kidney graft. Two very recent analyses derived from the 
same prospective study showed that MP characteristics such as perfusate flow, intravascular 
resistance and the biomarkers glutathione-S-transferase and heart-type fatty acid binding 
protein do have some predictive potential for delayed graft function. However, none had any 
relevant prognostic value for serious complications such as primary non-function and graft 
failure. Therefore, MP dynamics and perfusate biomarker measurements may help to fine-
tune postoperative recipient management (e.g. delay introduction of calcineurin inhibitors), 
although they should not be used to accept or discard a kidney.49,50
Kokkinos et al. conducted a comprehensive meta-analysis of currently available clinical data 
on DCD kidney transplant outcomes. Their study showed that, for all categories pooled, the 
incidence of DGF has an odds ratio (OR) of 3.64, when compared to DBD kidneys. PNF also 
occurs more frequently (OR 2.43). DCD kidney recipients tend to stay more days in-hospital 
after transplantation (OR 4.56). Graft survival of DCD kidneys is generally somewhat inferior 
to DBD grafts, with ORs of 0.70 at three months and 0.89 at 10 years posttransplant, although 
this last OR tested non-significant. Acute rejection rates and patient survival posttransplant do 
not differ from DBD kidney recipients.51 Snoeijs et al. showed that the use of elderly DCD donors 
was associated with unacceptable clinical outcomes. They concluded that transplantation of 
65+ DCD renal grafts cannot be justified without further refinement in their selection, for 
example, by histological assessment of pretransplant biopsies.52 In summary, DCD kidneys 
show an inferior short term function, but seem to have only a mild graft survival disadvantage 
in the long run, as long as donor age is under 65. Although these data will convince many 
transplant professionals that introduction of a DCD program can be a safe addition to the 
deceased donor pool, some consideration should be observed when interpreting long term 
results. Today, follow-up data of more than 5 years posttransplant are only available for a 
relatively small number of DCD kidney recipients. These were the patients who received a 
kidney transplant when DCD was cautiously re-introduced by some centers. Therefore, their 
grafts may have gone through a much stricter selection process than the average DCD kidney 
undergoes nowadays. This could bias the long term DCD outcome we are currently looking 
at, towards a better GS than DCD kidneys transplanted today will show after the same time 
interval. Ongoing monitoring of long term outcome therefore remains important to keep 
results in line with current clinical standards.




Figure 2 a-c:  DCD transplants performed per organ type in the USA and in Eurotransplant (an international 
organ exchange organization in Europe). Bars represent the percentage of DCD grafts in the total deceased 
donor transplant volume of this organ type. Above each bar, the actual number of DCD transplants is 
indicated. Source: UNOS and Eurtotransplant custom data requests.
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The liver
In contrast to the kidney, DCD liver transplantation is introduced into programs around 
the world with much more hesitation. Between 1996 and 2008, 1,683 DCD livers were 
transplanted in the USA, and 186 in Eurotransplant (Fig. 2b). Due to the lack of life-
sustaining replacement therapy, most extrarenal organs undergo a more stringent selection 
process in order to prevent PNF, which implies retransplantation or death within seven days 
posttransplant. Many studies have shown that the liver, especially its sinusoidal cells and the 
biliary system, is less tolerant to ischemic injury than a renal graft.53 The burden of increased 
ischemic type biliary complications in DCD livers may account for additional posttransplant 
morbidity that is not necessarily outlined by basic survival analyses.
To date, all livers are preserved by static CS. Although evidence coming from kidney 
preservation studies may be extrapolated to the liver as well, MP preservation of liver grafts 
has not reached the clinic yet. Clinical MP for livers is often considered less feasible due to the 
more complex system needed to perfuse both the hepatic artery and portal vein, rendering a 
potential device less transportable.54 However, if these technical concerns are overcome, MP 
could be a promising method to enlarge the potential DCD liver pool. In addition, MP may 
offer the option of in vitro viability testing as a tool to aid decisions on organ quality. The 
question remains whether MP will help reduce ischemic type biliary lesions.
In a retrospective analysis by Freeman et al., overall posttransplant outcome of DCD liver 
transplants in the USA between 2000 and 2006 (n = 1,007 in their study) was inferior 
compared to DBD livers: four-year adjusted graft survival was almost 20% lower.55 Both, 
Mateo et al. and Lee et al. have published detailed analyses of DCD liver transplant outcome. 
Much effort was directed at identifying selection criteria for the acceptance of a DCD liver. 
From the evidence currently available, it is clear that non-steatotic liver grafts from relatively 
young DCD donors (≤45 years) with short WI time (≤15 min.), kept on CS preservation for 
≤10 hours are safe candidates for transplantation. Interestingly, recipient characteristics 
had no relevant predictive value for graft survival, as long as the aforementioned criteria 
were met. GS for this group (84.9% at 1 year; 69.4% at 5 years) was comparable to that of 
DBD livers.56,57 To summarize, data currently available suggest that with careful selection 
of suitable donors, DCD liver transplantation is within reach of everyday transplantation 
practice and could reduce the number of patients on the waiting list.
The lung
Clinical DCD lung transplantation is a slowly emerging field (Fig. 2c). Approximately one 
decade ago a few centers started small DCD lung transplant programs. Data derived from 
animal studies had pointed out that lungs do not rely on arterial perfusion to deliver oxygen 
for cellular respiration. Since parenchymal cell oxygenation occurs through air spaces, merely 
ventilating non-perfused lungs will provide sufficient oxygen to prevent serious ischemic 
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tissue injury.58 Therefore, pulmonary grafts derived from DCD donors will suffer less from 
WI compared to other organs, especially when procurement can be planned in advance. In 
category III DCD, the donor can be rapidly re-intubated and ventilated after the legal five 
minute no-touch period following cardiac arrest. In an uncontrolled donation setting, lung 
viability may also be preserved as long as adequate artificial ventilation is started immediately 
after cardiac arrest.
With only scarce evidence available, DCD lung preservation seems to rely on rapid organ 
cooling, as soon as ventilation is discontinued. For uncontrolled donors, Steen et al. have 
advocated intrapleural cooling within the intact body, followed by warm ex vivo functional 
evaluation.59 However, in a controlled DCD donor, systemic cold flush after rapid aortic 
cannulation may be sufficient to preserve organ viability.
Although various groups have reported cases or small numbers of successful DCD lung 
transplants at conferences, only a handful of such series has been published so far. One of 
the largest studies appeared in 2007, presenting posttransplant outcome of 17 uncontrolled 
(categories I and II) DCD pulmonary grafts. The authors report that, even with an organ 
discard of around 87%, the rate of primary graft dysfunction in the recipient (53%) was much 
higher than in DBD lungs (10–20%). Three year patient survival was 58%.60 Early results of 
another series in Australia were recently reported by Snell et al. Out of 11 donation attempts, 
eight Maastricht cat. III lungs were retrieved and successfully transplanted. At the moment 
of their report, all eight recipients survived for a mean of 311 days with an acceptable early 
clinical course.61 In an OPTN database analysis, Mason et al. compared outcomes of 36 DCD 
lung transplants in the USA to average outcomes of DBD lungs. They concluded that DCD 
resulted in survival up to two years which was at least equivalent to that after DBD.62 In the 
University Medical Center Groningen, The Netherlands, a significant DCD lung transplant 
program exists since 2005. So far, 24 pulmonary grafts retrieved from DCD cat. III donors 
were successfully transplanted, with an early postoperative course comparable to DBD lungs. 
(M.E. Erasmus, personal communication, May 1, 2009). In conclusion, DCD has had a minimal 
impact on lung transplantation so far. However, interest in this new practice is increasing and 
larger studies presenting outcomes after transplantation are awaited with anticipation.
Other organs
The University of Wisconsin group from Madison, WI has published outcomes of a large 
consecutive series of DCD simultaneous pancreas and kidney transplants (n = 37). The 
authors report that 5-year patient, pancreas, and kidney survival was similar to that of DBD 
transplants.63 DCD pancreas-only transplants are hardly ever reported, with some rare 
exceptions coming from Japan. Currently, most DCD pancreatic grafts are used to obtain 
islets for transplantation.64
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Transplantation of cardiac grafts derived from DCD donors has remained in a predominantly 
pre-clinical phase so far. Myocardial vulnerability to ischemic injury would make donor 
management in the DCD setting challenging.58 Although the potential donor pool expansion 
could be interesting,65 no centers have transplanted DCD hearts on a relevant scale. Clinical 
cases using a normothermic resuscitation and preservation device have been reported at 
meetings, but no reliable outcome data have ever been published.38
For DCD intestinal transplantation, only scarce data are available. The number of suitable DBD 
grafts outnumbers the relatively small group of serious candidates for an intestinal allograft. 
Moreover, small bowel tissue is highly susceptible to WI injury. Therefore, no rationale seems 
to exist for transplanting intestines recovered from DCD donors.66 
CONCLUSION
Donation after cardiac death is rapidly earning its place in everyday clinical transplantation 
practice. Prolonged WI leads to organ injury at various levels, which should be minimized to 
preserve organ viability. This poses considerable challenges to DCD donor management. In 
contrast to widespread sceptisism only a few years ago, many centers today have adapted 
their protocols to incorporate the option of DCD. For the kidney, large series of long term 
follow-up are now becoming available, with encouraging results. Transplantation of extrarenal 
organs is gaining acceptance, with livers and lungs as the most serious candidates. Also, there 
is increasing evidence that DCD pancreata are likely to perform equally well compared to 
those recovered from DBD donors. However, long term clinical outcome data are very scarce, 
and more evidence has to become available before these organs can be considered to safely 
reduce the number of patients on the waiting list.

Chapter 3
The influence of deceased donor age and
 old-for-old allocation on kidney transplant outcome
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ABSTRACT
Background
Transplantation of older deceased donor kidneys is gaining wide acceptance in most 
countries. Many previous studies have concluded that advanced donor age negatively impacts 
posttransplant outcome, but detailed data on the extent to which a few years increase in 
donor age will influence early graft function and graft survival (GS) are scarce. 
Methods
We used the Organ Procurement and Transplantation Network database (cohort 1994–2006, 
n = 99,860 recipients) to evaluate the effect of deceased donor age on posttransplant results, 
and to obtain regression models which are relevant to guide clinical organ allocation policies. 
In addition, we simulated the effect that old-for-old allocation would have on transplant 
outcome.
Results
In the context of other risk factors, donor age increased the risk of delayed graft function 
(DGF) and graft failure with odds/hazard ratios of 1.02 and 1.01, respectively. Absolute 
DGF risk increased by 0.35–0.37% and GS decreased with each year increase in donor age. 
Kidney discard rates in the USA increased with donor age, up to 66.9% for 65+ donors. In our 
simulation, we found that old-for-old kidney allocation would have no large impact on overall 
renal transplant outcome.
Conclusions
This study shows that donor age strongly influences posttransplant outcome, not only in 
the upper extremes, but for the whole range of donor ages ≥11. Implementation of old-for-
old kidney allocation is likely to be safe. Such a policy could reduce waiting time for aged 
candidates, but it will not necessarily improve overall kidney transplant outcome.
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INTRODUCTION
With increasing numbers of patients on the waiting list, transplantation of kidneys from 
sub-optimal donors has gained wide acceptance in most countries. Older donors, expanded 
criteria donation (ECD), and donation after cardiac death (DCD) have nowadays become 
important sources of kidney grafts.18,67-69 Various studies indicate that organs derived from 
such elevated-risk donors can be used successfully, provided that careful selection criteria are 
employed. Nevertheless, in most large registry analyses advanced donor age remains one of 
the most important risk factors for inferior posttransplant outcome.70-75 Although a number 
of previous studies have superficially assessed the impact of donor age, detailed data on the 
extent to which a few years increase in donor age will influence early graft function and graft 
survival are scarce.
Within Eurotransplant, an international organ exchange organization in Europe, a 
well-established old-for-old allocation program exists since 1999.2 In this kidney exchange 
program, 65+ deceased donor grafts are allocated to non-immunized recipients of 65 years 
and older, employing only ABO blood group matching and a policy to keep preservation 
times short. Results of this program and other senior-recipient organ exchange programs are 
encouraging, with a higher utilization rate for older donor kidneys, shorter waiting times for 
older patients, and reduction of the number of older patients on the waiting list. Overall long 
term outcomes after transplantation appear not to be negatively affected by this policy.76
Our current analysis focuses on the influence of deceased donor age on renal 
transplantation in the USA, and addresses the question whether old-for-old allocation is safe. 
Aims of the study were to obtain regression models that show in detail the effect of donor age 
on short- and long-term outcome, and to simulate kidney graft survival rates if an old-for-old 
kidney allocation program were implemented in the USA.
METHODS
Study population
A January 10, 2007 extract of the Organ Procurement and Transplantation Network (OPTN) 
database was used. The study population consisted of deceased donor single-kidney recipients 
who were transplanted from January 1, 1994 through December 31, 2006. Only transplants 
from donors aged ≥11 years were included in the analysis. We chose 1994 as lower boundary 
of this cohort, since several important variables were not collected before this year, and also 
because postoperative care before this year would be too different from today’s regimen. The 
upper limit was 2006 as database completeness for transplants performed thereafter was 
still too low at the time of analysis.
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Figure 1: a) Distribution of deceased donor kidney transplants (cohort 1994–2006) per donor age, 
stratified into the two major causes of death; b) Total number of deceased donor kidney transplants per 
year, distributed over five different donor age categories. 
Endpoints
Endpoints for short-term outcome after kidney transplantation were delayed graft function 
(DGF) and primary non-function. DGF was defined as any dialysis requirement in the first 
week after transplantation. As reliable data on primary non-function could not be easily 
derived from the OPTN database, graft loss within three months posttransplant was used 
as a surrogate. Graft survival (GS) up to 10 years posttransplant served as endpoint for long-
term outcome.
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Statistical method
Donor, transplant, and recipient demographics were calculated for the study cohort, and 
plotted in graphs showing causes of death and the number of transplants per year. For 
each year between 1994 and 2006, kidney discard rate was visualized as the percentage 
of kidneys actually transplanted from all deceased donors recovered in various donor age 
categories. The correlation between donor age and recipient age was calculated by Pearson’s 
method. A binary logistic regression model was employed to identify independent donor-, 
preservation-, and recipient-related risk factors for DGF and for graft loss within three months 
posttransplant. Cox regression models examined which factors significantly contributed to 
the risk of graft failure and death with a functioning graft up to 10 years posttransplant.77 
We used the Kaplan-Meier method to analyze death censored GS in recipients. Univariate 
linear regression models were constructed with DGF, or one, five, and 10-year death censored 
graft survival as dependent variable and donor age as independent variable. In the model for 
DGF, the data were split into patients who received a DCD kidney and those who received 
a graft derived from donation after brain death (DBD), since DCD has a well documented 
independent effect on the incidence of DGF.40,48
We followed the approach outlined in figure 4a to simulate graft survival, as if an 
old-for-old allocation program had been employed in the time period studied. Old-for-old 
matching was performed following the Eurotransplant Senior Program (ESP) allocation rules: 
Donor and recipient age ≥65 years, only recipients with no prior transplants, recipient panel 
reactive antibodies (PRA) ≤5%, no human leukocyte antigen (HLA) matching, and a policy 
to keep cold ischemic time (CIT) relatively short. For our old-for-old simulation, CITs of 65+ 
grafts were artificially reduced by a factor 12/19, thus mimicking the effect observed in the 
ESP.78 For each existing or newly matched donor kidney + recipient combination, a theoretical 
graft survival time was calculated. Based on the shape of the actual baseline survival data 
points underlying a Cox model for graft failure in our dataset, we estimated that the baseline 
survival function would follow an exponential course:
[1]    
where t is time posttransplant. Values for a and c were derived by means of a least square fit 
to the baseline survival data points derived from this Cox model. Next, a survival function 
was obtained for each existing or newly matched combination:
[2]     
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where bi is the i-th regression coefficient and xi is the value of the i-th factor in the Cox 
model.77 From equations [1] and [2], an equation for graft survival time (time-to-failure) of 
any donor kidney + recipient combination was derived:
[3]  
        
where s is a random number between 0 and 1 generated for each recipient, and T is the 
simulated time-to-failure for the graft.
Statistical analyses were conducted using SPSS and SigmaPlot software. Two-sided 
p-values <0.05 were considered to indicate statistical significance.
Donor demographics Whole cohort Only 65+ donors
Donor agea (yr) 39 (11–85) 67 (65–85)
Female donor (%) 41 55
DCD donor (%) 4 2
ECD donor (%) 15 100
Traumatic cause of death (%) 46 14
Donor history of hypertension (%) 21 46
Donor history of diabetes mellitus (%) 4 7
Recipient demographics  
Recipient agea (yr) 49 (0–90) 60 (6–90)
Female recipient (%) 39 38
Total time spent on the waiting lista (yr) 1.4 (0–22) 1.4 (0–16)
Previous transplants (% ≥1) 10 5
PRA level >5% (%) 19 13
Transplant demographics  
HLA mismatches (% of 0 mismatches) 16 7
Hypothermic machine perfusion (%) 15 24
Cold ischemic timea (h) 18 (0–78) 19 (0–67)
 
Table 1:  Donor, recipient, and transplant demographics for the whole study cohort (n = 99,860 deceased 
donor kidney transplants between 1994 and 2006), and for all kidney transplants performed from deceased 
donors aged 65 years and older in this same cohort (n = 1,011).
a Median (range).




Between January 1, 1994 and December 31, 2006, 99,860 deceased donor single-kidney 
transplants from donors aged ≥11 years were performed in the USA. Table 1 shows basic 
demographic statistics for the study population. Figure 1a shows that in young donors, the 
leading cause of death was trauma, whereas in older donors death following a cerebrovascular 
accident (CVA) was predominant. Between 1994 and 2006, the total number of kidney 
transplants per year from deceased donors increased by 39.5% (fig. 1b). This increase came 
primarily from donors above the age of 35, and therefore the relative share of older donor 
kidney transplants has risen during these 13 years. There was no relevant correlation between 




 Odds ratio / Hazard ratio 
 (95% CI)b 
P-value
Delayed graft function  
Donor age (yr) 1.02 (1.02–1.02) <0.0005
DCD donor vs. DBD donor 3.01 (2.86–3.32) <0.0005
ECD donor vs. non-ECD donor 0.99 (0.94–1.04) 0.6
Donor cause of death: CVA 1.02 (0.97–1.07) 0.4
Donor cause of death: trauma 0.87 (0.82–0.91) <0.0005
Donor history of hypertension 1.33 (1.28–1.39) <0.0005
Donor history of diabetes mellitus 0.99 (0.92–1.06) 0.8
Machine perfusion vs. static storage 0.53 (0.51–0.56) <0.0005
Cold ischemic time (hrs) 1.04 (1.04–1.05) <0.0005
Number of HLA mismatches 1.08 (1.07–1.09) <0.0005
Recipient age (yr) 1.00 (1.00–1.00) 0.002
Total time spent on the waiting list (yr) 1.10 (1.09–1.11) <0.0005
Most recent PRA level (%) 1.00 (1.00–1.00) <0.0005
Number of previous kidney transplants 1.22 (1.16–1.28) <0.0005 
Graft loss within three months posttransplant (surrogate for primary non-function)
Donor age (yr) 1.01 (1.01–1.01) <0.0005
DCD donor vs. DBD donor 1.31 (1.13–1.53) <0.0005
ECD donor vs. non-ECD donor 1.35 (1.22–1.48) <0.0005
Donor cause of death: CVA 1.27 (1.14–1.41) <0.0005
Donor cause of death: trauma 1.02 (0.92–1.13) 0.8
Donor history of hypertension 1.14 (1.05–1.23) 0.002
Donor history of diabetes mellitus 1.13 (0.99–1.30) 0.07
Machine perfusion vs. static storage 0.94 (0.87–1.03) 0.2
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Table 2  Continued
Variable
 Odds ratio / Hazard ratio 
 (95% CI)b 
P-value
Cold ischemic time (hrs) 1.02 (1.02–1.02) <0.0005
Number of HLA mismatches 1.09 (1.07–1.11) <0.0005
Recipient age (yr) 0.99 (0.99–0.99) <0.0005
Total time spent on the waiting list (yr) 1.02 (1.01–1.04) 0.006
Most recent PRA level (%) 1.01 (1.00–1.01) <0.0005
Number of previous kidney transplants 1.43 (1.32–1.55) <0.0005 
Graft failure within the first 10 years posttransplantc 
Donor age (yr) 1.01 (1.01–1.01) <0.0005
DCD donor vs. DBD donor 0.89 (0.81–0.97) 0.009
ECD donor vs. non-ECD donor 1.21 (1.16–1.27) <0.0005
Donor cause of death: CVA 1.05 (1.00–1.11) 0.04
Donor cause of death: trauma 0.99 (0.94–1.04) 0.7
Donor history of hypertension 1.08 (1.04–1.13) <0.0005
Donor history of diabetes mellitus 1.23 (1.15–1.32) <0.0005
Machine perfusion vs. static storage 1.09 (1.05–1.14) <0.0005
Cold ischemic time (hrs) 1.00 (1.00–1.01) 0.001
Number of HLA mismatches 1.09 (1.08–1.10) <0.0005
Recipient age (yr) 0.98 (0.98–0.98) <0.0005
Total time spent on the waiting list (yr) 1.00 (0.99–1.00) 0.2
Most recent PRA level (%) 1.00 (1.00–1.01) <0.0005
Number of previous kidney transplants 1.22 (1.17–1.27) <0.0005
DGF vs. no DGF in recipient 2.22 (2.15–2.28) <0.0005 
Death with a functioning graft within the first 10 years posttransplant
Donor age (yr)  1.00 (1.00–1.01)d <0.0005
DCD donor vs. DBD donor 0.87 (0.76–0.98) 0.03
ECD donor vs. non-ECD donor 1.06 (0.99–1.13) 0.08
Donor cause of death: CVA 1.06 (1.00–1.14) 0.07
Donor cause of death: trauma 1.01 (0.95–1.08) 0.8
Donor history of hypertension 1.02 (0.97–1.08) 0.4
Donor history of diabetes mellitus 1.13 (1.03–1.24) 0.01
Machine perfusion vs. static storage 1.01 (0.95–1.07) 0.7
Cold ischemic time (hrs) 1.00 (1.00–1.00) 0.2
Number of HLA mismatches 1.00 (0.99–1.02) 0.5
Recipient age (yr) 1.05 (1.05–1.05) <0.0005
Total time spent on the waiting list (yr) 1.02 (1.01–1.03) 0.004
Most recent PRA level (%) 1.00 (1.00–1.00) 0.002
Number of previous kidney transplants 1.10 (1.03–1.18) 0.007
DGF vs. no DGF in recipient 1.45 (1.39–1.51) <0.0005
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Table 2: Multivariate risk analysisa for delayed graft function, early graft loss, graft failure, and death with a 
functioning graft.
a    Logistic regression models for delayed graft function and for graft loss within three months posttransplant, 
and Cox proportional hazards models for graft failure and for patient death with a functioning graft. 
For each covariate in the Cox models, the proportional hazards assumption was tested graphically with 
stratified survival plots for binary covariates, and with partial residual plots for non-binary covariates. We 
judged that the assumption was well met for all covariates in the models, except for traumatic cause of 
death in the Cox model for graft failure in the first 10 years posttransplant. However, since the effect of 
this covariate in the model was minimal and non-significant, it was not converted into a time-dependent 
covariate.
b    Odds ratios apply to the logistic regression models and hazard ratios apply to the Cox proportional 
hazards models.
c    Censored upon death with a functioning graft.
d    Value in three decimal numbers: 1.004 (1.002–1.006)
Kidney discard
In figure 2a relative deceased donor kidney usage is plotted as the percentage of kidneys 
that were actually transplanted from donors recovered each year. 35+ Donor kidney usage 
decreased between 1994 and 2006, especially in kidneys derived from 50+ donors. Discard 
rates were higher for each subsequent donor age category, up to 36.9% and 66.9% for 50–64 
year old and 65+ donor kidneys, respectively in 2006.
Risk factors for delayed graft function and early graft loss
In a binary logistic regression model, all included factors were significant independent 
determinants of the risk for DGF, except for ECD donor vs. non-ECD donor, CVA as cause 
of death in the donor, and donor history of diabetes mellitus (table 2). Donor age increased 
DGF risk with an OR of 1.02 (p < 0.0005), indicating that for each year increase in donor age, 
the relative risk for DGF in the recipient  increased by 2%. Each additional year of donor age 
significantly increased the risk of early graft loss with an OR of 1.01 (p < 0.0005).
Risk factors for graft failure and death with a functioning graft
All factors included in the Cox model, except traumatic cause of death of the donor and 
the number of years the recipient spent on the waiting list, significantly influenced the risk 
of graft failure. Donor age increased the risk of graft failure with a HR of 1.01 (p < 0.0005) 
for each subsequent year of age. Each year increase in donor age was also associated with a 
significantly higher risk of recipient death with a functioning graft (OR 1.004, p < 0.0005). 
Kaplan-Meier graft survival analysis
Figure 2b shows that for each subsequent donor age category above 11–34, graft survival up 
to 10 years was significantly lower (log rank test, p < 0.0005). Graft survival was as low as 
39% at 10 years posttransplant for 65+ donor grafts, versus 70% for kidneys derived from 
donors aged 11–34 years.
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Figure 2: a) Relative deceased donor kidney usage: Percentage of kidneys actually transplanted from all 
donors recovered each year, per donor age category; b) Kaplan-Meier plots of 10-year death censored graft 
survival in recipients of deceased donor kidneys, stratified into five different donor age categories.
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DGF risk as a function of donor age
In figure 3a the incidence of DGF is plotted with donor age as an independent variable, 
stratified into DBD and DCD donor kidneys. These univariate regression analyses show that 
the absolute risk of DGF increased by 0.35% and 0.37% with each year increase in donor age 
for DBD and DCD grafts, respectively (p < 0.0005). DGF risk in DCD kidneys derived from 
donors aged 11–65 years was 17–18% higher than in DBD grafts. Both effects were present 
for the whole spectrum of donor ages between 11 and 75 years (R2 = 0.90 for DBD recipients 
and R2 = 0.30 for DCD recipients).
Graft survival as a function of donor age
Figure 3b shows 1-, 5-, and 10-year death censored graft survival rates as a function of donor 
age, for three different cohorts within the study population. Quadratic univariate regression 
functions were fitted to these data points, which yielded three curves predicting death 
censored graft survival. For all three follow-up intervals, graft survival rates decreased when 
donor age increased. This effect was present for the whole range of donor ages between 11 
and 75 years, and most pronounced with advanced donor age.
Simulation of old-for-old allocation
In order to give an impression of the simulation accuracy of our model, figure 4d shows 10-
year death censored graft survival for the entire study population. One Kaplan-Meier curve 
is based on real survival data, while the other curve was simulated for the same cohort of 
recipients. Although the model failed to accurately predict graft survival in the first year, 
differences between the real and the simulated Kaplan-Meier curve were only minimal 
from 1 year posttransplant onwards. At 10 years after transplantation both curves virtually 
overlapped. 
In our analysis, donor age was a significant independent risk factor for death with a 
functioning graft in a Cox model for this outcome (Table 2), but there was no significant 
interaction between donor age and recipient age in the model (p = 0.5), implying that an old 
patient receiving an old kidney is not more at risk for death with a functioning graft than a 
younger patient who receives an old kidney. Figures 4b and 4c show the results of the old-for-
old allocation simulation outlined in figure 4a. 65+ Grafts that are normally predominantly 
allocated to recipients aged <65 years (old-to-young) showed a drop in 10-year graft survival 
when artificially re-allocated to recipients aged ≥65 years (old-to-old) (20.9% => 12.9%; 
p < 0.0005). When cases were censored upon death with a functioning graft (fig. 4c), this 
difference disappeared (39.7% => 38.9%; p = 0.9). Younger-than-65 donor grafts which were 
previously allocated to recipients of 65 years and older (yound-to-old) may have a better 
10-year graft survival if these kidneys are allocated to recipients under 65 years (young-to-
young), although the difference observed did not reach statistical significance (19.4% => 
26.2%; p = 0.4). When censored upon death with a functioning graft, no such improvement 
could be observed anymore (56.1% => 53.5%; p = 0.05). 
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Figure 3: a) The incidence of DGF per year of donor age, with fitted regression lines predicting DGF risk. 
Linear regression equations obtained from these data are as follows: [%DGF in DBD recipients] = 0.35 x 
[donor age] + 10; [%DGF in DCD recipients] = 0.37 x [donor age] + 27. In the univariate regression analysis 
for DGF, a quadratic (or even higher order) fit did not improve the R2 to such an extent that it would be 
relevant to incorporate this more complex approximation; b) 1-, 5-, and 10-year graft survival rates per year 
of donor age, with fitted quadratic regression curves predicting graft survival. The equations obtained for 
these curves are as follows: [1-year GS] = -0.0039 x [donor age]2 + 0.15 x [donor age] + 93 (R2 = 0.81, p < 
0.0005); [5-year GS] = -0.0061 x [donor age]2 + 0.13 x [donor age] + 82 (R2 = 0.86, p < 0.0005); [10-year GS] 
= -0.0065 x [donor age]2 + 0.0079 x [donor age] + 69 (R2 = 0.91, p < 0.0005). For this analysis, a quadratic 
fit yielded much better R2 values than a linear fit.
p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s  41
3
Recipients aged 65 years and older who had previously received a graft derived from a donor 
under the age of 65, had a significantly worse 10-year graft survival in the hypothetical new 
situation where they would have received a 65+ graft (non-death censored: 19.4% => 12.9%; p 
< 0.0005, death censored: 56.1% => 38.9%; p < 0.0005). Conversely, recipients under the age 
of 65 who had originally received a 65+ graft, would now receive a kidney with a significantly 
improved 10-year graft survival (non-death censored: 20.9% => 26.2%; p = 0.001, death 
censored: 39.7% => 53.5%; p < 0.0005). As the curves in figures 4b and 4c demonstrate, the 
disadvantage for the former recipients would approximately equal the benefit in the latter 
group. For reference, figures 4b and 4c also show a real, non-simulated survival curve of those 
1,011 65+ donor kidneys that were actually transplanted to non-immunized 65+ recipients in 
the study cohort.
a
Figure 4: a) Schematic overview of old-for-old simulation methodology.






Figure 4: b) 10-year non-death censored graft survival after simulation; c) 10-year death 
censored graft survival after simulation; d) Impression of model simulation accuracy: 
Overall 10-year death censored graft survival for the whole study cohort, based on real 
graft survival data, and on simulated values for the same cohort of recipients (n = 99,860). 
The real, non-simulated old-for-old survival curves in figures 4b and 4c should be regarded as 
reference only and cannot be compared with the simulated old-for-old curves. The reason is 
that in those 1,011 real transplants HLA matching was performed, whereas in the simulation 
kidneys were not matched for HLA and CITs were artificially reduced by a factor 12/19. 
* = Newly matched donor graft + recipient combinations.
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DISCUSSION
In this retrospective OPTN database analysis, we have shown that donor age has an important 
impact on short- and long-term outcome after deceased donor kidney transplantation. This is 
true not only for selected categories, but for the whole range of donors aged 11 years and older. 
From 1994 through 2006, the relative share of older donor grafts in the kidney transplant 
pool has increased. Older donor kidney discard rates in the USA are known to be higher than 
in other parts of the world and there is much debate why this discrepancy exists.79 Donor 
biopsies may have contributed to these statistics: Cecka and colleagues showed that in the 
USA the percentage of donor kidneys biopsied increases with donor age, thus giving recipient 
centers an additional diagnostic tool to select kidney grafts derived from older donors.79 It 
is plausible that transplant centers are hesitant to accept kidneys with a documented high 
percentage of glomerulosclerosis, even if other organ quality measures are favorable and the 
centers would have accepted the kidney without a biopsy. Apart from biopsy interpretation, 
donor age itself may also be an important motivation for not accepting kidneys from older 
donors.80 Irrespective of the reason for kidney discard, the impact of advanced donor age on 
outcome may be underestimated due to the fact that more stringent qualitative selection 
criteria are applied to older donor grafts, compared to younger donor kidneys. It should be 
kept in mind that our results represent the effect of donor age in the context of current 
clinical transplantation practice in the USA, and in the presence of a high kidney discard rate 
for donors of advanced age. 
An important limitation of our study is that we had to use early graft loss as a surrogate 
marker for primary non-function, and that DGF was the only available indicator for early renal 
function. Serum creatinine or creatinine clearance values would have offered a more detailed 
tool to assess graft function, but these were not available in the database at standardized 
time points after transplantation.
In the context of relevant covariates, donor age proved to be an independent predictor 
of DGF risk, early graft loss, and graft failure within 10 years posttransplant. Although the 
odds and hazard ratios seem rather low at first sight, it should be noted that donor age was 
included in the model as a continuous variable, in contrast to most analyses where donor 
age is a categorical variable with only a few possible alternatives. The Kaplan-Meier analyses 
show that for each subsequent donor age category above 11–34 years, death censored GS up 
to 10 years was significantly lower. The quadratic regression models present a more detailed 
analysis, which reveals that there is a weak negative effect of donor age on GS for donor ages 
≤34. This effect becomes increasingly stronger from this age onwards. Not surprisingly, the 
incidence of DGF was higher in DCD kidney recipients. Overall, the 17–18% higher rate versus 
DBD graft recipients is well in line with findings of other studies.40,67,81-83 The higher variance 
in the DCD data can be explained by the smaller number of available cases per single year 
of donor age (~60 DCD recipients versus ~1500 DBD recipients). These univariate data show 
that donor age accurately predicts DGF risk, not only in the upper extremes, but for the whole 
range of deceased donor ages between 11 and 75 years.
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Advanced recipient age does not appear to be a relevant risk factor for an inferior short- 
or long-term posttransplant graft outcome, when death with a functioning graft is not 
considered a failure. The multivariate Cox model even points at a graft survival benefit when 
recipient age increases. However, this observation is most likely to be an artifact associated 
with censoring cases upon death with a functioning graft in combination with the long 
survival period studied by the model.
If advanced recipient age does not negatively contribute to death censored posttransplant 
graft outcome, old-for-old allocation could become interesting. Between 1994 and 2006 
some organ procurement organizations in the USA have practiced old-for-old kidney 
allocation.84 When we correlated donor age with recipient age, however, we found that in 
the time period studied such policies did not exist on a large scale. An important rationale 
for senior recipient exchange policies is that a transplanted kidney which outlives its recipient 
can be considered a success. Theoretically, it would be expected that the disadvantage of 
receiving an older kidney is less severe in aged recipients, since they have a higher chance 
of dying before the relatively short lifespan of their graft is over. Conversely, kidney grafts 
derived from younger donors would be expected to have a higher yield in younger recipients, 
as these patients would make more use of the longer lifespan that a young graft has to offer. 
Although both effects mentioned above were observed in our simulation, the net effect of 
implementing an old-for-old allocation program in terms of total functional graft time gained 
or lost would most likely be close to zero. Our analysis did show that 65+ grafts will function 
equally well in non-HLA matched older recipients, compared to their performance in HLA 
matched younger patients. The simulated data suggest that it could be safe to sacrifice HLA 
matching for obtaining shorter CITs and – perhaps even more important – reducing waiting 
times of selected senior transplant candidates. Results of the ESP show that the system also 
significantly reduced discard rates of aged donor kidneys,85 but it is difficult to predict whether 
the same would happen in the USA, since the exact reasons for current high kidney discard 
rates remain elusive. As a side effect, allocation of kidney grafts derived from relatively young 
donors to relatively young recipients may even further improve outcomes for this group. 
We found that re-transplantation is associated with a marked increase in the risk of graft 
failure. This may be a good reason to give longer-lasting kidneys to longer-living patients, in 
order to keep the number of re-transplants as low as possible for recipients in this group. Our 
calculations also showed that advanced donor age puts a recipient more at risk for death with 
a functioning graft. Although the magnitude of this effect does not differ between old and 
young recipients, an old-for-old policy might imply that the average patient survival of older 
recipients decreases, whereas patient survival will increase with the same amount in younger 
recipients. Such potential shifting of life years from one group to another is likely to cause 
serious ethical dilemmas for policy makers. It is difficult to predict whether a shorter time 
on dialysis for older patients will balance or even outweigh this survival disadvantage, but 
reports from existing old-for-old programs suggest that the algorithm can be implemented 
without compromising graft and patient survival.76,78,84-89 Nevertheless, only 3% of all 
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kidney transplants in our study’s cohort came from donors aged 65 years and older. If a senior 
recipient allocation program is to make any difference on overall renal transplant outcome, 
older kidney utilization rates in the USA would probably have to become substantially higher. 
Presently, introducing such a new algorithm seems to be much effort for only a very small 
percentage of the transplant population, with a net benefit which is likely to be nearly zero.
A possible limitation of our old-for-old analysis is that part of it is inevitably bas ed on 
theoretical assumptions about the survival conduct of a graft in its recipient. However, all 
calculations are also based on real donor kidneys and real recipients in the OPTN database, 
with many of their relevant characteristics taken into account by means of a Cox model. 
Formal mathematical sensitivity analyses are beyond the scope of this paper, but our model 
did replicate the overall real graft survival curve with a high accuracy. This suggests that 
the simulated survival curves are likely to reliably predict clinical reality. Another potential 
limitation is our assumption that old-for-old allocation would decrease CIT for 65+ kidneys in 
the USA with the same amount as it did in Eurotransplant. It remains to be seen whether this 
is true, since the current American ECD program already accounts for a relatively short CIT 
when donor age is above 60.
In summary, our results show that deceased donor age is a strong predictor of inferior 
short- and long-term outcome after kidney transplantation for the whole range of donor ages 
from 11 years and above. When it is taken into account that older donor grafts are subjected 
to an exceptionally strict quality selection in the USA,79 the real biological adverse effect of 
donor age on outcome may even be more pronounced. As a result of this selection, kidney 
graft utilization rates from old donors are very low, with discard rates up to 66.9% for 65+ 
donors. Even with such high kidney discard in older donors, the risk of DGF, early and late 
graft failure increases for each subsequent year of donor age. Provided that the average 
CIT of 65+ kidneys would decrease with a few hours by abandoning HLA matching, broad 
implementation of old-for-old kidney allocation in the USA is likely to be safe and could be a 
tool to reduce waiting time for older patients. However, our simulation suggests that it will 
not necessarily improve the overall outcome after kidney transplantation.
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SUPPLEMENTARY APPENDIX
Old-for-old simulation methodology
We followed the approach outlined in the figure below (Fig. 4a in the article) to simulate graft 
survival, as if an old-for-old allocation program had been employed in the time period studied. 
Old-for-old matching was performed following the Eurotransplant Senior Program (ESP) 
allocation rules: Donor and recipient age ≥65 years, only recipients with no prior transplants, 
recipient panel reactive antibodies (PRA) ≤5%, no human leukocyte antigen (HLA) matching, 
and a policy to keep cold ischemic time (CIT) relatively short. For our old-for-old simulation, 
CITs of 65+ grafts were artificially reduced by a factor 12/19, thus mimicking the effect 
observed in the ESP:
For each existing or newly matched donor kidney + recipient combination, a theoretical graft 
survival time was calculated, following the methodology outlined below.
In Cox proportional hazards analysis, the model is given by:
[1] 
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where H(t) is the hazard function for a given set of covariates with their respective values, 
H0(t) is the baseline hazard function (the hazard function when all covariates are at their 
baseline value), bi is the i-th regression coefficient, and xi is the value of the i-th covariate in 
the Cox model. The hazard function can be converted into a survival function:
[2] 
This also implies that the baseline survival function (the survival function when all covariates 
in the Cox model are at their baseline value) will be:
[3] 
Using SPSS, we derived the actual baseline survival function data points underlying a Cox 
model for graft failure in our dataset. These data points were plotted in a graph:
y = 0,9964e-0,017x 
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ﬁtted line y=a*exp(-cx)
Based on the shape of this graph, and on established knowledge about survival analysis in 
organ transplantation, we estimated that the baseline survival function would follow an 
exponential course:
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[4]   
where t is time posttransplant. Values for a and c were derived by means of a least square fit 
to the baseline survival data points derived from this Cox model (black fitted line in figure 
above, with values for a and c shown in the fitted formula, upper right corner). Next, a 
survival function was obtained for each existing or newly matched combination by combining 
equations [1], [2], and [3]:
[5]    
where bi is the i-th regression coefficient and xi is the value of the i-th factor in the Cox 
model. However, to construct a Kaplan-Meier graft survival curve for the whole group of 
newly matched pairs, we needed a distinct time-to-failure for each new case, not a survival 
function. By combining equations [4] and [5], an equation for graft survival time (time-to-
failure) of any donor kidney + recipient combination was derived:
[6]    
where s is a random number between 0 and 1 generated for each recipient, and T is the 
simulated time-to-failure for the graft. The random number s can be understood as follows: 
By converting equations [4] and [5] from S(t) into T(s) (by simple algebraic inversion), equation 
[6] was obtained. Graphically, this can be visualized as switching both axes of the survival 
plot. The number s would actually represent the survival probability (possible range 0-1) for 
this particular new case at a given time posttransplant. Since time is now a function of the 
survival probability, this survival probability s needs to be filled in into equation [6] to obtain 
a time-to-failure for this case. If a probability needs to be filled in, there is no reason why any 
particular value between 0 and 1 would be favoured more than another. Therefore, for each 
simulated new case, we generated a random number between 0 and 1 for s and filled in this 
number into equation [6]. Doing so yielded a simulated time-to-failure for this particular case. 
The basis for this calculation is pure chance, but then this chance is “weighed” by the shape of 
the survival curve for this unique case, defined by the weight of all individual risk factors that 
apply for this newly matched donor kidney and recipient pair.
Using the calculated time-to-failure value of each new case, the simulated Kaplan-Meier 
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ABSTRACT
Kidneys recovered from donation after cardiac death (DCD) are increasingly used to enlarge 
the deceased donor pool. Such renal grafts, especially those derived from uncontrolled DCD, 
have inevitably sustained profound warm ischemic injury, which compromises posttransplant 
function. Normothermic recirculation (NR) of the deceased donor’s body before organ cooling 
could be an interesting approach to mitigate the detrimental effect of warm ischemia. To 
date, however, there is no evidence coming from preclinical studies to support the principle of 
NR in kidney transplantation. In this study, we subjected 48 Lewis rat kidneys to 15 or 30 min 
of warm ischemia, and subsequently 0, 1, or 2 h of NR. After 24 h cold storage kidneys were 
transplanted into a recipient animal and 24 h later we measured the percentage of cortical 
necrosis, and determined gene expression of heme oxigenase-1, heat shock protein-70, 
transforming growth factor-β, kidney injury molecule-1, interleukin-6, hypoxia inducible 
factor-1α, monocyte chemoattractant protein-1, and α-smooth muscle actin in kidney 
tissue. We found that NR had no significant influence on any of these markers. Therefore, we 
conclude that this preclinical study by no means supports the presumed beneficial effect of 
NR on kidneys that have been severely damaged by warm ischemia.
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INTRODUCTION
To partially resolve the persistent donor organ shortage, kidneys recovered from donation 
after cardiac death (DCD) are increasingly used to enlarge the deceased donor pool. Compared 
to renal grafts recovered from donors after brain death, DCD kidneys have by definition 
sustained additional injury due to warm ischemia (WI) between cardiocirculatory arrest and 
cold organ perfusion. Although the duration of WI varies among the different types of DCD 
donors, recipients of such kidneys are known to have a substantially increased risk of delayed 
graft function and primary non-function, especially when WI has been very profound such as 
in uncontrolled DCD.90
Most established organ preservation protocols are based on rapid cooling immediately 
after cardiac arrest, followed by organ procurement and either static cold storage or 
hypothermic machine perfusion of the kidney graft.91 To mitigate the detrimental effect of 
warm ischemia, some studies have suggested the use of normothermic recirculation (NR) 
before organ cooling is instituted. NR is an early organ preservation strategy, in which the 
deceased donor’s body is artificially recirculated with warm oxygenized blood quickly after 
the declaration of cardiocirculatory death, for a limited period of time such as one or two 
hours. NR is typically administered through an extracorporeal membrane oxygenator, 
connected to a closed circuit with cannulae in the femoral vessels of the deceased donor.92 A 
few studies have reported beneficial effects of this strategy on posttransplant graft function 
and survival. Most of these reports focus on NR prior to DCD liver transplantation.39,92,93 So 
far, only one published clinical study presented results of NR in renal transplantation.39,94 
The authors reported a significant reduction of delayed graft function and an improved graft 
survival after transplantation when NR was compared with a protocol in which organs were 
immediately cooled. To our knowledge, the Hospital Clínic in Barcelona, Spain – the group that 
published these data – is the only center worldwide with a clinical NR protocol for potential 
uncontrolled (Maastricht category I and II)13 DCD donors.
Before a novel preservation strategy such as NR can be widely implemented in human 
renal transplantation practice, more basic evidence is needed to quantify the magnitude of 
its presumed effect and to unravel the mechanism through which NR could be beneficial to a 
DCD kidney graft. To date, there is no evidence coming from preclinical studies to support the 
principle of NR in kidney transplantation. We have conducted an animal study to investigate 
the potential of NR to reduce WI injury in a standardized renal transplantation model. Aim of 
the present study was to determine whether NR can reduce the amount of tubular necrosis 
after transplantation, and whether NR influences the expression of genes that are involved 
in renal damage, inflammation, interstitial fibrosis formation, cytoprotection, and tissue 
regeneration in kidneys that have sustained severe warm ischemic injury in the donor.
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METHODS
Animals and housing
Ninety-six adult male Lewis rats weighing 250–300g, obtained from Harlan (Zeist, The 
Netherlands) were used as kidney donors (n=48) and recipients (n=48). Before surgery, 
animals were kept in standard polycarbonate housing (model 1354F, Tecniplast, Buguggiate, 
Italy), with a maximum of four animals together in one cage. After surgery, recipient animals 
were housed individually in the aforementioned polycarbonate housing. Throughout the 
experiment, all animals were allowed free access to a standard laboratory animal diet and 
acidified tap water. All experimental procedures were approved by the animal experiment 
committee of the University of Groningen, and the principles of laboratory animal care (NIH 
publication no. 85-23, revised 1985), as well as regulations imposed by the Dutch law on 
animal experiments were followed.
Experimental design
We employed a syngeneic Lewis to Lewis rat renal transplant model with orthotopic 
transplantation of the left donor kidney, leaving the recipient’s native right kidney in situ. 
Renal grafts in six experimental groups (eight transplants per group) received either 15 or 
30 min of WI, followed by either no NR, 1 h NR, or 2 h NR, and subsequently 24 h cold 
storage (CS) preservation and transplantation into a recipient animal. Recipient animals were 
sacrificed exactly 24 hours posttransplant. Experimental groups were as follows:
Group 1: 15 min WI – no NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
Group 2: 30 min WI – no NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
Group 3: 15 min WI – 1 h NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
Group 4: 30 min WI – 1 h NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
Group 5: 15 min WI – 2 h NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
Group 6: 30 min WI – 2 h NR – 24 h CS – transplantation – 24 h reperfusion in the recipient
We chose 15 and 30 min for the duration of WI time, since we had previously demonstrated 
that the combination of 15 min WI and 24 h CS results in a seriously damaged kidney graft, 
leading to delayed graft function after transplantation.95 Since NR is most interesting in the 
uncontrolled DCD (Maastricht categories I and II) setting which leads to severely damaged 
kidneys, we deliberately chose not to test the method on kidneys that have sustained only 
mild ischemic injury. We added the duration of 30 min WI to provide for an even heavier 
variant of this DCD animal model. We chose 1 h and 2 h for the duration of NR, as these 
seem realistic times to apply NR in the human setting, which are also comparable to the time 
periods that the Barcelona group reports for NR in their center.
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Donor operation and organ preservation
After induction of inhalation anesthesia with 5% isoflurane/oxygen, donor animals received 
250 IU heparin via the penile vein. Through a midline incision, the left kidney, both renal 
vessels, and the ureter were isolated. The left renal artery and vein were subsequently 
clamped for 15 min or 30 min to induce WI. In stated experimental groups NR was induced 
by removal of the clamps and reperfusion of the left kidney for 1 or 2 h. Next, a ligature was 
placed around the aorta, superior to the right renal artery, to prevent flushing of the liver and 
intestine. The inferior caval vein was cut and both kidneys were flushed by inserting a 20G 
needle into the aortic bifurcation and infusing 10 ml of 0.9% NaCl at 37 °C, directly followed 
by 10 ml of University of Wisconsin (UW) organ preservation solution at 4 °C. Glutathione 
(0.922 mg/ml) was freshly added to the UW solution. Immediately upon flushing, the left 
kidney was removed. Donor kidneys were preserved during exactly 24 h by means of static CS 
at 0–4 °C, submerged into 25 ml of UW solution with added glutathione.
Recipient operation
After induction with 5% isoflurane/oxygen, maintenance inhalation anaesthesia with 3% 
isoflurane/oxygen was used. Orthotopic kidney transplantation was performed on the left 
side: First, the native left kidney was removed after clamping both renal blood vessels. The 
graft renal artery was anastomosed end-to-end to the recipient’s renal artery using eight 
interrupted Dafilon® 10-0 (B.Braun) non-absorbable sutures, and the graft renal vein was 
anastomosed to the recipient’s renal vein with a running suture of the same material. 
Vascular anastomosis time was standardized to exactly 25 min for each procedure. The graft 
ureter was anastomosed end-to-end to the recipient ureter using four interrupted sutures. 
The abdominal fascia and skin were closed in layers with two separate absorbable Safil® 
4-0 (B.Braun) running sutures. Analgesia was managed subcutaneously with buprenorfine: 
Animals received 0.01 mg/kg during surgery, 0.04 mg/kg immediately after transplantation, 
and 0.05 mg/kg 10-12 hours post surgery. An electric warming blanket was placed under 
the cage floor to prevent hypothermia in the first hours after surgery. At exactly 24 h 
posttransplant, recipient animals were sacrified by exsanguination under anesthesia.
Sample collection and analysis
At termination, the donor kidney was collected and one tissue sample was fixed in 4% 
formalin for histological examination. Another tissue sample was immediately snap frozen 
in liquid nitrogen. Histological slices were stained by the periodic acid-Schiff (PAS) method 
and were quantitatively assessed for cortical necrosis. Digital images of each slice were taken 
and Aperio ImageScope software was used to calculate the percentage cortical necrosis 
as the quotient of the necrotic cortical area and the total cortical area. Figure 1 shows a 
representative example of the scoring method.
Real-time quantitative RT-PCR (qPCR) analysis of heme oxigenase-1 (HO-1), heat shock 
protein-70 (HSP-70), transforming growth factor-β (TGF-β), kidney injury molecule-1 (KIM-1), 
56  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
interleukin-6 (IL-6), hypoxia inducible factor-1α (HIF-1α), monocyte chemoattractant 
protein-1 (MCP-1), and α-smooth muscle actin (α-SMA) gene expression was performed to 
detect cytoprotection (HO-1 and HSP-70), tissue regeneration (TGF-β), renal tubular injury 
(KIM-1), aspecific inflammation (IL-6, HIF-1α, and MCP-1), and early signs of interstitial 
fibrosis (α-SMA) 24 h after transplantation. Amplification primers (Table 1) were designed 
with Primer Express software (Applied Biosystems, Foster City, CA, USA) and validated in 
a 6-step twofold dilution series. RNA was extracted from snap frozen tissue using TRIzol 
(Invitrogen, Breda, the Netherlands). Total RNA was treated with DNase I, Amp Grade 
(Invitrogen). cDNA synthesis was performed from 1 μg total RNA using T11VN oligos and 
M-MLV Reverse Transcriptase, according to supplier’s protocol (Invitrogen). Amplification and 
detection were performed with the ABI Prism 7900-HT Sequence Detection System (Applied 
Biosystems) using emission from SYBR Green (SYBR Green master mix, Applied Biosystems). 
All assays were performed in triplicate. After an initial activation step at 50 °C for 2 min and a 
hot start at 95 °C for 10 min, qPCR cycles consisted of 40 cycles of 95 °C for 15 sec and 60 °C 
for 60 sec. Gene expression was normalized with the mean of β-actin mRNA content and 
calculated relative to healthy controls. Results were expressed as 2–ΔCT (CT threshold cycle).










Table 1: Primers used for qPCR analyses.
Statistics
To minimize the number of animals required per group, a 2x3 between-subjects factorial 
design was constructed in which the levels of two independent variables (WI time 15 or 30 
min, and NR time 0, 1, or 2 h) were varied among the six groups. Using Mead’s formula for 
sample size estimation in factorial designs, we calculated that a minimum of five animals per 
group would be required to obtain adequate statistical power. Some interaction between WI 
time and NR time could be assumed, and variances could be different among the six groups. In 
addition, prior experience showed that in 15-20% of the transplants a technical complication 
would occur. Therefore, we determined that the initial number of animals per group should be 
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eight. Statistical analyses were performed with SPSS software, version 18. One-way ANOVAs 
were performed which tested whether the dimensions WI time and NR time significantly 
influenced each of the nine dependent variables (cortical necrosis, and the expression of eight 
genes) after transplantation, and whether there was any significant interaction between WI 
time and NR time. In case a significant effect of NR time was found for a certain dependent 
variable, we used Turkey’s post-hoc test to determine between which of the three levels of NR 
time the significant difference existed. Since none of the independent variables were normally 
distributed, all values were transformed to ranks before being entered into the analyses. Two-
sided p-values below 0.05 were considered to indicate statistical significance.
Dependent variable P-value for WI P-value for NR









Table 2: P-values resulting from the one-way ANOVAs which tested whether either warm ischemic time, 
or normothermic recirculation time significantly influenced each dependent variable.
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Figure 1: Representative example of the cortical necrosis scoring method. Histological slices were stained 
by the periodic acid-Schiff (PAS) method and were quantitatively assessed. Digital images of each slice 
were taken and Aperio ImageScope software was used to calculate the percentage cortical necrosis as the 
quotient of the necrotic cortical area and the total cortical area. Overview of a kidney at 10x magnification 
(a), and a more detailed view at 50x magnification (b). The total cortical area and the necrotic sections are 
encircled with black lines. In panel (b), the necrotic area on the lower left hand side is bounded by a black 
line, on the other side of which vital cortical renal tissue can be seen.
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RESULTS
In nine out of 48 transplants (19%), technical complications occurred, which were mostly 
related to inadequate vascular flushout in the donor and/or leakage or occlusion of the 
vascular anastomosis in the recipient. These nine cases were excluded from further analysis. 
Exclusions led to a median of seven animals per experimental group. In the remainder of 
procedures, all recipient animals survived until sacrifice at 24 h after transplantation.
Cortical necrosis
Figure 2a shows a plot of the percentage cortical necrosis for each individual transplant, 
categorized per experimental group. In all groups, we found profound cortical necrosis 24 h 
after transplantation with an overall median of 65% (interquartile range 37–86%) of the total 
renal cortical area. In kidneys that had sustained 15 min of WI, the median cortical necrotic 
area was 43% (interquartile range 34–71%), whereas renal grafts with 30 min of WI in the 
donor had a significantly higher median cortical necrotic area of 82% (interquartile range 
43–95%; P=0.01). In contrast, NR did not have any significant effect on the percentage of 
cortical necrosis after transplantation: In kidneys that underwent no NR the median cortical 
necrotic area was 71% (interquartile range 35–92%) 24 h posttransplant, and for kidneys 
that were treated with 1 h or 2 h of NR this figure was 53% (interquartile range 36–74%) and 
76% (interquartile range 41–95%), respectively (p=0.34). There was no significant interaction 
between WI time and NR time (p=0.25) for the dependent variable cortical necrosis.
Figure 2a
acortical necrosis



















Figures 2b–i present the results of qPCR analyses for each individual transplant, categorized 
per experimental group. Overall, the expression of genes that are involved in cytoprotection, 
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tissue regeneration, tubular injury, inflammation, and interstitial fibrosis was only minimally 
influenced by WI time and/or NR time. For some markers (KIM-1, HIF-1α, and IL-6), WI 
time seemed to have a mild influence on gene expression 24 h posttransplant, but none 
of the tests passed the p<0.05 threshold to be qualified as statistically significant (p=0.10, 
p=0.10, and p=0.13, respectively). Only for HO-1 NR time had a significant influence on gene 
expression 24 h after transplantation (p=0.01). In the post-hoc test, this effect was explained 
by the difference between no NR and 1 h NR (p=0.02), and not by the difference between 1 
h and 2 h of NR (p=0.19). For all other markers tested, NR did not significantly influence gene 
expression in the kidney graft 24 h posttransplant.
Figure 2b-i
HO-1 expression
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TGF-β expression
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HIF-1α expression
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Figure 2: Percentage of cortical necrosis in kidney grafts 24 h after transplantation (a), and the expression 
of heme oxigenase-1, heat shock protein-70, transforming growth factor-β, kidney injury molecule-1, 
interleukin-6, hypoxia inducible factor-1α, monocyte chemoattractant protein-1, and α-smooth muscle 
actin 24 h after transplantation (b–i). Each black dot represents a single case, and horizontal lines indicate 
median values per experimental group.
DISCUSSION
Interventions that aim at better preserving donor organ quality prior to transplantation are 
becoming increasingly important in an era with more marginal deceased donor grafts in 
the pool96,97. Normothermic recirculation immediately after cessation of cardiopulmonary 
resuscitation measures was initially instituted by the group of the Hospital Clínic in Barcelona, 
Spain to gain extra time to obtain the compulsory judicial permission for uncontrolled 
(Maastricht category I and II) DCD organ donation.92 As a side effect, clinicians observed an 
improved early function of those renal grafts that had been subjected to NR in the donor, 
compared to kidneys that came from donors whose organs were immediately cooled when 
cardiopulmonary resuscitation was stopped, with 12.5% versus 75% delayed graft function 
incidence).39,94 These findings, together with favorable results of DCD liver transplantation 
after NR (posttransplant course of uncontrolled DCD livers after NR comparable to that 
of livers recovered from DBD donors without NR), have led to the hypothesis that NR may 
somehow resuscitate a DCD donor kidney that has been exposed to severe WI injury.98 
However, to date, the mechanism as well as the magnitude of its postulated effect remains to 
be unraveled. Interestingly, NR is already clinically utilized at a small scale, although there is 
no convincing preclinical evidence which supports its principle and/or effectiveness. The aim 
of the present study was to provide a first piece of such evidence. Much to our surprise, we 
could not find any indication that NR will somehow protect or resuscitate renal grafts that 
have sustained profound WI injury. Therefore, the present study does not support the scarce 
evidence which suggested that NR could have a beneficial effect on kidneys recovered from 
uncontrolled DCD.
Apart from merely being a preclinical study in a standardized animal model, this study 
has a few other relevant limitations that should be considered when translating our findings 
to the human clinical setting. First, in our model WI injury was induced by clamping the 
renal vessels after systemic heparinization, which is not fully comparable with cardiac arrest 
followed by cardiopulmonary resuscitation and cessation of such measures as it occurs in 
human uncontrolled DCD.40 We chose not to employ a genuine cardiac arrest model, because 
we wanted to focus on the effect of NR after a clear-cut duration of real WI, avoiding the more 
complex situation of slowly worsening hypoxia, hypotension, and the associated systemic 
neurologic and humoral responses that could all have their own isolated effect on the kidney 
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graft. In addition, we needed a physiologically intact circulation in the donor animal for NR 
after WI. We employed an auto-NR model, since artificial warm and oxygenated recirculation 
of small rodents is technically challenging and therefore likely to introduce more variation 
in our model. A second limitation is that our study lacks functional end points in terms of 
renal function or graft survival after transplantation. To obtain such data, recipient animals 
need to stay alive for at least a few weeks posttransplant and the native contralateral kidney 
of the recipient would have to be removed at the same moment when the donor graft is 
implanted, or shortly after, to be able to measure early renal function of only the transplanted 
kidney. Normally, with donor kidneys that have sustained only minimal injury, an orthotopic 
renal transplant model with native contralateral nephrectomy is easily applicable and rather 
stable.99 However, for the present study donor kidneys needed to be severely damaged. Hence, 
most kidneys would develop delayed graft function in the first days after transplantation. 
Without a native contralateral kidney in situ, most animals would die of uremia soon after 
transplantation, or become unacceptably ill in those first days.95 Dialysis of small rodents is 
technically very complex and would introduce too much variation in our data. With a native 
contralateral kidney in situ, as in our model, reliable isolated measurement of graft function 
is impossible. As a consequence, this study lacks functional end points.
Another limitation of this study could be that we have possibly chosen a too heavy 
model of WI injury, which rendered most kidneys in a condition that was beyond any recovery. 
Thus, we may have missed a potential beneficial effect of NR because renal grafts in our 
study sustained too much damage to be repaired by this intervention. However, even though 
NR might show some measurable effects in kidneys that are only minimally injured, it is a 
logistically challenging and rather costly method in humans. We feel that its application is 
only warranted when NR would lead to a significant improvement of severely damaged donor 
grafts, which would otherwise not be sufficiently suitable for transplantation.
An earlier preclinical study by Net et al showed that, in DCD liver transplantation, the effect 
of NR could be mediated by a form of ischemic preconditioning.93 Although proven to be 
protective against ischemia/reperfusion injury in liver transplantation, ischemic precondition 
does not seem to have such an effect on kidney grafts.100 This may in part explain why NR 
does reduce ischemia/reperfusion related injury in DCD liver grafts, but the method does not 
significantly protect and/or resuscitates ischemically damaged kidneys.
It is well established that although ischemia itself does lead to tissue injury, subsequent 
reperfusion will cause even more damage through a multitude of pathways including acute 
aspecific inflammation and the detrimental effect of reactive oxygen species.33,101,102 A donor 
procedure with NR, followed by transplantation of the kidney will follow the sequence warm 
ischemia – warm oxygenized reperfusion – cold ischemia – warm oxygenized reperfusion and 
therefore has two instead of just one potentially detrimental episodes of reperfusion. As a 
consequence, NR might even lead to more instead of less ischemia-reperfusion related kidney 
injury. In our study, donor kidneys after 30 min of WI and 2 h of NR had significantly more 
cortical necrosis than renal grafts that had also sustained 30 min of WI, but underwent only 1 
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h of NR. This finding carefully supports the hypothesis that a long period of NR after profound 
WI could actually be detrimental to a kidney graft. In addition, in the human setting NR would 
most likely reperfuse a substantial part of the donor’s body, all of which has endured WI. In 
contrast to our animal model in which only the kidney sustained WI, a human DCD kidney 
would also be exposed to circulating inflammatory mediators and oxygen free radical that are 
released upon warm reperfusion of the intestine and the liver.
In conclusion, the present preclinical study could not show any beneficial effect of 
normothermic recirculation in terms of more cytoprotection, elevated tissue regeneration, 
less interstitial fibrosis formation, a lower level of aspecific inflammation, or a decreased 
percentage of tubular necrosis in transplanted kidneys that had sustained severe warm 
ischemic injury in the donor. Our data do have several relevant limitations which preclude 
a direct translation to the human clinical setting. Nevertheless, this study by no means 
supports the concept of normothermic recirculation for DCD kidneys. We feel that more 
preclinical evidence is needed before this method can be implemented in human uncontrolled 
DCD, as neither the mechanism nor its effectiveness have been proven and the method might 
even be detrimental to renal grafts.
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ABSTRACT
Background
Static cold storage is generally used to preserve kidney allografts from deceased donors. 
Hypothermic machine perfusion may improve outcomes after transplantation, but few 
sufficiently powered prospective studies have addressed this possibility.
Methods
In this international randomized, controlled trial, we randomly assigned one kidney from 
336 consecutive deceased donors to machine perfusion and the other to cold storage. All 
672 recipients were followed for 1 year. The primary end point was delayed graft function 
(requiring dialysis in the first week after transplantation). Secondary end points were the 
duration of delayed graft function, delayed graft function defined by the rate of the decrease 
in the serum creatinine level, primary nonfunction, the serum creatinine level and clearance, 
acute rejection, toxicity of the calcineurin inhibitor, the length of hospital stay, and allograft 
and patient survival.
Results
Machine perfusion significantly reduced the risk of delayed graft function. Delayed graft 
function developed in 70 patients in the machine-perfusion group versus 89 in the cold-
storage group (adjusted odds ratio, 0.57; P=0.01). Machine perfusion also significantly 
improved the rate of the decrease in the serum creatinine level and reduced the duration 
of delayed graft function. Machine perfusion was associated with lower serum creatinine 
levels during the first 2 weeks after transplantation and a reduced risk of graft failure (hazard 
ratio, 0.52; P=0.03). One-year allograft survival was superior in the machine-perfusion group 
(94% vs. 90%, P=0.04). No significant differences were observed for the other secondary end 
points. No serious adverse events were directly attributable to machine perfusion.
Conclusions
Hypothermic machine perfusion was associated with a reduced risk of delayed graft function 
and improved graft survival in the first year after transplantation.
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INTRODUCTION
Two different forms of organ preservation — static cold storage and hypothermic machine 
perfusion — are used clinically for renal allografts obtained from deceased donors. In static 
cold storage, the kidney is flushed, cooled with one of several cold preservation solutions, 
and transported on ice. In hypothermic machine perfusion, after an initial washout of 
blood, the kidney is connected to a perfusion device, and a solution is pumped continuously 
through the renal vasculature at temperatures between 1 and 10°C.54 The typical deceased 
kidney donor today is older and has been exposed to more concomitant disease than 
donors were several decades ago; these factors may have a detrimental effect on allograft 
quality.2,18 In addition, the use of organs received from donors after cardiocirculatory death 
is increasing in most countries.40 Such allografts are known to have significantly higher 
rates of delayed graft function.40,52 Evidence suggests that organs that do not function 
immediately after transplantation have an increased risk of acute rejection, and allograft 
survival may be inferior.31,103 In addition, delayed graft function increases the costs of 
kidney transplantation.104,105 Retrospective studies have suggested that machine perfusion 
could result in a better short-term outcome, with lower rates of delayed graft function after 
transplantation of kidneys from all types of deceased donors.46,105,106 Therefore, interest in 
machine perfusion is increasing. Our international randomized, controlled trial compared 
machine perfusion with cold-storage preservation in deceased-donor kidney transplantation 
with a primary end point of delayed graft function.
METHODS
Study design
This investigator-driven, international randomized, controlled study included the 
Netherlands, Belgium, and the federal state of North Rhine–Westphalia in Germany. All 
consecutive deceased-donor kidney pairs identified in these regions that met the initial 
inclusion criteria were eligible for randomization by Eurotransplant, the international organ-
exchange organization of Austria, Belgium, Croatia, Germany, Luxemburg, the Netherlands, 
and Slovenia (Croatia became a member after the present study was completed). Since we 
aimed to include the whole spectrum of deceased donors, no previous selection of donor 
types to be included was made. Thus, the study reflects the effect of machine perfusion as 
compared with cold storage in everyday practice within an international organ-exchange 
organization. From each donor, one kidney was randomly assigned to machine perfusion and 
the contralateral organ to cold storage. The organ could be transplanted into any recipient 
within the Eurotransplant region.107 Approval for the study was obtained from the ethics 
review boards in each trial region and from the Eurotransplant Ethical Advisory Committee 
and Kidney Advisory Committee. Since the random assignment of kidneys to a preservation 
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method was limited to organs isolated before transplantation, no informed consent from 
recipients was required for this intervention.
An independent scientific steering committee composed of clinicians and scientists from 
each trial region was solely responsible for the design, conduct, data analysis, and manuscript 
preparation for this study.
Inclusion and exclusion criteria
Organ donors had to be 16 years of age or older. Only kidney pairs from deceased donors were 
included in the study, either from donation after brain death or donation after cardiocirculatory 
death. The category for donors without a heartbeat had to be Maastricht category III (awaiting 
cardiocirculatory death after withdrawal of treatment) or IV (cardiocirculatory death in a 
brain-dead donor).13 Kidney pairs were included only if both organs were actually transplanted 
into two different recipients. If one kidney was transplanted into the same recipient together 
with another organ, this kidney pair was excluded. The only exclusion criterion for recipients 
was the death of the patient in the first week after transplantation, since a follow-up of at 
least 1 week was required to determine the primary end point.
Randomization
A randomization scheme based on permuted blocks within regions was used with separate 
randomization lists for each trial region. A detailed description of the randomization process 
is available in the Supplementary Appendix, available with the full text of this article at NEJM.
org. Surgical teams were allowed to switch preservation methods only if the kidney assigned 
to machine perfusion had an aortic patch that was too small or if it had too many renal 
arteries for a reliable connection to the machine-perfusion device; this switch in preservation 
methods changed the initial randomization.
Logistics
In each trial region, a team of trained perfusionists was on hand 24 hours per day, 7 days per 
week to respond when a donor became available. The perfusionists transported the machine-
perfusion device to the donor hospital and assisted donor surgeons with connecting one 
kidney to the machine. No changes were made to the existing Eurotransplant rules for organ 
allocation or to transportation protocols. Kidneys that underwent machine perfusion as well 
as those that were preserved with cold storage were transported to their respective recipient 
center without any monitoring.
Hypothermic machine perfusion
LifePort Kidney Transporter machines (Organ Recovery Systems) were used for perfusion, 
delivering a pulsatile flow of University of Wisconsin machine preservation solution (Kidney 
Preservation Solution-1)108 at 1 to 8°C, with no changes in perfusion settings throughout the 
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preservation period. The systolic perfusion pressure was fixed at 30 mm Hg, and the kidneys 
underwent machine perfusion from organ procurement until transplantation. To prevent bias 
in clinical decisions about transplanting or discarding an organ, intravascular resistance and 
flow readings were never revealed to the transplantation team.
Cold storage
No changes were made to the standard cold-storage protocols. After an initial vascular 
washout, kidneys were submerged in the preservation solution and stored on melting ice, 
according to the established Eurotransplant routine.
Data collection
Follow-up data were provided by each participating transplantation center through a secure 
online database hosted by Eurotransplant. A random sample of 10% of all patients was 
audited externally; no relevant irregularities were found.
Study end points
The primary end point was delayed graft function, defined as the requirement for dialysis 
during the first week after transplantation. The secondary end points were the duration of 
delayed graft function, primary nonfunction (permanent lack of function of the allograft 
from the time of transplantation), the area under the curve of the daily serum creatinine level 
at days 1 to 14, the creatinine clearance at day 14, biopsy-proven acute rejection, toxicity of 
the calcineurin inhibitor, the length of the recipient’s hospital stay, and survival of the graft 
and patient up to 1 year after transplantation. Data on graft survival were censored at the 
time of death in patients who died with a functioning allograft. In addition to the primary 
end point, which was defined in terms of the requirement for dialysis after transplantation, 
we also examined delayed graft function as a secondary end point. This secondary end point, 
functional delayed graft function, was defined in terms of the absence of a decrease in the 
serum creatinine level of at least 10% per day for at least 3 consecutive days in the first 
week after transplantation, not including patients in whom acute rejection, toxicity of the 
calcineurin inhibitor, or both developed within the first week.109 All end points described 
above were prespecified in the study protocol, except primary nonfunction, which was added 
post hoc.
Statistical analysis
This study was powered to detect a reduction in delayed graft function of at least 10%, based 
on a presumed incidence of 35% among recipients of kidneys that had been preserved by 
means of cold storage. With a statistical power of 0.8 and a one-sided type I error of 0.05, 
the minimum required sample size was 300 kidney pairs; this is equivalent to the required 
sample size for a logistic-regression analysis with a two-sided type I error of 0.05 and similar 
power.110 The primary analysis of the primary end point — delayed graft function — consisted 
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of a logistic-regression model, which examined whether machine perfusion as compared 
with cold-storage preservation, in the context of other relevant factors, influenced the risk 
of delayed graft function.31,111 Covariates for this model (see the Supplementary Appendix) 
were prespecified in the study protocol and were based on relevant literature.112,113 The 
final model was determined by entering all covariates together in the analysis, with a built-
in normal gamma frailty term for the donor to account for the paired study design.114 For 
end-point variables, univariate differences between the groups were assessed with the use 
of McNemar’s test or the Wilcoxon signed-rank test. For demographic variables, differences 
were assessed with the use of Fisher’s exact test or the Mann–Whitney test. The Kaplan–
Meier method was used to analyze graft and patient survival. Differences between survival 
curves were determined with the use of log-rank tests. A Cox proportional-hazards model 
was applied to examine which variables significantly influenced the risk of graft failure.77 To 
construct this model, an approach similar to the logistic-regression model for delayed graft 
function was followed.
We performed prespecified subgroup analyses to determine the treatment effect on the 
primary end point according to donation after cardiocirculatory death versus donation after 
brain death and according to expanded-criteria donation versus standard-criteria donation.115 
Expanded-criteria donation was defined as a donor age of 60 years or more or a donor age 
between 50 and 60 years, with at least two of the following additional donor characteristics: 
history of hypertension, death due to a cerebrovascular cause, and a serum creatinine level of 
more than 132 μmol per liter (1.5 mg per deciliter) before removal of the kidney.12 
All reported P values are two-sided and not adjusted for multiple testing. A P value of 0.05 
or less was considered to indicate statistical significance. Analyses were conducted with the 
use of the SPSS, SAS, and R software packages and were based on all organ pairs that met the 
inclusion criteria.
No interim analyses of study end points were carried out. At regular intervals, confidential 
safety analyses were performed by the trial safety board, which compared the reported rates 
of adverse events between the two trial groups. The sponsor was not involved in the conduct 
of the study, the analysis or storage of the data, or the preparation of the manuscript. The 
scientific steering committee vouches for the accuracy and completeness of the data and 
analyses.
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RESULTS
From November 1, 2005, through October 31, 2006, there were 654 potential deceased 
kidney donors 16 years of age or older in the three trial regions. Figure 1 shows a flow 
diagram of the 336 kidney pairs (672 recipients) included in our analysis. In 25 donors (4.6%), 
preservation methods were switched because of the aberrant vascular anatomy of the kidney 
assigned to machine perfusion. Vascular anomalies were not observed to have a significant 
effect on delayed graft function. Aberrant vascular anatomy did not significantly increase 
the risk of graft failure, and the addition of this factor to the Cox model had no effect on the 
hazard ratio for graft failure associated with machine perfusion versus cold storage (see the 
Supplementary Appendix).
The 20 “other reasons for exclusion” of the kidney pairs (Figure 1) were as follows: 12 adverse 
events that occurred during the donor procedure, 5 cases in which the donor had one kidney, 
2 cases in which the consent for kidney donation was withdrawn just before procurement, and 
1 procedure involving a donor after cardiocirculatory death that was planned as a Maastricht 
category III donation but was changed to a Maastricht category II donation (cardiocirculatory 
death after unsuccessful resuscitation).
Study patients
Table 1 summarizes the characteristics of the study groups. All kidneys donated after 
cardiocirculatory death were in Maastricht category III, as defined earlier. There were no 
significant differences between the two groups with regard to relevant baseline characteristics.





group (N  =  336)
Cold-storage  
group (N  =  336) P value*
Donor characteristics
Age (yr)  
Median 51
Range 16–81
Type of donation (no.)   
After brain death 294
After cardiocirculatory death 42
Standard criteria 242  
Expanded criteria 94
Vascular flush solution (no.)








Duration of pretransplantation dialysis (yr)   0.59
Median 4.5 4.4
Range 0.15–18 0.19–24
Previous transplants (%)† 23 21 0.38





Prednisolone 98 99 0.77
Cyclosporine 50 54 0.25
Tacrolimus 49 46 0.39
Azathioprine 1 2 0.18
Mycophenolate mofetil 86 87 0.73
Antithymocyte globulin 14 13 0.82
Interleukin-2 receptor antagonists 42 47 0.18
Transplant characteristics
No HLA mismatches (% with no mismatches at the HLA-A, B,  
or DR loci)
16 15 0.90
Cold ischemic time (hr)   0.30
Median 15.0 15.0
Range 3.5–29.7 2.5–29.7
Allograft with >1 renal artery (%) 20 22 0.51
 





 group (N  =  336)
Cold-storage  
group (N  =  336) P value*
Primary end point  
Delayed graft function (%) 20.8 26.5 0.05
Secondary end points  
Functional delayed graft function (%)‡ 22.9 30.1 0.03
Primary nonfunction (%)§ 2.1 4.8 0.08
Duration of delayed graft function (days) 0.04
Median 10 13
Range 1–48 1–41
 Creatinine clearance at day 14 (ml/min) 0.25
Median 42 40
Range 0–171 0–175
Calcineurin-inhibitor toxicity within 14 days after  
transplantation (%)
6.3 5.7 0.86
Acute rejection within 14 days after transplantation (%) 13.1 13.7 0.91
 Post-transplantation hospital stay (days) 0.78
Median 19 18
Range 4–392 6–382
Table 1: Characteristics of donors, recipients, and transplants and univariate differences between the groups.
*  For baseline characteristics, P values were calculated with the use of Fisher’s exact test for discrete 
variables and the Mann–Whitney test for continuous variables. For end-point variables, P values were 
calculated with the use of McNemar’s test for discrete variables and the Wilcoxon signed-rank test for 
continuous variables.
†  This category was the percentage of recipients who had undergone one or more renal transplantations 
before the transplantation included in this analysis.
‡  Functional delayed graft function was defined as the absence of a decrease in the serum creatinine level of 
at least 10% per day for at least 3 consecutive days in the first week after transplantation. This category 
did not include patients in whom acute rejection, calcineurin-inhibitor toxicity, or both developed in the 
first week. 
§  Primary nonfunction was defined as the permanent lack of function of the allograft from the time of 
transplantation.
Delayed graft function
Delayed graft function occurred in 70 recipients in the machine-perfusion group (20.8%) 
as compared with 89 patients in the cold-storage group (26.5%). Table 2 shows the results 
of analysis using the logistic-regression model. As compared with cold storage, machine 
perfusion significantly reduced the risk of delayed graft function (adjusted odds ratio, 0.57; 
P=0.01).
Subgroup analysis
In September 2006, when enrollment of donors in the study was nearly complete, the 
scientific steering committee expected that an insufficient number of donors would be 
enrolled at trial completion to conduct a meaningful subgroup analysis for donation after 
cardiocirculatory death. At the suggestion of the steering committee and with the permission 
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of all centers, the inclusion of additional donors after cardiocirculatory death was extended 
by an amendment to the protocol, until a total of 82 donors were enrolled on August 17, 
2007 (see the Supplementary Appendix for details). Solely for the subgroup analysis involving 
donation after brain death versus donation after cardiocirculatory death, these inclusions 
were added to the main group of patients to provide more statistical power. Figure 2 shows 
a forest plot of the treatment effect in the prespecified subgroup analyses. In the main data 
set, we found no significant difference in the magnitude of the treatment effect on delayed 
graft function after standard-criteria donation versus expanded-criteria donation (P=0.75) 
and after donation after brain death versus donation after cardiocirculatory death (P=0.42). 
In the extended data set, the effect of the preservation method on delayed graft function did 
not differ significantly between patients who received kidneys from donors after brain death 
versus patients who received kidneys from donors after cardiocirculatory death (P=0.26).
Secondary end points
Functional delayed graft function occurred in 77 recipients in the machine-perfusion group 
and in 101 recipients in the cold-storage group (22.9% vs. 30.1%, P=0.03). The incidence 
of primary nonfunction in the cold-storage group (4.8% vs. 2.1%, P=0.08) was more than 
two times higher than in the machine-perfusion group, but this difference did not reach 
statistical significance. If delayed graft function developed, its duration was 3 days shorter 
after machine perfusion as compared with cold storage (10 days vs. 13 days, P=0.04). There 
were no significant differences between the study groups in creatinine clearance at 14 days 
after transplantation, length of hospital stay of recipients, the incidence of toxicity of the 
calcineurin inhibitor, and acute rejection rate in the first 14 days after transplantation. Daily 
serum creatinine values in the first 2 weeks after transplantation were significantly lower in 
recipients in the machine-perfusion group than in recipients in the cold-storage group (median 
area under the curve, 1456 [range, 385 to 5782] vs. 1787 [range, 288 to 6500]; P=0.01) (see 
Fig. S2 in the Supplementary Appendix).
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543 Kidney pairs underwent randomization
(one kidney to machine perfusion,
contralateral kidney to cold storage)
594 Potential donors were enrolled
51 Were excluded
47 Could not be reached in time
3 Donor centers declined to participate
1 Donor family declined to participate
518 Kidney pairs retained initial randomi-
zation status
25 Preservation methods were switched
184 Kidney pairs were excluded
14 Donor procedures were canceled
25 Donors had one kidney not transplantable
45 Donors had both kidneys not transplantable
80 Donors provided one or both kidneys plus
another organ to 1 recipient
20 Donors had other reasons for exclusion
654 Consecutive potential deceased 
donors were identified
60 Were excluded
20 Were mistakenly not assessed
40 Were reported after organ recovery
359 Kidneys were assigned
to machine perfusion
359 Kidneys were assigned
to cold storage
21 Were excluded
4 Were rejected at trans-
plantation center
7 Had technical failure 
of machine perfusion
10 Were excluded because
of exclusion of contra-
lateral organ
21 Were excluded
10 Were rejected at transplan-
tation center
11 Were excluded because




338 Cold-storage kidney recipients
2 Were excluded
1 Was excluded because
of death of recipient of
contralateral organ 
1 Was excluded because
recipient of contralateral
organ was lost to follow-up
2 Were excluded
1 Died within 1 wk after trans-
plantation
1 Was lost to follow-up




Figure 1: Enrollment, assignment of kidney pairs to machine perfusion or cold storage, follow-up, and 
assessment.
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Variable







Machine perfusion vs. cold storage 0.57 (0.36–0.88) 0.01
Panel-reactive antibody level — % 1.01 (0.99–1.02) 0.29
Recipient age — yr 1.01 (0.99–1.03) 0.28
Donor age — yr 1.03 (1.00–1.06) 0.04
ECD donor vs. SCD donor† 1.04 (0.46–2.34) 0.92
Cold ischemic time — hr 1.08 (1.03–1.14) 0.003
HLA mismatches — no. 1.13 (0.94–1.37) 0.18
Duration of pretransplantation dialysis — yr 1.16 (1.03–1.31) 0.01
Second or later transplantation vs. first transplantation 3.01 (1.75–5.18) <0.001
DCD donor vs. DBD donor 17.2 (8.16–36.2) <0.001
Graft failure within 1 yr after transplantation‡
Machine perfusion vs. cold storage 0.52 (0.29–0.93) 0.03
DCD donor vs. DBD donor 0.90 (0.28–2.92) 0.87
Recipient age — yr 0.97 (0.95–1.00) 0.02
Duration of pretransplantation dialysis — yr 1.00 (0.87–1.15) 0.97
Panel-reactive antibody level — % 1.01 (0.99–1.03) 0.31
Cold ischemic time — hr 1.04 (0.97–1.11) 0.25
Donor age — yr 1.05 (1.01–1.10) 0.02
ECD donor vs. SCD donor† 1.18 (0.42–3.27) 0.76
HLA mismatches — no. 1.23 (0.98–1.55) 0.08
Second or later transplantation vs. first transplantation 1.72 (0.88–3.35) 0.11
Table 2: Multivariate analysis of the risk of delayed graft function and graft failure.*
*  A logistic-regression model was used to determine the odds ratio for delayed graft function, and a Cox 
proportional-hazards model was used to determine the hazard ratio for graft failure. Odds ratios and 
hazard ratios are associated with a 1-unit increase in each covariate. CI denotes confidence interval, DBD 
donation after brain death, DCD donation after cardiocirculatory death, ECD expanded-criteria donation, 
and SCD standard-criteria donation.
†  Since donor age was a separate covariate in these models and donor age was also part of the ECD 
definition, the effect of ECD versus SCD on delayed graft function and the risk of graft failure may appear 
to be less pronounced than commonly reported.
‡ Data on graft survival were censored at the time of death in patients who died with a functioning allograft.
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Figure 2: Forest plot of the treatment effect in prespecified subgroup analyses.
In the main data set, there was no significant difference in the magnitude of the treatment effect on 
delayed graft function after standard-criteria donation versus expanded-criteria donation (P=0.75) and 
after donation after brain death versus donation after cardiocirculatory death (P=0.42). The extended 
data set consisted of the main data set plus the additional 80 recipients of kidneys from donors after 
cardiocirculatory death who were enrolled after the inclusions had ended. This extended data set of 752 
recipients was used solely to provide more statistical power for a meaningful subgroup analysis of donation 
after cardiocirculatory death versus donation after brain death. In the extended data set, the effect of 
the preservation method on delayed graft function did not differ significantly between patients who 
received kidneys from donors after brain death versus patients who received kidneys from donors after 
cardiocirculatory death (P=0.26). P values are for the interaction between the treatment effect (machine 
perfusion vs. cold storage) and any subgroup variable.
Patient and graft survival
In the cold-storage group, one patient died within 1 week after transplantation because of 
cardiac arrhythmia and was therefore excluded from the study along with the recipient of the 
contralateral kidney. At 1 year after transplantation, patient survival was 97% in both groups. 
Between 7 days and 1 year after transplantation, 11 patients in the machine-perfusion group 
died and 9 patients in the cold-storage group died (Table 3). One-year graft survival (Figure 
3) in the machine-perfusion group was significantly higher than in the cold-storage group 
(94% vs. 90%, P=0.04). Cox regression analysis (Table 2) showed that machine perfusion 
significantly reduced the risk of graft failure in the first year after transplantation, with a 
hazard ratio of 0.52 (P=0.03). A post hoc analysis in which delayed graft function was added 
as a time-dependent covariate to the Cox model indicated that recipients with delayed graft 
function had a significantly increased risk of graft failure (hazard ratio, 1.69; P<0.001); when 
this was applied, the hazard ratio for graft failure with machine perfusion versus cold storage 
increased to 0.60, and this covariate became nonsignificant in the model (P=0.08) (see the 
Supplementary Appendix).
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Adverse events
Table 3 summarizes reported adverse events and deaths. No serious adverse events directly 
attributable to machine perfusion were observed.
 No. at risk
 Machine-perfusion group 336 323 322 319 317 315 314 314 312 311 310 309 309
 Cold-storage group 336 318 313 308 304 304 304 303 302 302 299 299 296 
Figure 3:  Graft survival after transplantation. 
The rate of graft survival at 1 year in the machine-perfusion group was significantly higher than the rate in 
the cold-storage group (94% vs. 90%, P=0.04). Data on graft survival were censored at the time of death 

















group (N  =  336)
Cold-storage group 
(N  =  336)
no. of events (%)Adverse events
During donor procedure†
Vascular anatomy of both kidneys unsuitable for machine perfusion 7 (2)
Surgical team insisted on using machine perfusion for both kidneys 4 (1)
Surgical team declined to cooperate with study 3 (1)
13-yr-old donor mistakenly underwent randomization 1 (<1)
Renal polar artery overlooked during procurement‡ 1 (<1)
During organ preservation
Technical failure or malfunction during machine perfusion§ 7 (2) NA
Delayed delivery of cross-match material¶ 1 (<1) 0
Serious — in recipients
Any serious event 77 (23) 88 (26)
Severe urinary tract infection 11 (3) 10 (3)
Sepsis due to any cause 9 (3) 10 (3)
Diabetes mellitus 9 (3) 10 (3)
Severe respiratory tract infection 8 (2) 14 (4)
Postoperative bleeding 8 (2) 8 (2)
Peritonitis 6 (2) 5 (1)
Any arterial thrombosis 6 (2) 4 (1)
Any venous thrombosis 6 (2) 4 (1)
Any cancer 4 (1) 9 (3)
Severe gastrointestinal tract infection 4 (1) 5 (1)
Cardiac decompensation 3 (1) 3 (1)
Myocardial infarction 2 (1) 2 (1)
Ileus 1 (<1) 3 (1)
Gastrointestinal bleeding 0 2 (1)
Minor — in recipients
Any minor event 170 (51) 148 (44)
Uncomplicated urinary tract infection 43 (13) 47 (14)
Cytomegalovirus infection or reactivation of infection 23 (7) 29 (9)
Uncomplicated gastrointestinal tract infection 22 (7) 21 (6)
Seroma 20 (6) 13 (4)
Ureteral stenosis (graft) 12 (4) 5 (1)
Anemia 11 (3) 8 (2)
Electrolyte disturbances 9 (3) 5 (1)
Leukopenia 7 (2) 2 (1)
Wound abscess 5 (1) 3 (1)
Hydronephrosis of unknown cause (graft) 5 (1) 2 (1)
Mild cardiac arrhythmia 5 (1) 2 (1)
Incisional hernia 4 (1) 5 (1)
Upper respiratory tract infection 2 (1) 6 (2)
Renal capsular hematoma due to biopsy || 2 (1) NA




group (N  =  336)
Cold-storage group 
(N  =  336)
no. of eventsDeaths
Any cause 11 9
Multiorgan failure due to sepsis 4 2
Gastrointestinal bleeding 2 0
Death from unknown cause 2 0
Pneumonia 1 2
Malignant condition 1 1
Pulmonary embolism 1 0
Myocardial infarction 0 2
Cerebral abscess 0 1
Uncontrolled bleeding 0 1
Table 3: Adverse events and deaths reported in the first year after transplantation.*
*  All serious adverse events except the study end points are listed in this table. No serious adverse events 
directly attributable to machine perfusion were reported. Of all minor adverse events, only those that 
occurred in 1% or more of all patients are listed. No statistical tests were performed on the data in this 
table. NA denotes not applicable.
†  All these events led to exclusion of the kidney pair from the study.
‡   One kidney was unsuitable for transplantation because of the insufficient length of the remaining polar 
artery.
§   None of these events rendered the graft unsuitable for transplantation. When machine perfusion failed, 
the kidney was automatically preserved by means of cold storage inside the machine.
¶   Transplantation was postponed for 3 hours because of a delayed cross-match.
||   For an amendment to the study protocol that addressed additional research questions not reported in 
this article, cortical-biopsy specimens were obtained from several machine-perfused kidneys. Capsular 
hematomas did not compromise the function of these kidneys.
DISCUSSION
Static cold storage is the easiest and most widely used preservation method in kidney 
transplantation. In the United States, it is used in 80% of these procedures, and in Eurotransplant 
countries it is used in approximately 100%.36,91 Although retrospective studies have suggested 
that machine perfusion is superior,46,105,106 these registry analyses are biased because of the 
selection of donor kidneys to be perfused or allografts that are discarded on the basis of 
perfusion variables. Several prospective studies have either lacked adequate randomization 
or have had equivocal results because of small sample sizes.116-120 The present study indicates 
that machine perfusion significantly reduces the risk of delayed graft function; these findings 
are probably related to the study’s size and strictly paired design.
The relatively large number of exclusions in our study is typical for a paired study in organ 
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preservation, since logistics necessitated that randomization occur at a very early stage in 
the donation cascade, when a patient in an intensive care unit (ICU) was a potential kidney 
donor. Only after both kidneys had actually been transplanted could we determine whether a 
donor would meet the inclusion criteria. The exclusion of donors from whom one kidney was 
discarded may have led to a mild bias toward the “better” kidney donors in our study. The 
same might be true regarding donors who were not included because the donor hospital could 
not be reached in time by the perfusionist. Theoretically, such donors may have been patients 
in the ICU who had more unstable conditions. Conversely, excluding donors from whom 
combined kidney–pancreas transplantations were performed may have slightly biased the 
data in the opposite direction, since, in general, only the most optimal donors are considered 
for these procedures. In a small number of patients, the initial randomization was switched 
because of the vascular anatomy. It is unlikely that this practice has significantly biased the 
study’s outcomes, since aberrant vascular anatomy did not have a significant effect on delayed 
graft function or on the risk of graft failure, and the observed effect of the machine perfusion 
versus cold-storage covariate did not change when this factor was added to the Cox model.
The effect of machine perfusion on delayed graft function in our study is slightly stronger 
than the associations observed in retrospective studies and meta-analyses (odds ratios, 0.62 
to 0.73).46,105 The median cold ischemic time in both treatment groups was relatively short as 
compared with that in other data sets36; this may explain why the incidence of delayed graft 
function in the cold-storage group in this study was 8.5% lower than the originally anticipated 
incidence of 35.0%. In addition, the effect of machine perfusion may have been stronger if cold 
ischemic times had been longer.36 Machine perfusion was associated with a more pronounced 
decrease in functional delayed graft function than that observed in the primary end point. 
Hence, the magnitude of the beneficial short-term effect of machine perfusion may, in part, 
depend on how delayed graft function is defined.
The treatment effect on the primary end point did not differ between subgroups of 
deceased donors. On the basis of the evidence from this and other studies,106 it is probably 
most legitimate to assume that the effect of machine perfusion as compared with cold storage 
on delayed graft function is at or near the overall odds ratio of 0.57 in various subgroups. With 
this assumption, machine perfusion can be considered to have a beneficial effect on the short-
term outcome in all common types of deceased-donor kidney transplantation. Nevertheless, 
there is a higher incidence of delayed graft function among recipients of kidneys donated after 
cardiocirculatory death and with expanded-criteria donation.121 Hence, the absolute number 
of patients who would actually benefit from machine perfusion might be larger in these 
subgroups.
Machine perfusion was associated with a significant decrease in graft loss, which became 
apparent within 1 year after transplantation. The post hoc addition of delayed graft function 
as a covariate to the Cox model suggests that delayed graft function renders a kidney recipient 
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more at risk for graft failure. In addition, it was linked to an increase in the hazard ratio for 
graft failure associated with machine perfusion versus cold storage, and this covariate became 
nonsignificant in the model. Therefore, we think that the reduction in delayed graft function 
associated with machine perfusion contributes to the improvement in graft survival.
The number of patients with primary nonfunction was reduced by half in the machine-
perfusion group as compared with the cold-storage group. However, this difference was 
not statistically significant, which may be explained by the low overall incidence of primary 
nonfunction. In this trial, characteristics of machine perfusion were not allowed to be used as 
a diagnostic tool to identify kidneys that were at risk for a poor outcome. Although evidence 
is scarce, attention to these variables, as well as to perfusate viability markers, might further 
increase the effect of machine perfusion on transplantation outcomes.122 
In conclusion, the present trial showed that hypothermic machine perfusion reduced the 
incidence of delayed graft function in the kidneys obtained from the most common types 
of deceased donors. In addition, machine perfusion reduced the duration of delayed graft 
function, when it occurred. Machine-perfused renal allografts had a lower risk of graft failure 
in the first year after transplantation and, as a result, these kidneys showed an improved 
1-year graft survival as compared with kidneys preserved by static cold storage.
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SUPPLEMENTARY APPENDIX
List of participating transplant centers (centers and names)
Austria (4 centers, 17 recipients) – Landeskrankenhaus Graz: H. Müller, H. Holzer; 
Universitätsklinik für Chirurgie Innsbruck: R. Margreiter, C. Bösmüller, W. Mark, H. Fetz; 
Allgemeines Krankenhaus der Stadt Linz: C. Gross, B. Schmekal; Allgemeines Krankenhaus 
Wien: F. Mühlbacher, I. Kristo, M. Pones, G. Györi.
Belgium (7 centers, 183 recipients) – Universitair Ziekenhuis Antwerpen: D. Ysebaert, J.L. 
Bosmans, G. Van Beeumen, W. Van Donink; Universitair Ziekenhuis Brussel: J. Lamote, J. 
Sennesael, B. Amerijckx; Hôpital Erasme Bruxelles: A.D. Hoang, D. Mikhalski, D. Abramovicz, 
V. Brulein; Universitair Ziekenhuis Gent: C. Randon, P. Peeters, M. VanderVennet; Cliniques 
Universitaires St. Luc Bruxelles: M. Mourad, M. de Meyer, J. Malaise, L. De Pauw; Centre 
Hospitalier Universitaire Liège: J.P. Squifflet, L. Weekers, O. Detry, M.H. Delbouille; 
Universitaire Ziekenhuizen Leuven: J. Pirenne, Y. Vanrenterghem, F. van Gelder, B. 
Desschans.
Germany (38 centers, 327 recipients) – Universitätsklinikum Aachen: G. Jakse, D. Rohrmann, 
J. Floege, A. Homburg; Knappschaftskrankenhaus Bochum: R. Viebahn, O. Vonend, P. 
Schenker, A. Wunsch; Universitätsklinik Bonn: S.C. Müller, H. Klehr; Universitätsklinikum 
Düsseldorf: W. Sandmann, K. Ivens, A. Voiculescu, K. Balser; Universitätsklinikum Essen: 
A. Paul, O. Witzke, J. Treckmann, A. Jonait-Borkenhagen; Medizinische Universitätsklinik 
Köln-Lindenthal: D. Stippel, Th. Benzing, K. Prenzel, B. Hoppe; Städtische Krankenanstalten 
Köln-Merheim: M. Ströhlein, W. Arns, R. Hackenberg, U. Lange; Westfälische WU Klinikum 
Münster: H. Wolters, B. Suwelack; Zentralklinikum Augsburg: E. Nagel, H. Weihprecht, 
R. Eser, T. Breidenbach; Charité Berlin - Campus Benjamin Franklin: K. Miller, M. Van der 
Giet, E. Krusic, M. Tölle; Charité Berlin - Campus Mitte: F. Fuller, K. Budde; Charité Berlin 
- Campus Virchow: J. Pratschke, P. Reinke, Th. Mehlitz; Zentralkrankenhaus Bremen: S. 
Melchior, F.A. Zantvoort, Ch. Bahrs, S. Meier; Universitätsklinikum Carl Gustav Carus 
Dresden: M. Wirth, P. Gross, S. Leike, J. Passemer; Klinikum der JW Goethe Universität 
Frankfurt: M. Probst, E.-H. Scheuermann; Klinikum der AL Universität Freiburg: P. Pisarski, 
P. Gerke, M. Geyer, S. Hils; Universitätsklinikum Halle: A. Hamza, O. Rettkowski, K. Fischer, 
A. Haberland; Klinikum der Universität Heidelberg: J. Schmidt, M. Zeier, B. Schmied, C. 
Sommerer; Nephrologisches Zentrum Niedersachsen: J. Küster, V. Kliem; Medizinische 
Hochschule Hannover: F. Lehner, A. Schwarz, M. Hiss, N. Mogilewskaja; Universitätsklinik 
des Saarlandes Homburg/Saar: M. Stöckle, M. Girndt, M. Janssen, U. Sester; Medizinische 
Fakultät/Klinikum Jena: Th. Steiner, O.H. Undine, J. Schubert, G. Wolf; Universitätsklinikum 
Schleswig-Holstein Kiel: D.C. Bröring, U. Kunzendorf, P. Glass, F. Braun; Westpfalz-Klinikum 
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Kaiserslautern: W. Seybold-Epting, Th. Rath, A. Dahms; Universitätskrankenhaus Leipzig: 
J. Hauss, P. Martin, D. Weinert; Universitätsklinikum Schleswig-Holstein Lübeck: C. 
Bürk, M. Nitschke; Klinikum der Stadt Mannheim: M. Schwarzbach, P. Schnülle; Klinikum 
Rechts der Isar München: M.C. Raggi; Klinikum Grosshadern München: W.-D. Illner, M. 
Rentsch; Klinikum Lahnberge Marburg/Lahn: J. Geks, U. Kuhlmann, T. Maier, J. Hoyer; 
Klinikum der Joh. Gutenberg Universität Mainz: J. Thüroff, O. Schreiner, J. Jones, K. Allers; 
Universitätskrankenhaus Erlangen-Nürnberg: G. Schott, Ch. Hugo, K. Pressmar, K. Hirsch; 
Medizinische Fakultät Rostock: K. Stein, M. Burde; Katharinenhospital Stuttgart: M. 
Schock, G. Hasche, Ch. Olbricht, M. Kalus; Chirurgische Universitätsklinik Tübingen: W. 
Steurer, N. Heyne, Ch. Thiel, K. Knubben; Universitätskrankenhaus Ulm: J. Mayer, F. Keller, 
C. Brockschmidt, S. Stracke; Klinikum der Bayerischen J-M-U Würzburg: K. Lopau, R. Bonfig.
Luxemburg (1 center, 4 recipients) – Centre Hospitalier de Luxembourg: S. Lamy, P. Duhoux, 
E. Tasch, J. De Sousa.
The Netherlands (8 centers, 136 recipients) – Academisch Medisch Centrum Amsterdam: 
M.M. Idu, F.J. Bemelman, I. ten Berge, K. van Donselaar; Universitair Medisch Centrum 
Groningen: H.S. Hofker, V.B. Nieuwenhuijs, C. Krikke, M. van Dijk; Leids Universitair 
Medisch Centrum: J. Ringers, A.F.M. Schaapherder, J.W. de Fijter, J. Dubbeld; Academisch 
Ziekenhuis Maastricht: E. van Heurn, J. van Hooff, M. Christiaans; UMC St. Radboud 
Nijmegen: J.A. van der Vliet, A.J. Hoitsma; Erasmus Medisch Centrum Rotterdam: J.N.M. 
Yzermans, W. Weimar, J. Kal-van Gestel; Universitair Medisch Centrum Utrecht: R.W.H. 
van Reedt Dortland, R.J. Hené, V. Leydekkers, C. van Straalen; Wilhelmina Kinderziekenhuis 
Utrecht: M.R. Lilien.
Slovenia (1 center, 5 recipients) – University Medical Center Ljubljana: D. Kovac.
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Ethics committee approval
Approval for the study was obtained from ethical review boards in each trial region, and from 
the Eurotransplant Ethical Advisory Committee and Kidney Advisory Committee. As the 
randomized intervention was limited to isolated organs before transplantation, according to 
national laws no informed consent from recipients was required. In addition, ethical rationale 
for not requiring informed consent for the organ preservation method was as follows: At the 
moment of randomization, as well as at the time point at which the randomized intervention 
had to be initiated, most kidneys woud not yet be allocated to a potential recipient. Therefore, 
it would not be possible to obtain informed consent from the recipient before these important 
time points. As soon as organ allocation was known, no informed consent could be obtained 
from the potential recipient, as most national laws dictate a 24-hour consideration period, and 
it would be medically unacceptable to delay transplantation for this reason only. Moreover, 
should the potential recipient decide not to give informed consent, this would automatically 
imply that he or she would not receive the kidney, as the randomized intervention was already 
in progress at that moment. This would lead to an ethically unacceptable dilemma.
Two ethics committees (University Hospital Ghent and University Hospital of Leuven, 
Belgium) ruled that informed consent would be required to obtain follow-up data from 
recipients after transplantation in these hospitals, as this was a prospective study. This 
decision was respected by the steering committee. Other ethics committees did not require 
specific informed consent for this study’s follow-up data retrieval, since the prospective 
randomized intervention was limited to isolated organs before allocation, and no more than 
standard clinical data were collected retrospectively without additional requirements due to 
the study that would affect the patient.
Randomization process
To avoid regional imbalances between the two study arms due to slightly different allocation 
algorithms, a randomization scheme based on permuted blocks within regions was used with 
separate randomization lists for each of the three trial regions. Randomization lists were 
available only to the 24-hour Eurotransplant duty desk. Upon report of a kidney donor, the 
allocation officer first checked its eligibility and then assigned the left kidney to treatment with 
either machine perfusion or cold storage following one of the three randomization schemes, 
which automatically assigned the right kidney to preservation with the other method. Then 
both kidneys were offered according to the match list, without revealing the preservation 
method. Only if the kidney assigned to be machine perfused had a too small aortic patch 
or too many renal arteries preventing a reliable connection to the machine perfusion device 
were surgical teams allowed to switch preservation methods during organ procurement, thus 
frustrating randomization.
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Figure S1: Enrollment, group assignment, follow-up and analysis of non-heart beating donor inclusions.
Text and numbers in italics refer to the second era of non-heart beating donor inclusions, after main 
consecutive inclusions (heart beating and non-heart beating mixed) had ended. These extra non-heart 
beating donor cases were solely used for a subgroup analysis of the effect size of machine perfusion versus 
cold storage in non-heart beating versus heart beating kidney grafts. NHB denotes non-heart beating, HB 
heart beating, MP machine perfusion, and CS cold storage.
*   Switching randomization was only allowed when vascular anatomy made one kidney less suitable for 
the machine.
†   Whenever one or both kidneys were offered together with another organ to one recipient, e.g. for 
combined pancreas–kidney or liver–kidney transplantation.
‡   None of these failures rendered the graft unsuitable for transplantation. When machine   perfusion 
failed, the kidney was automatically cold stored inside the machine.
# Causes of death were one transplant related and two non-transplant related events.
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Trial safety board
To prevent any bias in clinical decisions about transplanting or discarding an organ, machine 
perfusion dynamics data – such as intravascular resistance and flow readings – were never 
revealed to the transplant team. A safety board of experienced transplant surgeons was 
established and consulted on three occasions: In two out of three cases it felt the need to 
reveal machine perfusion dynamics data to the recipient center. In both of these cases the 
recipient centers saw no reason to discard the organ based on the additional information and 
transplanted the kidney.
Prespecified covariates for the logistic regression and cox regression analysis
• Machine perfusion vs. cold storage
• Panel-reactive antibody level (%)
• Recipient age (yr)
• Donor age (yr)
• Expanded criteria donor vs. standard criteria donor
• Cold ischemic time (h)
• HLA mismatches (no.)
• Duration of pretransplantation dialysis (yr)
• Retransplantation vs. first transplantation
• Non-heart beating donor vs. heart beating donor
 Hazard ratio 
Variable (95% confidence interval) P value
Delayed graft function
 Machine perfusion vs. cold storage 0.59 (0.38–0.92) 0.02
 Aberrant vascular anatomy† 1.00 (0.56–1.77) 0.98
 Panel-reactive antibody level (%) 1.01 (0.99–1.02) 0.28
 Recipient age (yr) 1.01 (0.99–1.03) 0.37
 Donor age (yr) 1.03 (1.00–1.06) 0.05
 ECD donor vs. SCD donor 1.08 (0.47–2.45) 0.86
 Cold ischemic time (h) 1.08 (1.02–1.14) 0.005
 HLA mismatches (no.) 1.12 (0.93–1.35) 0.23
 Duration of pre-transplant dialysis (yr) 1.15 (1.02–1.29) 0.02
 Retransplant vs. first transplant 3.05 (1.77–5.25) <0.001
 NHB donor vs. HB donor 17.3 (8.15–36.9) <0.001
Table S2: Multivariate risk analysis for delayed graft function.*
*   Logistic regression model for the risk of delayed graft function, with aberrant vascular anatomy as extra 
covariate, added post hoc. SCD denotes standard criteria donation, ECD expanded criteria donation, 
NHB non-heart beating, and HB heart beating.
†  Aberrant vascular anatomy was defined as >1 renal artery of the kidney graft.







No. of values available
Cold storage-arm 327 329 328 319 322 309 316 282 295 268 266 242 248 278
Machine perfusion-arm 322 324 325 326 316 313 314 296 286 281 273 251 245 274 
Median serum creat. (μmol/l)
Cold storage-arm 592 507 406 327 283 248 221 210 200 195 180 180 177 166
Machine perfusion-arm 557 455 328 269 224 193 182 173 174 168 165 171 168 162
Figure S2: Time course of serum creatinine after transplantation.
Below the x-axis, the sample size available per posttransplant day, and median serum creatinine values per 
day are indicated. For each recipient, the area under the curve (AUC) was calculated. Missing values (12%) 
were imputed by means of linear interpolation. The median AUC of recipients in the machine perfusion-arm 
(1,456; range 385–5,782) was significantly lower than the median AUC of recipients in the cold storage-
arm (1,787; range 288–6,500) (P=0.01; Wilcoxon signed rank test).
Each median value is based on all available cases for that group, and includes patients who were dialysis 
dependent.
Additional non-heart beating donor inclusions
in September 2006, when donor inclusions into the study were nearly complete, the scientific 
steering committee expected that insufficient non-heart beating donors would be enrolled 
at trial completion to conduct a meaningful subgroup analysis for this donation type. At the 
suggestion of the steering committee and with permission of all centers, inclusions of only 
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  Hazard ratio 
Variable (95% confidence interval) P value
 Graft failure within 1 year posttransplant†
 Machine perfusion vs. cold storage 0.52 (0.29–0.92) 0.03
 NHB donor vs. HB donor 0.87 (0.27–2.81) 0.82
 Recipient age (yr) 0.97 (0.95–1.00) 0.02
 Duration of pre-transplant dialysis (yr) 1.00 (0.87–1.15) 0.97
 Panel-reactive antibody rate (%) 1.01 (0.99–1.03) 0.30
 Cold ischemic time (h) 1.04 (0.97–1.10) 0.29
 Donor age (yr) 1.05 (1.01–1.10) 0.02
 ECD donor vs. SCD donor 1.17 (0.42–3.27) 0.76
 HLA mismatches (no.) 1.23 (0.98–1.55) 0.07
 Aberrant vascular anatomy‡ 1.35 (0.66–2.74) 0.41
 Retransplant vs. first transplant 1.73 (0.89–3.36) 0.11
Table S3: Multivariate risk analysis for graft failure.*
*  Cox non-proportional hazards model for the risk of graft failure within 1 year posttransplant, with delayed 
graft function as extra covariate, added post hoc. SCD denotes standard criteria donation, ECD expanded 
criteria donation, NHB non-heart beating, and HB heart beating.
† Censored upon death with a functioning graft.
‡ Delayed graft function was added to the model as a time dependent covariate.
 Hazard ratio 
Variable (95% confidence interval) P value
 Graft failure within 1 year posttransplant†
 NHB donor vs. HB donor 0.48 (0.16–1.48) 0.20
 Machine perfusion vs. cold storage 0.60 (0.34–1.06) 0.08
 Duration of pre-transplant dialysis (yr) 0.96 (0.84–1.10) 0.56
 Recipient age (yr) 0.97 (0.95–0.99) 0.005
 Panel-reactive antibody level (%) 1.01 (0.99–1.02) 0.54
 Cold ischemic time (h) 1.02 (0.95–1.08) 0.61
 Donor age (yr) 1.04 (1.00–1.08) 0.03
 ECD donor vs. SCD donor 1.10 (0.44–2.72) 0.84
 Retransplant vs. first transplant 1.13 (0.58–2.18) 0.72
 HLA mismatches (no.) 1.19 (0.96–1.47) 0.12
 Delayed graft function‡ 1.69 (1.35–2.11) <0.001
Table S4: Multivariate risk analysis for graft failure.*
*  Cox proportional hazards model for the risk of graft failure within 1 year posttransplant, with aberrant 
vascular anatomy as extra covariate, added post hoc. SCD denotes standard criteria donation, ECD 
expanded criteria donation, NHB non-heart beating, and HB heart beating.
† Censored upon death with a functioning graft.
‡ Aberrant vascular anatomy was defined as >1 renal artery of the kidney graft.
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Fig. S1 and Table S1 in this appendix present a Consort diagram and demographics for the two 
eras of non-heart beating donor inclusions. Solely for the heart beating/non-heart beating 
subgroup analysis, these additional inclusions were added to the main set of cases to provide 
more statistical power. The main set of cases consisted of 336 kidney pairs (672 recipients), 
of which 42 (84 recipients) came from non-heart beating donors. The extended data set 
comprised a total of 376 kidney pairs (752 recipients). This total includes the 80 recipients 
of 40 non-heart beating kidney pairs who were later added to the main set for this analysis 
only. Therefore, the total number of non-heart beating kidney pairs in the extended data set 
was 82 (164 recipients). The same logistic regression model for delayed graft function with 
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ABSTRACT
Objective
Hypothermic machine perfusion may improve outcome after transplantation of kidneys 
donated after cardiac death (DCD), but no sufficiently powered prospective studies have been 
reported. Because organ shortage has led to an increased use of DCD kidneys, we aimed to 
compare hypothermic machine perfusion with the current standard of static cold storage 
preservation.
Methods
Eighty-two kidney pairs from consecutive, controlled DCD donors 16 years or older were 
included in this randomized controlled trial in Eurotransplant. One kidney was randomly 
assigned to machine perfusion and the contralateral kidney to static cold storage according 
to computer-generated lists created by the permuted block method. Kidneys were allocated 
according to standard rules, with concealment of the preservation method. Primary endpoint 
was delayed graft function (DGF), defined as dialysis requirement in the first week after 
transplantation. All 164 recipients were followed until 1 year after transplantation.
Results
Machine perfusion reduced the incidence of DGF from 69.5% to 53.7% (adjusted odds ratio: 
0.43; 95% confidence interval 0.20-0.89; P = 0.025). DGF was 4 days shorter in recipients 
of machine-perfused kidneys (P = 0.082). Machine-perfused kidneys had a higher creatinine 
clearance up to 1 month after transplantation (P = 0.027). One-year graft and patient survival 
was similar in both groups (93.9% vs 95.1%).
Conclusions
Hypothermic machine perfusion was associated with a reduced risk of DGF and better early 
graft function up to 1 month after transplantation. Routine preservation of DCD kidneys by 
hypothermic machine perfusion is therefore advisable.
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INTRODUCTION
Kidney grafts can be preserved by either static cold storage or hypothermic machine 
perfusion. Static cold storage preserves grafts on melting ice after a cold vascular flush with 
a preservation solution. Hypothermic machine perfusion preserves the graft by continuous 
or pulsatile administration of a recirculating cold preservation solution (1–10°C). Optimal 
preservation of kidney grafts is essential to reduce the risk of delayed graft function (DGF) after 
transplantation.31 Indeed, DGF negatively influences long-term graft survival, is associated 
with a higher risk of acute rejection, and causes increased mortality in older recipients.31,123-125 
DGF inevitably augments postoperative costs because of prolonged hospital stay, the need 
for dialysis, and additional diagnostic procedures.126,127
Currently, because of the persistent donor shortage, kidneys donated after cardiac death (DCD) 
have become an important additional source of renal allografts in many countries.128 They 
have the potential to increase the number of kidney transplantations up to 4.5 times.128,129 
DCD kidneys suffer from a substantially higher incidence of DGF (28%–88% vs 13%–35%), 
which seriously limits their use, than kidneys donated after brain death (DBD).40,51,128 This 
increased rate of DGF is caused by inevitable exposure of these kidneys to renal warm ischemic 
injury during the period of circulatory arrest. Therefore, optimal preservation of DCD kidneys 
is crucial to reduce their intrinsically increased risk of DGF and allow a safer and wider use of 
this potentially large donor source.
Previous studies have suggested that machine perfusion of DCD kidneys results in better early 
function and improved graft survival than those preserved by static cold storage.54,130,131 
Other studies do not support this conclusion, however, and a comprehensive meta-analysis 
failed to show a statistically significant risk reduction of DGF in machine-perfused versus static 
cold-stored DCD kidneys.105,120,132 Recently, a randomized controlled trial — the Machine 
Preservation Trial — demonstrated that machine perfusion reduces the risk and duration of 
DGF compared with static cold storage in kidneys from deceased donors.48 However, this trial 
included a majority of DBD donors (87.5%) and was not designed to allow detailed analysis 
of the effect of machine perfusion on DCD kidneys alone, thereby leaving this critical issue 
unresolved.
Given this persisting controversy, we conducted a prospectively planned study as a prespecified 
extension of the Machine Preservation Trial to specifically determine the effect of machine 
perfusion versus static cold storage on posttransplant outcome of DCD kidneys.
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METHODS
Trial enrollment criteria
This prospectively planned analysis assessed all consecutive DCD kidney donors reported 
in Belgium and the Netherlands during the Machine Preservation Trial. The study was fully 
integrated in the Eurotransplant system that manages waiting lists and organizes organ 
allocation in a part of western Europe.107 The trial included only Maastricht category III 
(cardiac arrest after withdrawal of treatment) DCD donors 16 years or older and a 5 minute 
“no-touch” period was always respected.128 A strictly paired design was maintained, in 
which both kidneys of 1 donor needed to be transplanted into different recipients. Both 
kidneys of a pair were excluded from the analysis when 1 or both recipients died within 1 
week after transplantation. To allow complete integration within Eurotransplant, to reflect 
current practice, and to ensure the participation of all transplant centers, current standard 
center protocols were not changed. Informed consent from recipients was not required, as 
kidneys were randomized before organ allocation. Ethical approval was obtained from the 
Eurotransplant Ethical Advisory Committee, the Kidney Advisory Committee, and ethics 
review boards in each trial region.
Randomization
Whenever a potential kidney donor meeting the inclusion criteria was reported, the 
Eurotransplant duty desk officer randomly assigned 1 kidney to machine perfusion and the 
contralateral kidney to static cold storage. Randomization lists were computer generated by 
the permuted block method. We used regional lists to avoid imbalances caused by small 
differences in allocation algorithms. When a reliable connection to the perfusion machine was 
impaired by a too small aortic patch or too many renal arteries, randomization for this kidney 
pair was changed and preservation methods were switched. Kidneys were allocated according 
to standard Eurotransplant allocation rules, without revealing the preservation method at 
organ offer. The recipient’s surgical team was unblinded at the time of transplantation.
Preservation methods
Hypothermic machine perfusion was performed with LifePort Kidney Transporter machines 
(Organ Recovery Systems, Itasca, IL). For the purpose of the study, a trained perfusionist 
attended each donor procedure to guarantee availability and correct use of the machines. 
Immediately after organ recovery, the donor surgeon, assisted by the perfusionist, connected 
the kidney randomized to machine perfusion to the perfusion machine. A pulsatile flow with 
Kidney Preservation Solution-1 (KPS-1) (1–8°C) was maintained until transplantation.108 
Systolic perfusion pressure was fixed at 30 mm Hg. Next, the machine-perfused kidney was 
transported to the recipient hospital without any monitoring. Flow readings and intravascular 
resistance were concealed to the transplantation team. As a result, the decision to accept or 
reject a kidney could not be biased by these parameters.
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Kidneys randomized to static cold storage were flushed and preserved according to the 
established Eurotransplant routine, using either University of Wisconsin solution (UW) or 
histidine-tryptophan-ketoglutarate (HTK) according to the center-specific practice. Organs 
were submerged in the preservation solution and stored on melting ice until transplantation.
Follow-up
No changes to center-specific patient follow-up protocols were made. Eurotransplant 
established a secure online database in which follow-up data could be provided by participating 
transplantation centers. To ensure maximal data completeness, recipient centers were 
financially compensated for providing follow-up data. No relevant irregularities were found 
during an external audit of a random sample of 10% of all patient follow-up data.
Study endpoints
The primary endpoint was DGF, defined as the need for dialysis in the first week after 
transplantation. As a secondary endpoint, early graft function was assessed in a more refined, 
objective way as functional DGF, which was defined as the absence of a decrease in serum 
creatinine level by a minimum of 10% per day during 3 consecutive days in the first postoperative 
week, not including patients in whom acute rejection, calcineurin inhibitor toxicity, or both, 
developed within the first week.109 Other secondary endpoints were as follows: duration of 
DGF, primary nonfunction (PNF), biopsy-proven acute rejection, calcineurin inhibitor toxicity, 
serum creatinine values, creatinine clearance, length of recipients’ hospital stay, and patient 
and graft survival up to 1 year after transplantation. Data on graft survival were censored at 
the time of death in patients who died with a functioning graft.
Statistical methods
All data analyses were performed using SPSS, SAS, and R software. Two-sided P values 0.05 
or less indicated statistical significance. The study was powered to detect a reduction in DGF 
due to machine perfusion of at least 20%, based on a presumed rate of DGF of 70% in the 
cold storage group. A minimum of 80 kidney pairs were required to obtain a statistical power 
of 0.8, assuming a univariate 1-sided type I error of 0.05; this is equivalent to the required 
sample size for a multivariate logistic regression with a 2-sided type I error and similar power.110 
The influence of machine perfusion compared with static cold storage on the risk of DGF 
was examined by a logistic regression model.110 Covariate selection was based on relevant 
literature and prespecified in the protocol before the trial started.112,113 To better reflect the 
paired study design, all covariates were entered in the analysis with a built-in normal-gamma 
frailty term for the donor. Demographic variables were analyzed by the Fisher exact test or 
the Mann-Whitney test. We applied the McNemar test or the Wilcoxon signed-rank test to 
evaluate univariate differences in endpoint variables between the 2 groups. Assessment of 
graft and patient survival was done by the Kaplan-Meier method and differences between 
survival curves were determined by log-rank tests. Endpoint interim analyses were not 
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performed, but confidential safety analyses comparing reported rates of adverse events in 
the 2 study groups were conducted at regular intervals by the trial safety board.
155  kidney pairs randomized
1  kidney to machine perfusion
Contralateral kidney to static cold storage
Excluded donors  (n=49 )
47 could not be reached 
2    refusals by donor center in time
Excluded kidney pairs (n=52)
 
20 cancelled donor procedures 
21 pairs with 1 or 2 kidneys not transplantable
3 donors with solitary kidney
4 kidneys could not be machine perfused
4 cases both kidneys machine perfused
103  kidneys allocated to
machine perfusion




10 static cold stored kidneys not transplantable
1 machine - perfused kidney not transplantable
3 technical failures of the perfusion machinea
2 recipients received both kidneys
2 cases in which no suitable recipient was found
 
82 r ecipients analyzed 82 recipients analyzed
Excluded recipients (n=3)
 
2 deaths < 1 week posttransplant
1 contralateral recipient excluded
Excluded recipients (n=3)
1 death < 1 week posttransplant
2 contralateral recipients excluded
204 kidney donors after 
cardiac death (Cat. III)
screened 
103  kidneys allocated to
static cold storage
85 static cold - stored
kidney recipients
Figure 1: Consort diagram showing enrollment and randomization of donors kidney pairs in the trial. 
a  Technical machine-related problems caused the machine to switch to the “fail safe” mode and led to cold 
storage of the kidney inside the machine. These kidneys remained suitable for transplantation but were 
excluded from analysis in the present study. Because the machine perfusion pump is pressure controlled, 
the “fail safe” mode is activated when a risk of possible barotrauma is detected. This occurred in 3 cases: 
(1) a sudden change in surrounding pressure during transport misguided the software, (2) a high resistance 
alarm, and (3) leakage of the perfusion fluid.
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Role of funding source
An independent scientific steering committee comprising clinicians and scientists from each 
trial region was responsible for the design, conduct, data analysis, and manuscript preparation 
for this study. The sponsor was not involved in the study design, follow-up data acquisition, 
data analyses, or writing of the manuscript. During the course of this trial, the sponsor 
provided the trial regions with machine perfusion devices and disposables free of charge and 
operated a 24-hour helpline that could be consulted by perfusionists in case of perfusion 
device–related technical issues.
RESULTS
Donors of DCD kidney pairs were enrolled into the present study in 2 phases. In the first 
phase (November 1, 2005, to October 31, 2006), enrollment was conducted as part of the 
larger Machine Preservation Trial.17 Near the end of donor enrollment in this main trial, 
the steering committee anticipated that insufficient DCD kidney pairs would be included 
to perform relevant analyses for the prespecified DCD subgroup. Inclusion of DCD donors 
therefore was continued in a second phase (November 1, 2006, to August 17, 2007) adhering 
to the protocol of the Machine Preservation Trial. The flow diagram (Fig. 1) shows enrollment 
and randomization of kidney pairs for the present study. Two hundred four potential DCD 
kidney donors were assessed for inclusion, 103 kidney pairs were included, and data from 
82 recipients in each study group were analyzed. In 9 cases, the connection of the kidney 
randomized to machine perfusion was unreliable because of aberrant vascular anatomy and 
therefore preservation methods of both kidneys were switched. Vascular anomalies, however, 
did not significantly increase the risk of DGF (data not shown, P = 0.064).
Study group characteristics
Table 1 shows the characteristics of kidney donors and recipients. Eighty-two recipients were 
included in each study group. There were no significant differences between the groups with 
respect to donor and recipient age, duration of pretransplant dialysis, number of previous 
transplants, panel reactive antibodies, cold ischemic time, flush solution, induction therapy, 
and maintenance immunosuppression regimens.
Primary endpoint
Forty-four recipients in the machine perfusion group and 57 recipients in the static cold 
storage group developed DGF (53.7% vs 69.5%; P = 0.007) (Table 2). Multivariate analysis 
(Table 3) showed a decreased probability of developing DGF in machine-perfused versus 
static cold-stored DCD kidneys (adjusted odds ratio: 0.43; 95% confidence interval: 0.20–
0.89; P = 0.025). Other significant risk factors for DGF were donor and recipient age and 
warm and cold ischemic times.
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 Machine perfusion   Static cold storage  
Variable  group (N = 82)   group (N = 82)  P 
Donor characteristics  
Age,∗ median (range), yr   43 (17–67)  
Warm ischemic time,† median (range), min   16 (6–38)  
n < 10 min   21  
n = 10–19 min   40  
n = 20–29 min   18  
n ≥ 30 min   6  
Flush solution: HTK/UW/other   62/18/2  
Cold ischemic time‡  
Median (range)  15.0 (4.3–28.9)   15.9 (8.6–46.6)  0.70 
Mean (25th–75th percentile)  16.6 (14.2–19.8)   17.3 (13.9–19.7)  0.41 
n > 24 h  4   6  
Recipient characteristics  
Age, median (range), yr  49 (24–73)   52 (24–77)  0.81 
Duration pretransplant dialysis, median (range), yr  4.2 (1.0–17.5)   4.0 (0.4–10.7)  0.48 
Previous transplants, n     0.82 
First transplant  71   70  
Retransplant  11   12  
Panel reactive antibodies, %     0.73 
n = 0–5  71   71  
n = 6–84  11   10  
n ≥ 85  0   1  
No mismatches at HLA-A, B, DR loci, %  2.4   3.7  0.50 
Immunosuppression,n  
Antithymocyte globulin  12   13  0.71 
Interleukin 2 receptor antagonist  37   31  0.34 
Azathioprine  1   1  0.61 
Cyclosporin A  37   31  0.34 
Tacrolimus  43   52  0.25 
Corticosteroids  81   81  1.00 
Mycophenolate mofetil  69   76  0.14 
Table 1: Characteristics of donors and recipients 
∗  Fourteen DCD donors also fulfilled the criteria for expanded criteria donors as determined by the United 
Network for Organ Sharing; 8 were older than 60 years.33 
†  Warm ischemic time: time from circulatory arrest until the start of cold perfusion. 
‡  Cold ischemic time: time from start cold perfusion until the start of kidney implantation. 
    HLA indicates human leukocyte antigen. 
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 Machine perfusion  Static cold storage  
Variable  group (N = 82)  group (N = 82)  P
Delayed graft function* 
Incidence, n (%)  44 (53.7)  57 (69.5)  0.007 
Duration    0.021 
<7d  12  6  
≥7 d  32  51  
Median duration, d  9 (1–48)  13 (2–43)  0.082 
Functional delayed graft function,† n (%)  16 (19.5)  42 (51.2)  <0.0001 
Primary nonfunction, ‡ n (%)  2 (2.4)  2 (2.4)  1.00 
Acute rejection within 14 d, n (%)  6 (7.3)  10 (12.2)  0.28 
Calcineurin inhibitor toxicity, n (%)  13 (15.9)  10 (12.2)  0.34 
Serum creatinine value, median (range), mg/dL   
14 d posttransplant  4.1 (0.9–11.2)  5.1 (1.0–11.3)  0.001 
1 mo posttransplant  1.7 (0.9–7.1)  2.1 (0.7–9.9)  0.017 
3 mo posttransplant  1.5 (0.8–5.4)  1.5 (0.6–8.3)  0.021 
Creatinine clearance, median (range), mL/min   
14 d posttransplant  23 (3–98)  13 (0–160)  <0.0001 
1 mo posttransplant  46 (10–98)  35 (1–113)  0.027 
3 mo posttransplant  57 (11–128)  49 (11–104)  0.117 
Length of recipient hospital stay, median (range), d  17 (7–392)  19 (8–65)  0.24 
Allograft survival at,n (%)   
3 mo  79 (96.3)  79 (96.3)  
1 yr  77 (93.9)  78 (95.1)  
Recipient survival at,n(%)   
3 mo  81 (98.8)  82 (100)  
1 yr  79 (96.3)  80 (97.6)  
Table 2: Univariate analysis of trial endpoints
∗  Delayed graft function: need for dialysis in the first week after transplantation. 
†  Functional delayed graft function: lack of ≥10% serum creatinine decrease per day during 3 consecutive 
days in the first week after transplantation.20 Recipients developing acute rejection or calcineurin 
inhibitor toxicity within the first week were excluded from this category. 
‡ Primary nonfunction: permanent lack of graft function. 
Secondary endpoints
Table 2 shows the univariate analysis of all secondary endpoints. Functional DGF occurred in 
16 recipients in the machine perfusion group versus 42 recipients in the static cold storage 
group (19.5% vs 51.2%; P < 0.0001). The median duration of DGF in the machine perfusion 
group was 4 days shorter than in the static cold storage group, but this difference did not 
reach statistical significance (9 days vs 13 days; P = 0.082). However, DGF was more likely 
to be shorter than 7 days in a machine-perfused kidney than in a static cold-stored kidney. 
106  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
There were no differences in the median length of recipients’ hospital stay. PNF occurred in 
only 2 cases in each study group. Creatinine clearance was significantly higher in the machine 
perfusion group until 1 month after transplantation. At 1 year follow-up, 3 patients in the 
machine perfusion group and 2 patients in the static cold storage group had died. Graft 
survival at 1 year follow-up was similar in both groups (93.9% vs 95.1%) (Fig. 2).
 Adjusted odds ratio   
Variable (95% confidence Interval) P
Machine perfusion vs static cold storage 0.43 (0.20–0.89) 0.025
Donor age, yr  1.04 (1.01–1.08)  0.008 
Recipient age, yr  1.04 (1.00–1.08)  0.028 
Retransplant vs first transplant  0.77 (0.39–1.54)  0.46 
Panel reactive antibody level, %  2.97 (0.90–9.87)  0.075 
HLA mismatches, n  1.28 (0.87–1.88)  0.21 
Duration of pretransplantation dialysis, d  1.01 (0.88–1.27)  0.92 
Cold ischemic time, h  1.10 (1.01–1.21)  0.039 
Warm ischemic time (10 min)∗  3.40 (1.87–6.17)  <0.0001 
Table 3: Multivariate analysis of the risk of delayed graft function 
∗  Warm ischemic time: time from circulatory arrest until the start of cold perfusion. Warm ischemic time 
was grouped into 10-minute intervals and a warm ischemic time of less than 10 minutes was used as the 
baseline. 
  HLA indicates human leukocyte antigen. 
Complications
No vascular complications of the graft (arterial thrombosis, dissection, etc) were seen in 
either group. Cardiovascular, gastrointestinal, infectious, metabolic, urinary, and technical 
complications were comparable between the groups and within reported ranges in the 
literature (data not shown).
DISCUSSION
This multicenter randomized, controlled trial demonstrated the superiority of machine 
perfusion over static cold storage for the preservation of DCD kidneys. This is an important 
finding, as DGF after kidney transplantation adversely influences outcome, causes morbidity 
and even mortality in older recipients, and leads to additional costs.1–6 DCD kidneys are 
currently accepted by many transplant centers as an additional donor source and the potential 
of DCD kidneys is large. Because DCD kidneys are intrinsically more prone to developing 
DGF, decreasing the incidence of DGF by machine perfusion will be particularly beneficial for 
recipients of this type of kidney graft.40,51,128
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Figure 2: Death censored allograft survival at 1 year after transplantation. Graft survival in the machine 
perfusion versus the static cold storage group was similar (94% vs 95%) (log-rank test of equality: P = 0.7).
In the multivariate analysis, machine perfusion clearly reduced the risk of DGF. Furthermore, 
DGF was more likely to be short lasting (<7 days) in machine-perfused kidneys than in static 
cold-stored kidneys. We also explored the impact of machine perfusion on functional DGF, 
which is a more refined surrogate marker for early kidney graft function than DGF defined 
as dialysis requirement in the first postoperative week.109 We found that the incidence of 
functional DGF was strongly reduced by machine perfusion, even more than the incidence 
of DGF. Hence, the protective effect of machine perfusion shown in our study may be 
underestimated when using only the traditional definition of DGF as an outcome measure. 
However, we selected the traditional definition of DGF as the primary endpoint to allow 
for comparison of the results in the present analysis with those from previous studies. Our 
observation that creatinine clearance in recipients of machine-perfused kidneys was higher 
early after transplantation shows that actual early kidney function is also superior after 
machine perfusion.
Our study confirmed that donor age and cold ischemic time are independent risk factors 
for DGF in DCD kidneys, even though cold ischemic times were relatively short in both 
groups.112,113 Cold ischemic time was slightly but not significantly longer in the static cold-
stored group. However, with a previously reported odds ratio of 1.23 of DGF for every 6-hour 
increase in cold ischemic time,133 it is unlikely that these additional 54 minutes of cold 
ischemia caused a major bias of the primary endpoint. Moreover, the study revealed that the 
duration of warm ischemia is a more important independent additional risk factor for DGF.
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Even though DGF is a risk factor for graft failure after kidney transplantation and machine 
perfusion significantly reduced the risk for DGF, our study did not show improvement in 1-year 
graft survival of machine-perfused versus static cold-stored kidneys.31,123,125 We cannot 
exclude that the young donor age in our cohort in part masked an advantage of machine 
perfusion on graft survival. Nevertheless, this finding is in line with an increasing number of 
reports showing similar medium-term graft survival for DCD and DBD kidneys despite higher 
rates of DGF in DCD kidneys.51,128,134 DGF does not influence graft survival after DCD kidney 
transplantation in the same way as it does after DBD kidney transplantation. This could be 
explained by a possibly different nature of DGF in DCD versus DBD kidneys. The metabolic, 
hemodynamic, hormonal, and inflammatory changes that occur after brain death and during 
donor management, but not after cardiac death, may impair kidney function more and could 
have more long-term impact than warm ischemic injury alone.135,136
The present study yielded a few surprising results. First, despite the significant reduction 
of DGF by machine perfusion, the incidence of PNF was not reduced. A PNF incidence of 
only 2.4% may seem surprisingly low. The exclusion of uncontrolled (Maastricht category I 
and II) DCD donors who are more prone to PNF and the relatively short median warm and 
cold ischemic times in our donor population may account for the low rate of PNF. However, 
when compared with reported PNF incidences in other series of controlled DCD kidney 
transplantations (0%–17%) and the previously conducted main trial (1/42), the observed 
incidence of PNF was not exceptionally low.48,120,130,131,137,138 Nevertheless, it is likely that 
the overall incidence of PNF was too low to detect an effect of machine perfusion. Second, 
hospital stay is usually longer in recipients of DCD versus DBD kidneys because of the increased 
rate of DGF in the former group.51 Despite reduced duration and severity of DGF, our study 
showed no significant reduction in hospital stay for recipients of machine-perfused kidneys. 
This unexpected observation may, at least in part, be explained by the fact that the trial was 
conducted in Eurotransplant countries. Healthcare systems with greater pressure to limit the 
use of resources will have a tendency toward shorter hospital stay.139,140 We believe that 
in countries with such a healthcare system, the reduction in DGF seen in our trial might be 
paralleled by a significant reduction in hospital stay. This observation also reflects the relative 
unreliability of hospital stay as a valid outcome parameter, as suggested by other studies.
To date, no definitive evidence of the superiority of machine perfusion over cold storage 
for the preservation of DCD kidneys has been available. Although an advantage of machine 
perfusion has been suggested, all previous studies were relatively small in size compared 
with the present prospective trial.54,105,130,131 The effect of machine perfusion on DCD kidney 
preservation was recently studied in the United Kingdom. A randomized controlled trial with 
sequential analysis suggested that machine perfusion of DCD kidneys does not decrease 
DGF.138 Differences in study design may account for this discrepancy. The present trial was 
not only larger but also fully integrated into Eurotransplant. Kidneys were allocated strictly 
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and solely according to standard Eurotransplant rules, and recipient centers were blinded to 
the preservation method at the time of organ offer. Furthermore, all kidneys were perfused 
immediately after retrieval until transplantation, which was not necessarily the case in other 
studies. The need to perfuse kidneys immediately after retrieval to benefit fully from the 
“perfusion effect” needs to be investigated further, as this practice has important logistic 
consequences.
The present study has some limitations. The strictly paired design of the trial, and the 
necessity to randomize kidney pairs immediately after the report of a potential donor, 
accounts for the large number of exclusions. First, donor kidney pairs, of which 1 kidney was 
not transplanted, were excluded, possibly leaving kidneys with a higher risk of DGF out of 
the study. Second, less hemodynamically stable donors, in whom organ recovery had to be 
performed as an emergency procedure, could not always be reached in time. Another possible 
limitation is the difference in preservation solutions in both groups. Only 1 pharmaceutical 
formulation of machine preservation solution is Food and Drug Administration approved; 
therefore, machine-perfused kidneys were preserved with KPS-1. Static cold-stored kidneys 
were preserved in HTK (75.6%) or UW (22.0%), and although UW is still the gold standard for 
cold storage of kidneys, analysis of the United Network of Organ Sharing data showed that 
HTK preservation has no effect on DGF compared with UW.141
In conclusion, this international randomized, controlled trial showed that hypothermic 
machine perfusion of DCD kidneys reduced the risk of DGF and improved graft function until 1 
month after transplantation. When DGF occurred, it was of a shorter duration and less severe. 
We therefore suggest that machine perfusion should be routinely used for the preservation of 
DCD kidneys. Apart from being beneficial to the individual patient, these protective effects 
of machine perfusion might result in a substantial reduction of DGF-related costs. The cost-
effectiveness of hypothermic machine perfusion however remains to be investigated.

Chapter 7
Machine perfusion versus cold storage 
for preservation of kidneys from expanded 
criteria donors after brain death
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ABSTRACT
The purpose of this study was to analyze the possible effects of machine perfusion (MP) versus 
cold storage (CS) on delayed graft function (DGF) and early graft survival in expanded criteria 
donor kidneys (ECD). As part of the previously reported international randomized controlled 
trial 91 consecutive heartbeating deceased ECDs – defined according to the United Network 
of Organ Sharing definition – were included in the study. From each donor one kidney was 
randomized to MP and the contralateral kidney to CS. All recipients were followed for 1 year. 
The primary endpoint was DGF. Secondary endpoints included primary nonfunction and graft 
survival. DGF occurred in 27 patients in the CS group (29.7%) and in 20 patients in the MP 
group (22%). Using the logistic regression model MP significantly reduced the risk of DGF 
compared with CS (OR 0.460, P = 0.047). The incidence of nonfunction in the CS group (12%) 
was four times higher than in the MP group (3%) (P = 0.04). One-year graft survival was 
significantly higher in machine perfused kidneys compared with cold stored kidneys (92.3% 
vs. 80.2%, P = 0.02). In the present study, MP preservation clearly reduced the risk of DGF and 
improved 1-year graft survival and function in ECD kidneys. 
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INTRODUCTION
As a result of persistent donor organ shortage, kidneys from expanded criteria donors (ECDs) 
are nowadays accepted by many centers and successfully transplanted, thus shortening 
waiting times.12,142,143 Unfortunately, kidneys from ECDs appear to have a higher rate of 
delayed graft function (DGF) and a more complicated postoperative course, resulting in an 
inferior long-term graft survival overall.12,111-113,142 Although the use of kidneys from ECDs 
has an overall risk for graft failure of 1.7, it has also been shown that transplantation of these 
kidneys has a significant survival benefit compared with dialysis treatment.144
To enhance the outcome of using ECD kidneys, it is important to analyze the risk factors, 
including the role of the preservation method. A recently published systematic review 
suggests that hypothermic machine perfusion (MP) might be superior compared with simple 
cold storage (CS), reducing the relative risk of DGF by up to 20% and increasing 10-year 
graft survival by 6%.105,106 However, this evidence is based on studies that were limited by 
an uncontrolled patient selection, small patient numbers, the use of different and sometimes 
out-of-date preservation solutions, nonstandardized pumping modes and times, as well as 
inconsistent application of currently available pump technology.
We recently reported the overall results of an international multi-center randomized trial 
comparing MP versus CS in unselected consecutive donors ≥16 years of age, demonstrating 
the safety of MP and a significant reduction in both DGF and 1-year graft loss.48 As this effect 
might be even more pronounced or clinically relevant in ECD kidneys,12,145 the purpose of this 
study was to provide an analysis of the possible effects of MP versus CS on DGF and early 
graft survival in ECD kidneys.
METHODS
As part of the previously reported multi-center randomized trial48 all consecutively retrieved 
kidney pairs from heart-beating deceased ECDs in the Netherlands, Belgium, and the federal 
state of North Rhine-Westphalia in Germany between November 1, 2005 and October 31, 
2006 were eligible for randomization. ECDs were defined according to the United Network of 
Organ Sharing (UNOS) definition,12,143 which includes: donor age ≥60 years or 50–60 years 
with at least two of the following criteria: history of hypertension, cerebrovascular cause of 
death and serum creatinine 132 μmol/l (1.5 mg/dl) prior to retrieval.
Donors were only included in the study for analysis if both organs were transplanted 
into two different recipients. Donors accepted for combined organ transplantation (e.g., liver–
kidney transplantation) by the recipient center were excluded from the trial.
Recipient centers were blinded to the method of preservation (MP or CS) at the time of 
acceptance of the kidney for a specific recipient.
The study protocol was approved by ethics committees in each trial region. The study 
114  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
was sponsored by the Deutsche Forschungsgemeinschaft (DFG TR 811/1-1) and by Organ 
Recovery Systems (Itasca, IL, USA).
Randomization and logistics
From each donor, one kidney was randomized to MP and the contralateral kidney to CS. 
The randomization process and logistic management have been described in an earlier 
publication.48
Preservation methods
All kidneys underwent in situ vascular washout with cold preservation solution (histidine–
tryptophan–ketoglutarate or University of Wisconsin solution). Kidneys assigned to 
hypothermic MP were connected to a LifePort Kidney Transporter® (Organ Recovery Systems) 
shortly after procurement and machine perfused until transplantation. A pulsatile flow of 
machine preservation solution (Kidney Preservation Solution-1®; Organ Recovery Systems, 
Itasca, IL, USA) at 1–8 °C and a fixed systolic perfusion pressure of 30 mmHg were maintained. 
The transplant team was blinded to MP intravascular resistance and flow data. Kidneys 
assigned to CS were submerged in preservation solution and stored on melting ice.
Endpoints and data collection
The primary endpoint of this ECD study was DGF defined as the need for dialysis during the first 
week posttransplant. Secondary endpoints were: functional delayed graft function (f-DGF), 
which is defined as the absence of a decrease in serum creatinine levels of at least 10% per day 
for at least three consecutive days in the first week after transplantation;109 duration of DGF; 
primary nonfunction (PNF) of the transplanted kidney; serum creatinine levels at 1–14 days 
and 1, 3  and 12 months; creatinine clearance at 1 and 2 weeks and 1, 3 and 12 months; biopsy-
proven acute rejection and calcineurin inhibitor toxicity within the first 2 weeks; recipient 
hospital stay length; graft and patient survival; and the number of biopsy-proven rejection 
and calcineurin inhibitor toxicity episodes up to 1 year posttransplant.
In addition, standard donor and recipient data and the type of induction immunosuppression 
therapy were recorded. Follow-up data were collected in a secure online database hosted by 
Eurotransplant and were provided by each of the 60 participating transplant centers.
Statistics
The analysis was powered to detect a reduction in DGF of at least 20% based on the assumption 
of a 40% incidence of DGF in recipients with kidneys preserved by CS. With a power of 0.8 
and a type I error of 0.05, the required sample size was 82 pairs of ECD kidneys. The primary 
analysis of the DGF endpoint consisted of a logistic regression model with the covariates 
shown in Table 3.
Secondary endpoint variables were assessed for univariate differences between groups 
by the McNemar or the Wilcoxon signed rank test. Differences between survival curves were 
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determined by the log rank test. A Cox proportional hazards model was applied to examine 
which variables significantly influenced the risk of graft failure. All P-values are two-sided 
and not adjusted for multiple testing. Analyses were conducted using SPSS (IBM Corporation, 
Somer, NY, USA), SAS (SAS Institute Inc., Cary, NC, USA) and R software packages (The R 
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Between November 1, 2005 and October 31, 2006, 336 out of 654 deceased donors 16 years 
of age and older were included in the overall study. Of these 654 donors, 200 were ECDs. 
There were 109 ECDs who were not studied, thus 91 donors were included in the subgroup 
analysis. The reasons for exclusion are described in Table 1. The main reason was that one or 
both kidneys were not transplantable (42/109). Preservation methods were switched in five 
donors. In two cases this was attributable to aberrant vascular anatomy, whereas in three 
cases no reason could be found.
Reason for exclusion N
Reported after procurement 1
Could not be reached in time 8
Donor center refusal 0
Donor family refusal 0
Donor procedure canceled 5
One or both kidneys not transplantable  42
Combined organ offer 7
Other reasons 32
Kidney rejected at transplant center 4
Technical failure MP 2
Not assessed by mistake 0
Unknown 8
Table 1: Reasons for exclusion of donors. Potential donors N = 200, donors included N = 91, reasons for 
excluding N = 109, MP, machine perfusion.
Donor and recipient characteristics are summarized in Table 2. The median donor age was 66 
years (50–81 years) and the median recipient age was 65 years in both groups. There were no 
significant differences between the two groups concerning relevant baseline characteristics.
Further subset analysis showed no differences concerning median cold ischemia time 
between MP and CS for donors older than 65 years (9 h vs. 10 h, P = 0.61) or the subset of 
transplants with more than three HLA mismatches (10 h vs. 10 h, P = 0.92).
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  MP arm  CS arm P  value
Donor characteristics
Age (years)   66 (50–81)
Sex (M/F)   49/42
BMI   27 (21–42)
Duration of ICU stay (days)   2.5 (0.1–17 )
Serum creatinine (μmol/l)
 mean  96 
 max  310
 median (range)  86 (50–310)
(Nor)adrenalin (Y/N/unknown)   72/19/0
Preservation solution
 UW  50
 HTK  40 
 other  1
Recipient characteristics
Age (years)  65 (20–79)  65 (32–79) 0.75
Sex (M/F)  55/36  57/34 0.88
Pre-Tx dialysis duration (days)  1728 (149–3,866)  1728 (137–5,154) 0.68
Previous transplants (0/1/2/3)  69/19/3/0  64/19/6/2 0.29
Current PRA (0-5/6-84/85+%)  85/5/1  81/9/1 0.43
HLA mismatches (% with 0)   12.1  8.8 0.63
Cold ischemic time (hours)  13 (3–23)  13 (4–29) 0.97
Endpoints
DGF (Y/N)  20/71 (22.0%)  27/64 (29.7%) 0.27
Duration of DGF (days)  14 (3–31)  15 (4–41) 0.45
Duration of DGF <7 days (Y/N)  5/15  4/23 0.22
f-DGF (Y/N)  15/57 (20.8%)  22/52 (29.7%) 0.31
PNF (Y/N)  3/88 (3%)  11/80 (12%) 0.04
CNI intoxicity (Y/N/unknown)  5/78/8  3/81/7 0.63
Acute rejection (Y/N/unknown)  17/64/10  16/67/8 0.98
Creatinine clearance at 1 year (mean±SD, ml/min) 78±41  69±48 0.01
Table 2: Donor and recipient characteristics and results of the univariate analyses. If not indicated 
otherwise, values for continuous variables represent median (range).
In this ECD subgroup, DGF occurred in 27 patients in the CS group (29.7%) and in 20 patients in 
the MP group (22%). This difference was not statistically significant in the univariate analysis (P 
= 0.27) (Table 2). The analysis using the logistic regression model showed that MP significantly 
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reduced the risk of DGF compared with CS (adjusted odds ratio 0.460, P = 0.047) (Table 3).
The number of kidney pairs from the same donor for which both kidneys developed DGF after 
transplantation was nine.
There was no significant difference in the incidence of DGF in the ECD subgroup 
compared with the main data set48 in neither machine perfused kidneys (22% vs. 20.8%) nor 
in cold stored kidneys (29.7% vs. 26.5%). Further significant factors affecting the risk for DGF 
were cold ischemia time, duration of pretransplant dialysis, and whether it was a retransplant 
versus a first transplant.
Secondary endpoints
The incidence of PNF in the CS group (12%) was four times higher than in the MP group (3%) 
(P = 0.04). Of the cold stored kidneys with PNF in the main dataset, 68% were from ECDs; 
however, only 42.5% of machine perfused kidneys with PNF came from ECDs (P = 0.52). The 
PNF in cold stored ECD kidneys was significantly more frequent than in the whole group of 
cold stored kidneys (P = 0.025), whereas there was no difference in the occurrence of PNF in 
the machine perfused kidneys when ECDs were compared with all donors. The incidence of 
f-DGF was 29.7% after CS and 20.8% after MP (P = 0.31) (Table 2).
There were no significant differences between the two groups concerning creatinine 
clearance up to 3 months, daily creatinine values up to day 14, the incidence of biopsy-
proven calcineurin inhibitor toxicity, acute rejection episodes, and the length of hospital stay. 
Creatinine clearance after 1 year was significantly higher in the MP group compared with the 
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Figure 1: (a) Posttransplant graft survival rates. All consecutive renal transplants from expanded criteria 
donors after brain death, N=182. Logrank test of equality MP vs. CS p=0.02. (b) Posttransplant graft 
survival rates. All consecutive renal transplants from expanded criteria donors after brain death, N=182. 
Logrank test of equality: within CS group DGF vs. no DGF P<0.0001; within MP group DGF vs. no DGF 
P=0.164; within no DGF group MP vs. CS P=0.48; within DGF group MP vs. CS P=0.003.
post post
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Patient and graft survival
No patient deaths occurred in the first 14 days after transplantation. Patient survival after 
1 year was 93.4% in the MP group and 96.7% in the CS group (P = 0.30). One-year death 
censored graft survival was significantly higher in machine perfused kidneys compared 
with cold stored kidneys (92.3% vs. 80.2%, P = 0.02) (Fig. 1a). This difference was even 
more pronounced if DGF had occurred. Although in the MP group there was a difference of 
nearly 10% for 1-year graft survival if DGF occurred compared with kidneys with immediate 
function, this difference was not statistically significant (94% vs. 85%, P = 0.164). In the CS 
group, graft survival was impressively reduced if DGF occurred (41% vs. 97%, P < 0.0001). If 
only recipients of grafts that developed DGF were analyzed, there was a significant difference 
in 1-year graft survival between machine perfused kidneys and cold stored kidneys (85% vs. 
41%, P = 0.003) (Fig. 1b).
Cox regression analysis showed that MP significantly reduced the risk of graft failure in 
the first year with a hazard ratio of 0.353 (P = 0.022) (Table 4). As a relevant defining factor 
for ECDs, donor age had no significant influence on DGF in this analysis. However, even in this 
older group of donors, it did significantly influence 1-year graft survival (hazard ratio 1.103, 
P= 0.016).
Covariate Odds ratio (95% CI)  P-value
Treatment arm MP vs. CS 0.460 (0.213–0.989) 0.047
CIT (hours) 1.151 (1.057–1.254) 0.001
Number of HLA mismatches  1.905 (0.454–8.000) 0.379
Most recent PRA (%) 1.004 (0.980–1.029) 0.742
Recipient age (years) 1.586 (0.569–4.424) 0.378
Donor age (years) 1.036 (0.957–1.122) 0.385
First vs. re-transplant 2.307 (1.257–4.234) 0.007
Pre-Tx dialysis duration (days) 1.001 (1.000–1.001) 0.021
Table 3: Logistic regression model for the risk of DGF.
DISCUSSION
In the context of this randomized trial48 we have now focused on the effect of MP in kidneys 
from ECDs. This effect was even more pronounced than in the overall study, with an odds 
ratio (OR) of 0.46 for the risk of developing DGF (overall OR of 0.57). Nevertheless, direct 
comparison of the treatment effects on DGF between expanded criteria donation and 
standard criteria donation that also included deceased donation after cardiac death showed 
no significant difference.
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It is interesting to see that in this study, the incidence of DGF in ECD kidneys is only slightly 
higher than in the main data set, irrespective of the preservation method. The incidence of 
DGF found in this trial is clearly lower than that reported in previous studies using ECD.121,146 
One explanation for this might be the relatively short cold ischemic times in this study.
The hazard ratio for graft failure was also more reduced for ECDs with a value of 0.35 
than in the overall study with 0.52. The number of recipients receiving an ECD kidney with 
PNF was fourfold higher in the CS group compared with the MP group. Such early graft failure, 
in addition to subsequent graft failures, puts a severe burden on patients and waiting lists for 
kidney transplantation. The effect we observed was much stronger than described in a recent 
meta-analysis.105
Covariate Hazard ratio (95% CI) P-value
Treatment arm MP vs. CS 0.353 (0.145 - 0.862) 0.022
CIT (hours) 1.082 (0.994- 1.179) 0.068
Number of HLA mismatches  4.070 (0.484- 34.208) 0.196
Most recent PRA (%) 1.006 (0.983- 1.030) 0.600
Recipient age (years) 0.629 (0.219- 1.805) 0.388
Donor age (years) 1.103 (1.018-1.195) 0.016
First vs. re-transplant 0.938 (0.480 -1.832) 0.851
Pre-Tx dialysis duration (days) 1.000 (1.000-1.001) 0.495
Table 4: Cox proportional hazards model for the risk of graft failure within 1 year posttransplant.
For ECDs, we also show for the first time that at 1 year posttransplant, the function of the 
surviving grafts was better if the kidney was preserved by MP compared with CS. These results 
differ from retrospective studies as these studies show only short term beneficial effects of 
MP with a reduction of DGF but no improvement in graft survival.147-149
Although donor age is already part of the ECD definition, it was the only significant 
predictive factor in the Cox proportional hazard model for graft survival after 1 year, apart 
from the treatment modality MP versus CS (Table 4).
The effect of MP on the reduction in serum creatinine levels in the first 14 days compared 
with cold stored kidneys could not be demonstrated in the ECD group, although, this was 
shown in the main data set. This is probably because of the smaller sample size of the present 
study.
f-DGF was chosen instead of the creatinine reduction ratio (CRR) since the CRR only takes 
into account days 1 and 2 posttransplant. f-DGF has a scope of 7 days after transplantation 
and has also been validated by Boom et al.109 The scope of the classical DGF definition (in 
terms of dialysis requirement) is also 1 week, so in our view f-DGF is a more functional 
definition which uses the same time frame.
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Parameters characterizing the individual kidney during perfusion – such as vascular resistance, 
and flow and perfusate viability markers – were not used as potential predictors of outcome. 
In a separate analysis, renal resistances during MP were shown to correlate with DGF and 1 
year graft survival (univariate analysis), but not with PNF.150 Hence, further analysis of these 
parameters and perfusate biomarkers might help to identify kidneys at risk for DGF and PNF, 
also recently shown in an experimental study.151-153 Interestingly, but not fully analyzed yet, was 
that kidneys with DGF after MP and after CS were seldom from the same donor in this study. 
This could imply that parameters of MP providing a prognosis for the development of DGF in 
the perfused kidney will in most cases not help to identify renal grafts at risk for DGF after CS.
A striking fact is that the proportion of ECDs in Germany, where donation is only 
allowed after brain death, is almost 50% (47.7% in 2006 and 48.2% in 2007) (Eurotransplant 
analysis). The proportion of ECDs in the main study was 27.9% (94/336) when donation after 
cardiocirculatory death was included and 30.9% (91/294) when only donation after brain death 
was considered. This relatively small proportion of ECDs is an effect caused by the procurement 
policy in Belgium and the Netherlands and could imply a strong bias toward better-quality 
ECD categorized donors in the present study. It can be assumed that ECD populations in other 
countries are not fully comparable to our study’s inclusions and, therefore, the effect of MP 
versus CS as described in this article could be somewhat different.
The high rate of exclusion could represent a possible bias, but is explained by the early 
randomization process and high exclusion rate because one or both kidneys were eventually 
not transplanted. Exclusion for a combined organ transplantation was rare. This too could 
provide a bias toward the ‘better’ expanded criteria donor, and perhaps effects of MP could 
be even more pronounced in a series with more marginal ECD kidneys.
There were no kidney pairs that could not be randomized. All consecutive ECD donor kidney 
pairs were assessed for inclusion, randomized if they met the initial inclusion criteria, and only 
if vascular anatomy of the kidney randomized for MP prevented a reliable connection of the 
kidney to the perfusion machine, could the preservation methods for this pair be switched, thus 
indeed frustrating randomization. We checked whether the presence of vascular anomalies had 
any relevant influence on posttransplant outcome, and this was not the case. Therefore, the few 
cases in which preservation methods were switched did not introduce any bias to our results.
The recent review of Yuan et al. critically describes the possibilities and developments in 
the field of MP over the last decades. The authors emphasize the importance of investigating 
the relevance of MP for marginal donor organs. We feel that the present study adds important 
new data which support the benefit of MP for the preservation of such donor organs.154
In summary, this study shows that MP reduces the risk of DGF and improves 1-year graft 
survival and function in ECD kidneys. The development of better pretransplant predictors for 
DGF155 could increase the cost-effectiveness of MP in expanded criteria donation. We believe 
that as long as there are no such reliable predictors, every ECD kidney should be machine 
perfused, because in the first year after transplantation alone, 12% more grafts could be 
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In 2009, we showed in an international randomized controlled trial that hypothermic 
machine perfusion of deceased-donor kidneys significantly reduced the risk of delayed graft 
function compared to cold storage preservation. We also found that 1-year graft survival 
was significantly better after machine perfusion.48 As preservation related effects have so far 
been shown to affect early function only, we decided to extend the follow-up period of our 
study and investigate whether this substantial graft survival advantage would persist 3 years 
after transplantation.
In our study, one kidney of each included donor was randomly assigned to machine 
perfusion, and the contralateral organ to cold storage. For the present analysis, all 60 
collaborating transplant centers were contacted. Three-year follow-up data were collected of 
all 672 recipients of consecutive kidneys donated after brain death or after cardiocirculatory 
death in the main data set, as well as 164 recipients of kidneys donated after cardiocirculatory 
death in the extended data set. End points were 3-year graft survival, patient survival, and 
serum creatinine. Statistical analyses were performed using the same methodology as 
described in our previous paper.48
Overall, 3-year graft survival was better for machine perfused kidneys (91% vs. 87%, 
adjusted hazard ratio for graft failure 0.60, p=0.04). Differentiated to donor type, 3-year graft 
survival after machine perfusion was superior to that after cold storage for kidneys donated 
after brain death (91% vs. 86%, adjusted hazard ratio 0.54, p=0.02), but not for kidneys 
donated after cardiocirculatory death. The 3-year graft survival advantage after machine 
perfusion was most pronounced for kidneys recovered from expanded criteria donors,12 
(86% vs. 76%, adjusted hazard ratio 0.38, p=0.01) (Figure 1a-d). Delayed graft function had a 
profound impact on graft survival of kidneys donated after brain death (Figure 1e). Three-year 
patient survival and serum creatinine were equal in the two study arms.
We conclude that, 3 years posttransplant, graft survival of kidneys donated after brain 
death remained significantly better after machine perfusion compared to cold storage, 
especially in kidneys recovered from expanded criteria donors. Delayed graft function was 
associated with a notably lower graft survival of kidneys donated after brain death. Despite 
the large reduction in delayed graft function by machine perfusion in kidneys donated after 
cardiocirculatory death that we showed earlier,97 we found no beneficial effect of machine 
perfusion on graft survival in this subgroup. This could suggest a different type of delayed 
graft function in kidneys donated after cardiocirculatory death versus those donated after 
brain death.

























Machine perfusion vs. cold storage 91% vs. 87%, adjusted 
hazard ratio for graft failure 0.60 (95% CI 0.37–0.97, P=0.04)


























Main data set N=188 recipients of only ECD kidneys
Machine perfusion vs. cold storage 86% vs. 76%, adjusted 
























Machine-perfusion and no delayed graft function group
Cold-storage and no delayed graft function group
Machine-perfusion and delayed graft function group
Cold-storage and delayed graft function group
Main data set N=588 recipients of only DBD kidneys
Three-year graft survival from the top down: 94%, 92%, 77%, 


























Main data set N=588 recipients of only DBD kidneys
Machine perfusion vs. cold storage 91% vs. 86%, adjusted 


























Extended data set N=164 recipients of only DCD kidneys
Machine perfusion vs. cold storage 90% vs. 92%, adjusted 
hazard ratio for graft failure 1.16 (95% CI 0.41–3.28, P=0.78)
d
Figure 1 a-e: Three-year death censored graft 
survival of the overall group of consecutive 
deceased donor kidneys in the main data set 
(a), DBD kidneys only (b), ECD kidneys only (c), 
DCD kidneys in the extended data set (d), and 
DBD kidneys only with data split according to 
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ABSTRACT
Static cold storage (CS) is the most widely used organ preservation method for deceased donor 
kidney grafts but there is increasing evidence that hypothermic machine perfusion (MP) may 
result in better outcome after transplantation. We performed an economic evaluation of MP 
versus CS alongside a multi-center RCT investigating short and long term cost-effectiveness. 
336 consecutive kidney pairs were included, one of which was assigned to MP and one to CS. 
The economic evaluation combined the short term results based on the empirical data from 
the study with a Markov model with a 10-year time horizon. Direct medical costs of hospital 
stay, dialysis treatment and complications were included. Data regarding long-term survival, 
quality of life, and long term costs were derived from literature. The short-term evaluation 
showed that MP reduced the risk of delayed graft function and graft failure at lower costs than 
CS. The Markov model revealed cost savings of E 86,750 per life-year gained in favor of MP. 
The corresponding incremental cost-utility ratio was minus E 496,223 per quality-adjusted 
life-year gained. We conclude that life-years and QALYs can be gained while reducing costs at 
the same time, when kidneys are preserved by MP instead of CS.
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INTRODUCTION
Preservation of the kidney graft while it is transferred from donor to recipient is a critical and 
vulnerable phase. Traditionally, static cold storage (CS) is the method of choice, involving 
cooling with one of several cold preservation solutions available, and transportation on 
melting ice. Modifications of this procedure, e.g. by changing the type of preservation solution, 
have been shown to have an impact on costs and effectiveness of transplantation.103,104 Over 
the past decade, retrospective evidence has been accumulating suggesting that hypothermic 
machine perfusion (MP) of the kidney may result in better short term outcome than CS, with 
lower rates of delayed graft function (DGF) irrespective of whether kidneys are recovered 
from donors after cessation of circulation and cardiac death (DCD) or after brain death (DBD). 
MP involves the continuous pumping and recirculation of a preservation solution through the 
vasculature of the organ at temperatures between 1 and 10 °C, using a mechanical perfusion 
device.54 As a result of promising initial reports, interest in MP has been rising worldwide, 
especially since the average age of deceased kidney donors has been increasing and the 
inherently elevated exposure to more concomitant morbidity has been associated with an 
additional detrimental effect on graft quality and function.40,52,147 
Despite this preponderance of favorable data, a systematic review by Wight et al. 
concluded that insufficient high-quality prospective trials were available to allow firm 
conclusions about the clinical benefits of MP over CS, particularly with respect to delayed graft 
function and graft survival.106 In addition, existing economic evaluations were considered to 
be of poor quality, i.e. not based on randomized studies. 
Recently, our group has added evidence on the beneficial clinical effects of MP over CS 
with a large randomized controlled trial (RCT),48 that showed that MP results in a reduced 
risk of DGF and an improved graft survival versus CS in the first year after transplantation 
for all deceased donor kidneys, irrespective of the donor type (DBD or DCD). To consolidate 
the evidence and underpin policy decisions regarding reimbursement of MP we have now 
performed an economic evaluation of MP versus CS using the data of this clinical trial, and 
expanded our analysis with a Markov model to estimate long-term cost-effectiveness and 
cost-utility of MP versus CS in kidney transplantation.
METHODS
The economic evaluation was based on the data from the recent international RCT.48 In short, 
kidney pairs from consecutive deceased donors aged 16 years or older from the participating 
regions in the Netherlands, Belgium and the federal state of North Rhine-Westphalia in 
Germany were transplanted into two different recipients in the Eurotransplant region (Austria, 
Belgium, Germany, Luxemburg, the Netherlands, and Slovenia) after randomization to CS 
for one kidney and to MP for the contralateral kidney of each pair. Types of transplantation 
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included kidneys recovered from donors after cessation of circulation and cardiac death 
(DCD) or after brain death (DBD) and extended-criteria kidneys (ECD, donor age of 60 years 
or more or a donor age between 50 and 60 years, with at least two of the following additional 
donor characteristics: history of hypertension, death due to a cerebrovascular cause, and a 
serum creatinine level of more than 132 μmol per liter (1.5 mg per deciliter) before removal 
of the kidney).
Hypothermic pulsatile machine perfusion with the modified University of Wisconsin 
preservation solution was performed using LifePort Kidney Transporter machines (Organ 
Recovery Systems, One Pierce Place, Itasca IL, USA). Cold storage was performed according 
to established Eurotransplant protocols. The primary endpoint of the study was delayed graft 
function, defined as the requirement for dialysis during the first week after transplantation. 
Follow-up data until 1 year after transplantation were collected from the participating centers 
in 100% of the cases through a secure online database.
Economic evaluation
The economic evaluation was performed in a dual approach. Short-term cost-effectiveness, 
i.e. the costs and effects up to 1 year after transplantation, was evaluated based on data 
from the clinical study, using the percentage of functioning grafts as the primary outcome. 
Data regarding graft function (delayed graft function, primary non-function) and dialysis 
treatment during this period were used to calculate the costs per patient. Data regarding 
graft survival and costs were used to calculate the incremental cost-effectiveness ratio (ICER) 
by dividing the difference in total costs over 1 year (CostsMP – CostsCS) by the difference in 
functioning grafts (GraftsMP – GraftsCS) after 1 year. Direct - non-incremental - costs related to 
kidney transplant surgery and immunosuppressive drugs were not included in the economic 
evaluation.
For the evaluation of the long-term effects a Markov simulation model was constructed.156 
It encompassed the definition of three discrete states of patients, i.e. functioning graft, graft 
failure and death. The model had a cycle length of 1 year and transition probabilities derived 
from literature and/or clinical expertise were used to determine the annual flow of patients 
between states.
Short-term evaluation
Costs were calculated from a hospital perspective: direct medical costs associated with 
hospital stay, dialysis treatment157 and complications were included. The price level of 2007 
was used. Prices from previous publications were transformed to the year 2007 by indexing 
according to the Dutch consumer price index.
Since a few participating centers did record return to dialysis after primary or late 
graft failure, but failed to record all subsequent dialysis treatments, some follow-up data 
on dialysis were missing. In view of the importance of these data for the cost-effectiveness 
estimates these missing values were replaced by estimates of the expected number of dialysis 
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treatments based on established clinical practice. For each week of missing data concerning 
dialysis treatments, three hemodialysis treatments were added, and costs were calculated 
accordingly. In case of primary non-function (PNF) and graft failure after a period of function, 
missing values were replaced until 1 year posttransplant or until death of the patient. For 
hospital readmission days, missing values were replaced by zero based on the assumption 
that any readmission would have been registered and missing database entries would only 
occur if readmission had not taken place.
Peritoneal dialysis per day  E     109
Hemodialysis per treatment  E     465
Renogram   E     218
Renal angiography   E     326
Renal ultrasound   E       62
Renal biopsy   E    280
Graft removal (nephrectomy)  E 1,464
Hospital admission per day  E    505
Preservation - machine perfusion  
 LifePort annual depreciation E  2,880 
 Tx per year (2006, NL)       360 
 Number of machines (NL)         12 
 Costs per Tx  E      96
 Disposables, including fluids  E    635
 Transport costs  E     111 
Total costs MP preservation per Tx  E   842
Preservation - cold storage  
 Preservation fluid  E    147
 Disposables  E     20
Total costs CS preservation per Tx  € E   167
Table 1: Unit costs and prices in the short-term evaluation.
Tx  denotes transplantation
Unit costs used to calculate the treatment costs are presented in Table 1. Immediate costs of 
graft failure were calculated in accordance with a standard protocol established by consensus 
between participating centers and countries (renogram, renal ultrasound and renal biopsy), 
and graft removal in case of definitive non-function. Separate calculations were made 
for Germany and Belgium based on data provided by the centers in those countries (see 
supplemental information).
For the calculation of the costs of organ preservation we used a preliminary estimate 
of the purchase price of the LifePort preservation machine (E 14,400). Annual depreciation 
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was assumed to be 20% in accordance with general guidelines for technical equipment. The 
costs per transplant further depended on the number of transplants per year and the number 
of machines required to perfuse all kidneys involved in these transplants in the Dutch trial 
region. Costs of transportation of the empty preservation machine back to the hospital 
of origin were also calculated for the Dutch situation (80% of transplantations within the 
country and 20% outside in other countries of the Eurotransplant region,  average travel 
distance 800 kilometers). The standalone LifePort device requires no additional perfusionist 
or transport logistics than for CS transport, so personnel and transportation costs from donor 
to transplant center were not included.
For static CS, preservation costs were calculated based on the costs of preservation 
fluids and the costs of disposables used for packaging the organ. Histidine-tryptophan-
ketoglutarate (HTK) was considered to be used for 50% of the kidneys (E 69.95 per liter) and 
University of Wisconsin (UW) solution in the other 50% of kidneys (E 224.20 per liter). Costs 
of disposables for CS were estimated at E 20.00 per kidney.
Bootstrap analysis
To evaluate uncertainty surrounding the ICER, a bootstrap analysis was performed.158,159 This 
method implies replication of datasets from the original study data, simulating repetition 
of the study. Although this method gives an indication of the expected range of the ICER, 
it cannot be used to reduce uncertainty regarding the clinical outcome, e.g. in case of low 
numbers of events such as in our DCD subgroup. Therefore bootstrapping was not performed 
in this subgroup. For the overall results, as well as for the subgroup of patients receiving a 
kidney retrieved from extended criteria donation we performed bootstrapping with 5,000 
replications and plotted the results in a cost-effectiveness plane.
Long-term evaluation
The annual transition probabilities, costs and utilities are presented in Table 2 (see Appendix 
for further details). For each year that a simulated patient was in a certain state, costs 
corresponding to this state were calculated. In addition, transition costs were calculated for 
transition from functional to failure (i.e. costs associated with diagnosis and implications of 
failure) and for the transition to death.
The total costs per year were summed up to present total costs of transplantation for 
the CS arm and the MP arm of the clinical study’s cohort of kidney recipients. Summation 
was done with and without discounting, i.e. with and without reflecting depreciated value of 
future costs and effects. The net effect of discounting is that early costs and effects receive 
more weight in the summation than late costs and effects. Common annual discount rates 
in economic evaluations are 3 to 5%. A similar depreciation of future health outcomes, i.e. 
life-years and QALYs, was applied. 
The model was populated with patients in various states according to the 1-year data 
from the RCT. In the cold storage arm there were 296 functional grafts, 31 failures and 9 
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deaths; in the machine perfusion arm there were 309 functional grafts, 16 failures and 11 
deaths. The average patient age at the start of the Markov model simulation was set at 50 
years. A background age-specific mortality rate for 5-year categories was included in the 
model (source: CBS (Statistics Netherlands), www.cbs.nl). In view of the assumed age of entry 
into the model and the limited availability of long-term estimates of patient and graft survival, 
the time horizon of the long-term evaluation was restricted to 10 years posttransplant.
Transition probabilities Value  Source
Functional to graft failure
- Cold storage arm 0.076 baseline risk 5% annually (UNOS), tripled risk for patients after DGF  
   (26.5% of patients)48 
- Machine preservation arm 0.071 baseline risk 5% annually (UNOS), tripled risk in 20.8% of patients 
  0.066 multivariate estimate48
General
- graft failure to death
 - first transplant 0.15 Liem et al.161 
 - re-transplant variable average of background and Liem et al.
- graft failure to re-transplant 0.15 UNOS transplant and waiting list data
- re-transplant to graft failure 1.85 relative to initial failure risk48 
State/transition costs Value Source
- functional  E 10,324 annual costs after transplantation157,162
- transition to failure E 2,024 immediate failure costs (short-term analysis)
- failure (dialysis) E 83,599 annual costs dialysis157
- re-transplant  E 51,619 De Wit et al.157 
- death  E 1,000 --
State utilities  Value Source
- QALY in functional state 0.90 De Wit et al.157 
- QALY after graft failure 0.66 general population value, CHD157
- QALY after re-transplant 0.90 return to functional level assumed
- QALY death  0 --
Table 2: Transition probabilities, costs and utilities for the long term model.
Statistical analysis
The data were analyzed at the level of the recipient, regarding the recipient couples with a 
kidney from the same donor as independent. For the short-term analysis, cost data were 
calculated based on individual health care consumption data using the SPSS statistical 
package, version 16.0. The bootstrap analyses were performed using R-project software, 
version 2.5.1.
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 ECD DCD
 MP (n = 94) CS (n = 94) MP (n = 42) CS (n = 42)
DGF 22 (23.4%) 29 (30.9%) 22 (52.4%) 28 (66.7%)
PNF 3 (3.2%) 11 (11.7%) 1 (2.4%) 1 (2.4%)
Graft failure < 1 yr 8 (8.5%) 18 (19.1%) 2 (4.8%) 3 (7.1%)
Dialysis costs  E 3,581 E 9,986 E 3,992 E 5,369
Early dysfunction   E 178 E 344 E 328 E 408
Readmission costs E 2,561 E 2,792 E 1,466 E 1,514
Preservation costs E 842 E 167 E 842 E 167
Total costs € 7,162 € 13,289 € 6,628 € 7,458




The data from the clinical study showed that MP significantly reduced the risk of DGF (20.8% 
versus 26.5% univariate estimate, P = 0.046; multivariate estimate adjusted OR 0.57, P = 
0.01) and more than halved the incidence of primary non-function after transplantation 
(2.1% versus 4.8%, P = 0.08), when compared to CS. Furthermore, MP significantly reduced 
the duration of DGF (median 10 versus 13 days, P = 0.04). One-year allograft survival 
was significantly better in the machine perfusion group (94% versus 90%, P = 0.04). In a 
multivariate Cox model, MP also significantly reduced the risk of graft failure up to 1 year 
posttransplant compared to CS (adjusted hazard ratio 0.52, P = 0.03).
The mean costs in the CS arm were E 8,053 versus E 6,180 in the MP arm (see Appendix for 
details). The main components of total costs were costs of dialysis (E 5,405 for CS versus E 
3,130 for MP, after imputation of missing data) and readmission costs (E 2,263 for CS versus 
E 2,062 for MP). These cost differences were used for the bootstrap analyses together with 
actual graft survival after 1 year (Figure 1, panel a). Each dot represents the ICER of a replicated 
bootstrap sample. The white dot in the middle represents the estimated average ICER 
(-50,251 Euro/additional functioning graft, non-parametric 95% confidence interval -151,382 
– 35,558). Clearly, the majority of the replications (93.9%) results in lower costs for MP, and 
an even larger proportion (97.0%) shows better graft survival for MP. The combination of 
better graft survival and lower costs occurs in 92.9 % of replications. 
A separate bootstrap analysis for ECD transplants is presented in panel b. The underlying 
cost and effectiveness data, including those for DCD transplants, are presented in Table 3. For 
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ECD, the results were even more favorable than the overall results, both with respect to the 
differences in effects and the difference in costs.
Outcome Conservative Adjusted
Incremental costs
 undiscounted E  -3,381,907 E  -4,447,707
 discounted* E  -3,020,963 E  -3,865,575
Incremental life-years
 undiscounted 49.76 59.61
 discounted* 37.34 44.56
Incremental QALYs
 undiscounted 11.90 12.88
 discounted* 7.29 7.79
Table 4: Markov model estimates of incremental costs, life-years and QALYs for crude and adjusted effect 
size estimates# with a time horizon of 10 years.
#  Crude and adjusted (multivariate) estimation of DGF risks with MP (see Table 2)
*  Discount rate: 4%
Long-term evaluation
The main results of the long-term model are summarized in Table 4. They reveal a clear cost 
difference in favor of MP as well as positive incremental life-years and QALYs, indicating gains 
in patient survival and QALYs for MP compared to CS, resulting in a cost-effectiveness ratio of 
minus E 86,750 per life-year gained and a cost-utility ratio of minus E 496,223 per quality-
adjusted life-year gained.
Sensitivity analyses
Sensitivity analyses were performed with variations of various parameters for the short-term 
evaluation (e.g. national cost differences, costs of equipment and materials) and the long-term 
evaluation (crude versus corrected effect estimates, time horizons of 5 and 8 years, variable 
discount rates, see Appendix). Only changes to the costs of machine perfusion disposables 
(organ cassette plus preservation solution) had a profound impact on the cost-effectiveness. 
Bootstrapping showed that the likelihood of cost-effectiveness decreased to 67% if the price 
of disposables was doubled and to 47% if the price was tripled (see Appendix).
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Figure 1: Results of bootstrap analysis of the short-term cost-effectiveness of MP versus CS. Percentages 
indicate proportion of simulations in the respective quadrants. (a) Overall results after imputation. (b) 
Patients receiving a kidney retrieved from expanded criteria donation (ECD).
a
b
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DISCUSSION
This is the first economic evaluation of MP versus CS based on an international prospective 
RCT. Both the short-term and the long-term analyses show that MP dominates CS, i.e. results 
in lower costs and better outcomes in the mixed overall population of deceased donor kidneys 
irrespective of donor type (DBD or DCD) and for both standard and extended donor criteria. 
For the short-term analysis, the advantage is expressed as a higher proportion of functioning 
grafts after 1 year with MP versus CS, while average costs over the first year were lower for 
MP than for CS. This applies especially for the subgroup of ECD transplants (n=188). For DCD 
transplants (n=84) the low number of graft failures (n=5) prevents firm conclusions. For the 
long-term analysis, the advantage of MP is expressed as better survival (life-years) both with 
and without correction for quality of life. Although largely insensitive to changes in discount 
rates, time horizon, and national cost and clinical policy differences, the outcome was very 
sensitive to increases in costs of MP disposables.
The short-term results are derived directly from the data in the RCT by Moers et al.48 with 
respect to graft function and several cost-related variables such as dialysis requirement and 
duration of hospitalization. The data collection for some non-endpoint variables (such as the 
number of dialysis treatments after graft failure) was not entirely complete, and as a result 
assumptions had to be made in order to allow analysis of all cases. This shortcoming of the 
data collection process is significant, since return to dialysis constitutes the major part of 
costs associated with graft failure. However, the cost-effectiveness of MP was also superior to 
CS without imputation of these data. Imputation of missing values associated with hospital 
readmission by replacing them with zero obviously lowered the mean costs of readmission in 
both groups, but the difference between the groups remained around E 200. Therefore, this 
correction is not expected to affect the overall results.
Exploration of differences in cost-effectiveness for donor type (ECD and DCD) showed 
remarkable results. For ECD transplants, the dominance of MP over CS was even more 
convincing than in the total population. For DCD, the benefit of MP in terms of costs and 
effects was minimal. This finding may be explained by the fact that DGF is usually associated 
with only a limited number of dialysis treatments posttransplant (until sufficient graft 
function occurs), whereas a graft failure implies dialysis for a much longer period (i.e. until 
end of follow-up, retransplant, or death). Although in the DCD subgroup MP was associated 
with a 17-fold reduced risk of DGF,48 no benefit of MP in terms of graft survival was found. As 
a result, cost differences caused by dialysis treatments remained relatively low between the 
two study arms. A recent study by Watson et al. with a sample size comparable to our study 
(45 pairs of DCD kidneys) showed considerably worse effectiveness of MP in DCD donation 
with respect to DGF than our study.160 These differences may be related to differences in 
ischemia and other disturbances of the kidneys in both studies. It can be expected that more 
frequent occurrence of DGF would further deteriorate the cost-effectiveness of MP in DCD.
140  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
The long term model required more assumptions and relied more on data from the literature 
than the short-term evaluation. Extrapolation to longer time horizons showed that the 
advantage of MP over CS continued to exist, but this observation should be interpreted with 
caution since reliable long-term survival data are very scarce. In a recent HTA report by Bond 
et al. with an economic model which took into account some of the preliminary data from 
our study, the importance of reliable long-term survival data was also stressed.47 Contrary 
to what was estimated by Wight et al. in their review performed in 2003,106 our data indicate 
that MP may be cost-effective in the short-term, and not only in the long term.
Overall, the results of our analyses suggest that implementation of MP preservation of all 
common types of deceased donor kidneys is likely to be cost-effective with lower costs per 
life-year and reduced costs per QALY compared to CS preservation. Although this analysis 
was focused on the Dutch situation, explorative analyses showed that adaptation to local 
costs and procedures for Germany and Belgium had no major impact on the results. Analysis 
of further scenarios with different numbers of MP equipment in relation to number of annual 
transplants suggest that the economic superiority of MP over CS is unlikely to be affected. As 
our sensitivity analyses demonstrate, only substantial increases in costs of disposables could 
affect the short-term cost-effectiveness of machine perfusion over static cold storage.
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SUPPLEMENTARY APPENDIX
Mean costs per treatment arm
The mean costs per treatment arm are tabulated below. The effect of imputation of missing 
data for dialysis treatment was considerable. Of the 23 subjects with PNF, 15 had missing 
data regarding dialysis. These caused average imputed costs of E 792 in the MP arm and 
E 1,839 in the CS arm. Of those patients with graft failure other than PNF, 16 had missing 
data, leading to costs of approximately E 100 for MP and E 1,500 for CS. After addition of 
actual and imputed costs of dialysis, there was a difference of about E 1,800 in favor of MP. 
As a result, addition of the costs of preservation and graft failure management (ultrasound, 
biopsy, etcetera) resulted in an average cost difference of nearly E 1,600 per transplant in 
favor of MP.
 MP-arm CS-arm
Dialysis (uncorrected) n = 334 €    746 n = 331 €    980
Imputed (PNF, n=15) n = 336 E 1,009 n = 336 E 1,839
Imputed (later failure, n=16) n = 336 E 1,023 n = 336 E 1,549
Dialysis (actual+imputed) n = 336 E 2,773 n = 336 E 4,354
Preservation n = 336 E    842 n = 336 E    167
Early dysfunction (DGF/PNF) n = 336 E    147 n = 336 E    218
Subtotal  E 3,762  E 4,739
Readmission (imputed) n = 336 E 2,062 n = 336 E 2,263
Total costs (imputed)  € 5,824  € 7,002
Average costs per patient by treatment
Due to the fact that data on hospital readmission were missing in a number of cases, the 
overall total costs could only be reliably calculated if readmission costs were imputed. For the 
sake of clarity, readmission costs with and without imputation are shown.
International variations in costs
For Belgium, this consisted of one additional ultrasound and biopsy, and weekly biopsies in 
case of persistent DGF. For Germany, the number of additional biopsies was 1.5 (the average of 
the specified number of 1-2 per patient), and one weekly biopsy plus two weekly ultrasounds 
in case of persistent DGF. In addition, 12.5% of German patients (1 in 8) were estimated to 
undergo a renal angiography. Fixed additional costs of biopsy and ultrasound were added to 
immediate failure costs. Variable costs of weekly procedures depending on length of DGF 
were added for a maximum period of 4 weeks. If graft survival was less than 4 weeks, variable 
costs were reduced accordingly. The results of these additions are presented as part of the 
sensitivity analyses.
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Transition probabilities, utilities and costs for the long-term model
The base-case transition probabilities from functional to failure were based on the crude 
univariate risk of DGF in both groups: 20.8% in the MP arm and 26.5% in the CS arm. This 
corresponds to a relative risk of 78.5% and an odds ratio (OR) of 0.728. Therefore, this is a 
conservative estimate compared to the OR reported for the multivariate comparison, which 
was 0.57. 
Patient survival rates were based on data by Liem et al.161 for the first transplant 
and a variable survival rate was used after re-transplant. An annual probability of re-
transplantation was included based on expert opinions and the probability of graft failure 
after re-transplantation was estimated to be 1.85 times the risk after the first transplant, as 
observed in the clinical study. Annual costs after transplantation were derived from De Wit 
et al.157 and Hilbrands et al.162 Costs of dialysis were calculated in an identical fashion as for 
the short-term model. Transition costs consisted of costs of graft failure, as in the short-term 
evaluation, and the costs of death, for which there were no good sources available. Since 
sensitivity analyses indicated that the results were largely insensitive to changes in these 
costs (less than 0.5% of total costs), an arbitrary amount of E 1,000 was used.
Utilities were based on quality of life measurements in patients with end-stage renal 
disease performed by De Wit et al.157 using the following instruments: EuroQol (EQ-5D) 
Instrument,163,164 Standard Gamble,165 and Time Trade Off.166 The EQ-5D is a widely accepted 
5-item generic questionnaire to measure quality of life. The last two methods are preference 
based measurements, allowing the expression of quality of life as a single indicator – usually 
a number between 0 and 1 – with 0 representing death and 1 representing full health. This 
single indicator can be used for the calculation of (cost per) QALY. In addition to the end-
stage renal disease patients, De Wit et al. also used data from a UK population sample on 
the valuation of health states167,168 and applied these to the health status as described by the 
patients. The quality of life experienced by these patients was used for the state of failure 
after transplantation in the present study. Utilities for a successful transplant were also 
derived from De Wit et al, who assumed that quality of life after transplantation was close to 
that in the general population based on previous literature.169-171
Sensitivity analyses
Apart from the bootstrap analysis of the short-term outcome and the effect of various effect 
sizes and time horizons in the long-term analysis presented above, the impact of country-
specific variations of procedures in case of graft failure was calculated. For Belgium, the 
costs of failure-related procedures were E 324 higher in the MP arm and E 400 higher in het 
CS arm. For Germany, costs were slightly higher (E 356 and E 434, respectively). The total 
costs increased by about 6%, and the ICERs for Belgium and Germany were -3,137,500 and 
-3,170,000 Euro per additional patient with a functional graft at 1 year, respectively. The 
change compared to the ICER without country-specific additional costs was 6.5% and 7.6%, 
respectively.
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The impact of assumptions made in the long term model was evaluated in a number of 
ways. First, the influence of the effect of MP versus CS was explored by using both the crude 
(univariate) and the adjusted (multivariate) risk of graft failure, constituting a 2-fold increase 
of the difference in failure rate. The impact of these two different estimates on the cost-
effectiveness and cost-utility ratios was minimal.
Second, the impact of variable discount rates and time horizons was explored. The 
results of these analyses showed that the number of life-years gained increased when the 
time horizon was expanded, reflecting a persistent advantage of MP over CS with respect to 
patient survival in the long term.
The impact of variations of the costs of equipment and materials for preservation was 
also assessed. If the ratio of machines to transplants was changed from 1 to 30 to 1 to 15, the 
costs per transplant increased by E 96. The same effect occurred if the purchase price of the 
LifePort machine was doubled. Changes of this magnitude are very small in relation to the 
total costs calculated. Changes to the costs of machine perfusion disposables (organ cassette 
plus preservation solution) will have a more profound impact since they will be entirely added 
to the costs per individual kidney. This is illustrated in the table below, which shows the 
consequences of doubling and tripling the price of these disposables on average costs and on 
the probability of MP remaining cost-effective.
 MP-arm CS-arm
Dialysis (actual+imputed) n = 336 € 2,773 n = 336 € 4,354
Early dysfunction (DGF/PNF) n = 336 €    147 n = 336 €    218
Readmission (imputed) n = 336 € 2,062 n = 336 € 2,263
Subtotal per patient  € 4,982  € 6,835
Actual current costs of disposables: € 635
Preservation  €    842  €    167
Total costs per patient  E 5,824  E 7,002
Likelihood of cost-effectiveness (bootstrap): 86%
Doubled costs of disposables: E 1,270
Preservation  € 1,477  €    167
Total costs per patient  € 6,459  € 7,002
Likelihood of cost-effectiveness (bootstrap): 67%
Tripled costs of disposables: € 1,905
Preservation  € 2,112  €    167
Total costs per patient  € 7,094  € 7,002
Likelihood of cost-effectiveness (bootstrap): 47% 
Sensitivity analysis of various price levels of MP disposables 
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ABSTRACT
Background
Retrospective evidence suggests that lactate dehydrogenase (LDH), aspartate amino-
transferase (ASAT), total glutathione-S-transferase (GST), alanine-aminopeptidase (Ala-AP), 
N-acetyl-β-D-glucosaminidase (NAG), and heart-type fatty acid binding protein (H-FABP) 
measured during kidney machine perfusion could have predictive value for posttransplant 
outcome. However, these data may be biased due to organ discard based on biomarker 
measurements, and previous analyses were not adjusted for likely confounding factors. No 
reliable prospective evidence has been available so far. Nevertheless, some centers already 
utilize these biomarkers to aid decisions on accepting or discarding a donor kidney.
Methods
From 306 deceased donor kidneys donated after brain death or controlled cardiac death and 
included in an international randomized controlled trial, these six biomarkers were measured 
in the machine perfusion perfusate. In this unselected prospective data set, we tested whether 
concentrations were associated with delayed graft function, primary non-function, and graft 
survival. Multivariate regression models investigated whether the biomarkers remained 
independent predictors when adjusted for relevant confounding factors.
Results
GST, NAG, and H-FABP were independent predictors of delayed graft function, but not 
of primary non-function and graft survival. LDH, ASAT, and Ala-AP had no independent 
prognostic potential for any of the end points. Perfusate biomarker concentrations had no 
relevant correlation with cold ischemic time or renal vascular resistance on the pump.
Conclusions
Elevated GST, NAG, or H-FABP concentrations during machine perfusion are an indication 
to adjust posttransplant recipient management. However, this study shows for the first time 
that perfusate biomarker measurements should not lead to kidney discard.
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INTRODUCTION
Recently, we conducted an international randomized controlled trial (RCT) investigating the 
effect of hypothermic machine perfusion (MP) versus static cold storage in deceased donor 
kidney transplantation. We found that MP reduced the risk of delayed graft function (DGF) 
with an odds ratio (OR) of 0.57 for all common donor types equally, and duration of DGF was 
three days shorter in MP kidney recipients. In addition, graft survival after MP was significantly 
better already at 1 year posttransplant, and MP reduced the risk of graft failure with a hazard 
ratio of 0.52.48 Together with evidence coming from earlier studies,46,105 these findings may 
lead to an increased usage of MP.
In addition to the beneficial effect that MP preservation has on postoperative outcome, 
many centers have advocated the method as a diagnostic tool to evaluate graft quality 
before transplantation. Several groups have suggested that perfusion characteristics, such as 
intrarenal vascular resistance, could have a predictive value for posttransplant outcome.106,122 
In addition, evidence points out that perfusate biomarkers during MP may have a prognostic 
potential,172-174 and as a result some centers use such measurements to aid decisions on 
transplanting or discarding a kidney. Nevertheless, the published data are scarce, using 
only retrospective data, and suffer from selection bias. Moreover, statistical analyses have 
been univariate, so far. Hence, likely confounding factors may have had an effect on the 
reported association between perfusate biomarkers and posttransplant results. No previous 
studies have addressed the question whether such measurements have a truly independent 
prognostic relevance.
In the present study, we have analyzed data from the MP-arm of our RCT to investigate 
whether six important perfusate biomarkers that have been advocated and are already in use 
by various centers have any true independent predictive value for renal transplant outcome. 
We deliberately chose not to search for novel biomarkers, but to test established biomarkers 
for the first time with multivariate analyses in a unique and unselected prospective data set.
We have studied six biomarkers that are commonly associated with renal cellular injury in 
general, and tubular damage in particular. The extent of such injury is thought to be a major 
cause of DGF and graft failure.3,31,175 Lactate dehydrogenase (LDH) is a non-specific cellular 
injury marker, but since perfusate samples were collected from an isolated kidney perfused on 
the pump, LDH release could reflect general renal injury. Aspartate aminotransferase (ASAT) is 
an enzyme that facilitates the conversion of aspartate and alpha-ketoglutarate to oxaloacetate 
and glutamate. Although clinically most often associated with the liver, ASAT is also found 
in renal parenchymal cells. ASAT is associated with acute damage to parenchymal cells.176 
Glutathione-S-transferase (GST) is an enzyme localized in the renal tubules. It is involved 
in deconjugation of waste products and excreted into the urine.177 Although α-GST is most 
directly associated with proximal tubular injury, total GST (the sum of α-GST and π-GST) is 
easier to measure. Total GST has been shown to also reliably reflect renal tubular injury and 
has become the most often used biochemical marker for kidney injury assessment during MP. 
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In the present paper, the abbreviation GST refers to total GST. Alanine-aminopeptidase (Ala-
AP) is an exopeptidase with a role in cell regulation and is also excreted into the urine.178 Ala-
AP release is associated with renal tubular injury. N-acetyl-β-D-glucosaminidase (NAG) is a 
lysosomal enzyme present in various tissues in the body, including the kidney, and its release 
is also associated with ischemic tubular damage.179 Heart-type fatty acid binding protein 
(H-FABP) is a cytosolic protein, located in the distal renal tubules and involved in free fatty 
acid transport from the cytosol to mitochondria, and is mainly found in the urine.180 Elevated 
H-FABP release has been associated with ischemic kidney tissue injury.181
METHODS
Donors and recipients
As previously published,48 a total of 376 deceased donor kidney pairs were included in the 
extended dataset of our RCT between November 1, 2005 and August 17, 2007. Of these 
inclusions, 294 were donors after brain death (DBD), and 82 were controlled DCD (Maastricht 
category III). One graft of each donor’s kidney pair was cold stored, and the contralateral 
organ was preserved by MP. For the present study, we analyzed perfusate biomarkers and 
follow-up data of the recipients in the MP-arm of our trial. For detailed information on study 
design, randomization, logistics, and data collection, we refer to our previous publication.48
Machine perfusion
LifePort Kidney Transporter® machines (Organ Recovery Systems, Itasca, IL, USA) were used 
for perfusion, delivering a pulsatile flow of University of Wisconsin MP solution (Kidney 
Preservation Solution-1®)108 at 1–8°C, with a systolic perfusion pressure fixed at 30 mmHg. 
Kidneys were machine perfused immediately following organ retrieval and flush-out, until 
transplantation. To prevent bias in clinical decisions about transplanting or discarding an 
organ, intravascular resistance and flow readings, as well as biomarker concentrations were 
never revealed to the transplantation team.
Sample collection and biochemical analysis
Perfusate samples of 10 ml were drawn after 10 minutes, after 1 hour, and at the end of 
the preservation period just prior to transplantation. All samples were stored on ice during 
transport, and thereafter at -80°C until further analysis. Details on the methodology of 
biochemical analysis are provided in the supplementary appendix.
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 Overall DBD DCD IF DGF PNF 
 (N = 306) (N = 231) (N = 75) (N= 230) (N = 76) (N = 7)
Donor demographics
Donor agea (yr) 50 (16–78) 52 (16–78) 43 (17–65) 50 (16–77) 50 (18–78) 44 (37–63)
Female donor (%) 39 42 28 39 40 57
DCD donor (%) 25 0 100 15 53 29
ECD donorb (%) 28 32 16 29 25 43
Traumatic cause of death (%) 23 22 27 24 21 0
Donor history of hypertension (%) 22 26 12 24 18 57
Donor history of diabetes mellitus (%) 5 5 5 4 9 0
Recipient demographics
Recipient agea (yr) 53 (11–79) 54 (11–79) 51 (24–73) 53 (11–79) 54 (13–73) 46 (13–67)
Female recipient (%) 42 43 37 44 36 71
Total time spent on the waiting lista (yr) 5 (1–8) 5 (1–8) 5 (2–8) 5 (1–8) 5 (1–8) 7 (3–8)
Previous transplants (% ≥1) 31 24 56 25 53 43
PRA level >5% (%) 13 13 13 13 20 43
Immunosuppressive drugs (%)      
       Prednisolone 98 97 99 97 99 100
       Cyclosporine 47 47 48 46 53 43
       Tacrolimus 51 51 49 51 49 57
       Azathioprine 1 <1 1 <1 1 0
       Mycophenolate mofetil 88 85 93 87 88 100
       Antithymocyte globulin 14 13 15 14 15 29
Transplant demographics
HLA mismatches (% of 0 mismatches) 13 17 3 13 13 14
Cold ischemic timea (h) 15 (4–30) 15 (4–30) 16 (4–27) 15 (4–30) 16 (8–27) 16 (14–25)
Posttransplant outcome    
Delayed graft function (%) 25 16 53 0 100 100
Duration of delayed graft function (days)a 10 (1–93) 9 (3–31) 10 (1–93) n/a 10 (1–93) n/a
Primary non-function (%) 2.3 2.2 2.7 0 9.2 100
Any acute rejection in first year (%) 23 24 21 19 36 14
1 year death censored graft survival (%) 95 95 93 97 87 0
Table 1: Donor, recipient, and transplant demographics and overall posttransplant outcome for the study 
group (n = 306 transplants in the MP-arm of the prospective study). Figures are presented as those for 
the whole group (Overall), as well as separate characteristics for kidneys derived from donation after 
brain death (DBD) and donation after cardiac death (DCD), and for patients with immediate function (IF), 
delayed graft function (DGF), or primary non-function (PNF). No statistical tests were performed on the 
data in this table. Note that the PNF group consists of only 7 cases, which makes a comparison with other 
groups less reliable. n/a denotes not applicable.
a   Median (range). 
b   ECD denotes expanded criteria donation, which was defined as donor age ≥60, or donor age between 50 
and 60, with at least two of the following additional donor characteristics: (1) history of hypertension, (2) 
cerebrovascular cause of death, (3) pre-retrieval serum creatinine >132 μmol/l.
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Study end points
Delayed graft function (DGF) and primary non-function (PNF) were analyzed as outcome 
measures of short-term graft function. DGF was defined as dialysis requirement in the first 
week posttransplant. PNF was scored when a kidney graft never showed sufficient function to 
prevent the need for dialysis after transplantation. Death censored graft survival (GS) served 
as end point for graft performance up to 1 year posttransplant.
Statistical analysis
First, univariate comparisons were made for each biomarker. The Mann-Whitney test 
investigated whether biomarker concentrations were significantly different in recipients with 
and without DGF and PNF. We used the Kaplan-Meier method with logrank tests to obtain 
a univariate comparison of graft survival up to 1 year between recipients of kidneys with a 
biomarker value below and above the median.
Second, for each individual biomarker, logistic regression models were constructed to 
find independent risk factors for DGF, and Cox proportional hazards models were used to 
identify independent risk factors for graft failure.77 Apart from the biomarker of interest, 
other covariates in these models were: Renal vascular resistance at the end of MP (mmHg/
ml/min), donor age (yr), donor type (DCD vs. DBD), CIT (hr), the duration of pre-transplant 
dialysis (yr), the number of previous transplants of the recipient, recipient age (yr), and the 
number of HLA mismatches. These particular covariates were chosen for the models of the 
present study because they were significant predictors of early posttransplant outcome in 
our data set.48 To prevent overfitting of the models, other covariates that had no significant 
impact on outcome in the RCT were not considered in the multivariate analyses of the present 
study. For all multivariate analyses, except those for NAG, biomarker concentrations had to 
be log-transformed to better approach a normal distribution.
Two-sided p-values under 0.05 were considered to indicate statistical significance.







Figure 1: Evolution of each biomarker’s perfusate concentration in time. Bullets represent mean biomarker 
concentrations per time point after the initiation of MP. Bold lines are a least square fit to the plotted data 
points, with thin upper and lower lines and a gray area indicating plus and minus standard error of the 
mean. The baseline function used for each least square fit was a typical equation for molecular saturation 
in fluids: y = ax / (x + b), where a and b are determined by the least square method. Curves were corrected 
for outliers using Dixon’s Q test. 
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RESULTS
In 306 out of 376 kidney transplants in the MP-arm of the RCT suitable perfusate samples 
were available for biomarker analysis. Table 1 shows baseline characteristics and outcome of 
these transplants. The baseline values did not differ significantly from the characteristics of 
the whole MP-arm of 376 cases.
We found that the concentration of most biomarkers, except for Ala-AP, did not change 
considerably after four to six hours of MP (Fig. 1). This finding is further supported by the 
observation that there was no relevant correlation between cold ischemic time (CIT) and the 
concentration of any of the six perfusate biomarkers measured at the end of MP.
Table 2
Biomarker concentration after 1 h of MP:  Overall 
Lactate dehydrogenase (U/l) 95 (57–151) 
Aspartate aminotransferase (U/l) 8 (5–13) 
Glutathione-S-transferase (U/l) 218 (172–280) 
Alanine-aminopeptidase (U/l) 80 (43–143) 
N-acetyl-β-D-glucosaminidase (U/l) 0.70 (0.46–1.14) 
Heart-type fatty acid binding protein (pg/ml) 4,340 (2,794–5,950) 
Biomarker concentration after 1 h of MP: no DGF DGF P-value
Lactate dehydrogenase (U/l) 91 (55–146) 104 (71–167) 0.089
Aspartate aminotransferase (U/l) 8 (5–12) 8 (6–14) 0.070
Glutathione-S-transferase (U/l) 214 (169–278) 235 (202–297) 0.026
Alanine-aminopeptidase (U/l) 81 (38–147) 75 (45–131) 0.61
N-acetyl-β-D-glucosaminidase (U/l) 0.70 (0.45–1.14) 0.70 (0.47–1.26) 0.98
Heart-type fatty acid binding protein (pg/ml) 4,018 (2,692–5,832) 4,914 (3,422–6,244) 0.028
Biomarker concentration after 1 h of MP: no PNF PNF P-value
Lactate dehydrogenase (U/l) 95 (57–148) 145 (44–175) 0.54
Aspartate aminotransferase (U/l) 8 (5–13) 8 (5–13) 0.98
Glutathione-S-transferase (U/l) 218 (172–281) 227 (164–307) 1.00
Alanine-aminopeptidase (U/l) 80 (42–145) 49 (25–97) 0.27
N-acetyl-β-D-glucosaminidase (U/l) 0.70 (0.46–1.14) 0.49 (0.44–1.42) 0.72
Heart-type fatty acid binding protein (pg/ml) 4,339 (2,804–5,966) 4,885 (2,115–5,656) 0.82
Biomarker concentration at end of MP:   Overall 
Lactate dehydrogenase (U/l) 304 (185–456) 
Aspartate aminotransferase (U/l) 19 (12–33) 
Glutathione-S-transferase (U/l) 324 (261–398) 
Alanine-aminopeptidase (U/l) 246 (137–423) 
N-acetyl-β-D-glucosaminidase (U/l) 1.44 (0.93–2.49) 
Heart-type fatty acid binding protein (pg/ml) 5,851 (4,442–8,608) 
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Table 2 Continued
Biomarker concentration at end of MP: no DGF DGF P-value
Lactate dehydrogenase (U/l) 285 (173–415) 358 (227–529) 0.015
Aspartate aminotransferase (U/l) 18 (12–28) 25 (14–43) 0.006
Glutathione-S-transferase (U/l) 302 (256–382) 379 (308–465) <0.0005
Alanine-aminopeptidase (U/l) 241 (122–420) 253 (184–444) 0.10
N-acetyl-β-D-glucosaminidase (U/l) 1.33 (0.91–2.22) 1.98 (1.21–3.39) 0.001
Heart-type fatty acid binding protein (pg/ml) 5,178 (4,120–7,980) 7,325 (5,020–12,248) <0.0005
Biomarker concentration at end of MP: no PNF PNF P-value
Lactate dehydrogenase (U/l) 304 (182–456) 276 (213–675) 0.88
Aspartate aminotransferase (U/l) 19 (12–33) 21 (8–26) 0.71
Glutathione-S-transferase (U/l) 324 (261–401) 291 (213–368) 0.39
Alanine-aminopeptidase (U/l) 243 (133–422) 313 (182–470) 0.25
N-acetyl-β-D-glucosaminidase (U/l) 1.43 (0.93–2.44) 2.50 (1.23–3.76) 0.11
Heart-type fatty acid binding protein (pg/ml) 5,855 (4,442–8,582) 5,833 (4,315–10,253) 0.80
Table 2: Univariate characteristics of biomarkers after 1 h and at the end of MP. Values are expressed as 
median (interquartile range).
Univariate tests
Table 2 shows that kidneys that developed DGF after transplantation were those that had 
significantly higher GST and H-FABP concentrations already after 1 h of MP. Since these 
two biomarkers appeared to show such an early discriminative potential, we also tested 
whether their concentrations in donor plasma just prior to organ retrieval were higher for 
kidneys that developed DGF after transplantation versus kidneys with immediate function. 
No significant difference was detected (also see the supplementary appendix). At the end of 
MP, all biomarkers except Ala-AP had a significantly higher median perfusate concentration 
for kidneys that developed DGF versus grafts with immediate function. In contrast, at both 
time points, there was no difference in biomarker release between kidneys that did and 
did not develop PNF. The Kaplan-Meier analyses (figures provided in the supplementary 
appendix) showed that death censored graft survival up to 1 year after transplantation was 
not significantly different for grafts with any biomarker concentration (end of MP) above 
the median, versus those with concentrations below the median. Receiver-operator curves 
(ROC) investigating each biomarker’s predictive accuracy for DGF yielded areas-under-the-
curve of 0.60 for LDH, 0.61 for ASAT, 0.67 for GST, 0.57 for Ala-AP, 0.64 for NAG, and 0.64 
for H-FABP (Fig. 2). In the Supplemental Digital Content we show Pearson’s correlation 
coefficients between the six biomarkers measured and for each biomarker’s correlation 
with renal vascular resistance at the end of MP and with CIT. None of the biomarkers had a 
relevant correlation with renal resistance or with CIT. The strongest correlation that we found 
was the one between LDH and ASAT (0.56). Supplemental figures show that (except for Ala-
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AP) the curve of each biomarker’s evolution over time was significantly higher for kidneys 
that developed DGF versus those with immediate function and for DCD versus DBD kidneys.
 Odds ratio / Hazard ratio
Biomarker covariate (95% CI)b P-value
Risk of delayed graft function
(biomarker measured after 1 h of MP)  
Lactate dehydrogenase (log[U/l]) 1.43 (0.94–2.19) 0.10
Aspartate aminotransferase (log[U/l]) 1.34 (0.90–2.00) 0.16
Glutathione-S-transferase (log[U/l]) 1.90 (0.82–4.42) 0.14
Alanine-aminopeptidase (log[U/l]) 0.81 (0.57–1.17) 0.26
N-acetyl-β-D-glucosaminidase (U/l) 1.17 (0.78–1.76) 0.45
Heart-type fatty acid binding protein (log[pg/ml]) 1.27 (0.84–1.93) 0.26
Risk of delayed graft function
(biomarker measured at end of MP)  
Lactate dehydrogenase (log[U/l]) 1.09 (0.68–1.74) 0.73
Aspartate aminotransferase (log[U/l]) 0.97 (0.63–1.51) 0.91
Glutathione-S-transferase (log[U/l]) 3.21 (1.37–7.50) 0.007
Alanine-aminopeptidase (log[U/l]) 1.03 (0.70–1.49) 0.90
N-acetyl-β-D-glucosaminidase (U/l) 1.31 (1.04–1.66) 0.02
Heart-type fatty acid binding protein (log[pg/ml]) 1.91 (1.18–3.08) 0.008
Risk of graft failure within the first year posttransplantc
(biomarker measured at end of MP) 
Lactate dehydrogenase (log[U/l]) 0.94 (0.43–1.97) 0.83
Aspartate aminotransferase (log[U/l]) 0.74 (0.36–1.50) 0.40
Glutathione-S-transferase (log[U/l]) 0.31 (0.06–1.49) 0.14
Alanine-aminopeptidase (log[U/l]) 1.05 (0.55–2.02) 0.89
N-acetyl-β-D-glucosaminidase (U/l) 1.06 (0.86–1.32) 0.57
Heart-type fatty acid binding protein (log[pg/ml]) 0.81 (0.41–1.60) 0.54
Table 3: Multivariate risk analysisa for delayed graft function and graft failure. For each of the six biomarkers, 
a separate multivariate model was built. In this table only the adjusted odds / hazard ratios and p-values for 
the biomarker of interest are shown.
a   Logistic regression models for delayed graft function, and Cox proportional hazards models for graft 
failure. Other covariates in each model were: Renal vascular resistance at the end of MP (mmHg/ml/
min), donor age (yr), donor type (DCD vs. DBD), CIT (hr), the duration of pre-transplant dialysis (yr), the 
number of previous transplants of the recipient, recipient age (yr), and the number of HLA mismatches.
b   Odds ratios apply to the logistic regression model and hazard ratios apply to the Cox proportional hazards 
model.
c  Censored upon death with a functioning graft.
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Multivariate models
The logistic regression and Cox proportional hazards models (table 3) showed that only GST, 
NAG, and H-FABP levels in the perfusate measured at the end of MP were true independent 
predictors for the risk of DGF. None of the six biomarkers had any significant independent 
predictive value for the risk of graft failure in the first year posttransplant.
Figure 2: Receiver-operator curves for each of the six perfusate biomarkers’ concentration at the end of MP 
at a continuous range of cut-off points. The numbers between brackets indicate the area-under-the-curve 
for each line.
156  p r e s e r v i n g  o r g a n  f u n c t i o n  o f  m a r g i n a l  d o n o r  k i d n e y s
DISCUSSION
Predicting outcome after kidney transplantation has been the topic of numerous, often 
retrospective, studies. Well-known pertinent donor and recipient factors, as well as cold 
and warm ischemic time and the organ preservation modality are usually included into such 
multivariate risk assessments. Recently, Rao et al. developed a comprehensive risk score to 
predict renal graft failure,182 and Moore et al. conducted a study comparing the predictive 
value of several existing risk scores for early graft (dys)function.183 Both studies yielded useful 
tools to aid decisions on organ acceptance and early recipient management. However, current 
risk scores are no more than a sophisticated mathematic compilation of routinely collected 
variables that are already known to the transplant team. In an attempt to add something 
genuinely novel to the decision-making process, several groups have introduced various 
biomarkers that may have predictive potential for short and long term outcome. For example, 
evidence suggests that donor serum interleukins could be indicative for posttransplant 
complications.184 In the past, Daemen et al. and Gok et al. have performed analyses of the 
biomarkers GST, H-FABP, Ala-AP, and/or LDH in renal MP perfusate. Their studies found that 
biomarker concentrations were elevated in perfusates of those kidneys that were discarded 
on other grounds, and that uncontrolled (Maastricht cat. II) DCD grafts tended to have 
higher GST, H-FABP, and Ala-AP concentrations in the perfusate than kidneys recovered 
from controlled (cat. III) DCD procedures. In addition, LDH and GST levels correlated with 
warm ischemic time.172-174,184,185 However, these studies did not investigate whether any 
of these biomarkers was independently associated with outcome after transplantation. It 
is very plausible that an association between the concentration of a certain substance in 
the perfusate and posttransplant results is no more than a surrogate marker for another 
underlying causal factor already known. For example, a longer warm ischemic time could 
result in an increased biomarker release into the MP perfusate due to more ischemic injury to 
the kidney. In that case, measuring these markers will not provide any extra information to 
the clinician, since simply considering warm ischemic time would be sufficient to appreciate 
the amount of injury to the graft. With this in mind, the univariate results of the present 
study could be biased by confounding factors such as DCD versus DBD: As our supplemental 
figures show, DCD kidneys release significantly more injury biomarkers into the perfusate, 
but such kidneys are already known to have inferior posttransplant outcome in terms of more 
DGF. Measuring perfusate biomarkers is only worth the extra effort and expense when the 
biomarker of choice has a truly independent predictive value in the context of traditional 
prognostic factors. Therefore, multivariate analyses that correct for such likely confounding 
factors are essential to appreciate any biomarker’s true prognostic potential.
This is the first prospective study which shows that GST, NAG, and H-FABP, measured in 
the MP perfusate at the end of MP, are independently associated with the risk of DGF, and that 
LDH, ASAT, and Ala-AP do not seem to have such predictive potential. Therefore, measuring 
the former three markers will indeed provide an extra piece of information to clinicians who 
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care for a kidney recipient. Nevertheless, since no marker could predict graft survival, we feel 
that there is no rationale to discard a kidney based on such measurements. DGF may be an 
unwelcome postoperative complication, but given the present donor organ shortage a known 
elevated risk of DGF will seldom be the reason to refuse a renal graft. Several centers worldwide 
already use one of the perfusate biomarkers discussed in this paper for pretransplant kidney 
quality assessment to aid decisions on acceptance or discard of donor kidneys. The results 
of the present analysis are of immediate clinical importance, since our data suggest that this 
so called “evidence based” decision making is probably not justified. Prior knowledge of an 
increased DGF risk could, however, be useful to fine-tune recipient management. Our data 
set is likely to be more reliable and has no selection bias compared to other studies: Data 
collection for the present study was multicenter, prospective, and no kidneys were discarded 
based on biomarker measurements or other MP related characteristics. 
With ROC analysis we sought for relevant cut-off values for each biomarker’s 
concentration.186 In the present analysis, all areas-under-the-ROC were well under 0.8, with 
the value for GST (0.67) most approaching a reliable predictive test. These results do not 
allow to determine cut-off values for the three predictive biomarkers, since either sensitivity 
or specificity will be poor. A more practical approach could be to consider the biomarker’s 
concentration as a continuous variable in the context of other predictive factors. As usual, 
it is the clinician’s task to make a balanced judgement of DGF risk, taking all such relevant 
factors into account.
The univariate results of the present study suggest that GST and H-FABP have significantly 
higher levels in the perfusate already after 1 h of MP in kidneys that develop DGF. However, 
our multivariate assessment shows that this association does not persist when tested against 
relevant confounding factors. In addition, GST or H-HABP measured in donor plasma did not 
predict DGF. Therefore, measuring these biomarkers in the donor or already after 1 h of MP 
may be too early to draw reliable conclusions about DGF risk.
Interestingly, no biomarkers correlated with renal intravascular resistance during MP. 
This finding suggests that perfusate biomarkers reflect a different aspect of renal injury than 
intravascular resistance does. Perfusate markers in our study are most likely related to tubular 
injury, whereas vascular resistance may reflect endothelial damage.
A possible limitation of this study is that the most important time point at which three 
biomarkers were independent predictors of DGF (i.e. end of MP) was not standardized, and 
could be anywhere between four and 25 hours after initiation of MP. This may have introduced 
more variance in these data. However, none of the six markers had a relevant correlation with 
CIT, and we found that five out of six curves showing the average accumulation of each of the 
biomarkers’ concentration in time followed an almost horizontal course after four to six hours 
of MP. This is in line with previous findings.185 Therefore, any time point after four to six hours 
is likely to be suitable to take a representative perfusate biomarker sample. This will add to 
clinical applicability, as organ transport logistics will not always allow perfusate sampling at a 
fixed time point. Since an elevated perfusate GST, NAG, or H-FABP concentration will at best 
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lead to adjusted recipient management and not to kidney discard or re-allocation, the rather 
late availability of test results at the end of MP should not be a major concern for clinicians.
It is important to note that the incidence of PNF was very low in our data set. Hence, 
comparisons between groups are unreliable for this end point. Nevertheless, since there was 
a considerable number of graft failures in the first year posttransplant, 1-year graft survival 
does provide a reliable end point in our data to assess this single most important outcome 
measure after transplantation.
Another limitation of our data is that this study did not include uncontrolled (Maastricht 
cat. I and II) DCD kidneys. These are the organs that have sustained most ischemic damage, 
rendering viability testing during MP even more relevant.40,185 In addition, it is conceivable 
that a biomarker will be predictive for graft failure in the context of such extremely marginal 
kidneys. Similar multivariate analyses with cohorts of recipients of these organs are needed 
to determine whether pefusate markers could predict more than just DGF. Unfortunately, to 
date, large series of such transplantations remain rare. 
In conclusion, the present study demonstrated that GST, NAG, and H-FABP released 
in the perfusate and measured at the end of machine perfusion are independent predictors 
for DGF, but not for graft survival in the first year after kidney transplantation. Since their 
prognostic value for DGF is at best moderate, these markers should always be considered 
in the context of other known variables. LDH, ASAT, and Ala-AP do not posess independent 
predictive potential for posttransplant outcome. Given the results of our analysis, an elevated 
GST, NAG, or H-FABP concentration in the MP perfusate could be an additional trigger to 
adjust postoperative recipient management. However, in defiance of the practice in various 
transplant centers worldwide, this prospective study for the first time showed that the values 
of any of these markers may not be used for the decision to either transplant or discard a DBD 
or controlled DCD kidney.
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SUPPLEMENTARY APPENDIX
Donor inclusions used for this study
We used the MP arm of the extended data set of our original study (376 recipients of a machine 
perfused kidney).48 This extended set consists of the 336 DBD and DCD machine perfused 
kidney recipients who were included between November 1, 2005 and October 31, 2006 
plus the machine perfused DCD kidney recipients who were included between November 1, 
2006 and August 17, 2007 following an amendment to the study protocol. This amendment 
is described in the Results section of the NEJM paper (pages 10 and 13), as well as in that 
paper’s figure 2, which shows subgroup analyses that were conducted on this extended data 
set of 752 recipients in total (i.e. 376 in the CS arm and 376 in the MP arm). All 376 recipients 
of machine perfused kidneys have therefore received a graft that was part of the same study, 
and those are exactly the kidneys that were also described in the NEJM paper. No additional 
inclusions were done solely for the biomarker analysis. For the present biomarker analysis, 
we chose to use this extended data set, as this would result in a superior  statistical  power to 
detect  any effects,  and  there would be significantly more DCD kidney recipients to analyze 
(82 instead of 42). This higher percentage of DCD kidneys in the extended data set does also 
account for the somewhat higher overall DGF incidence in the extended data set versus the 
main data set of our RCT.
Biomarker concentration in donor plasma:  Overall 
Glutathione-S-transferase (U/l) 252 (205–329) 
Heart-type fatty acid binding protein (pg/ml) 2,272 (1,129–4,713) 
  
Biomarker concentration in donor plasma: no DGF DGF p-value
Glutathione-S-transferase (U/l) 261 (207–342) 242 (192–300) 0.081
Heart-type fatty acid binding protein (pg/ml) 2,111 (1,128–4,907) 2,450 (1,168–4,359) 0.97
Table S1: Univariate characteristics of GST and H-FABP measured in donor plasma just before organ 
retrieval. Values are expressed as median (interquartile range).
Biochemical analysis
LDH and ASAT were measured using standard automated clinical photometric kit assays on 
a Modular P800 analyzer (kit category nrs. 04794940/04796217 and 04571100/04571118, 
respectively, Roche Diagnostics, Mannheim, Germany). The activity of GST was measured 
spectrophotometrically (Power Wave 200 Spectrophotometer, Bio-Tek Instruments, 
Winooski, USA) at 340 nm via the conversion of 1-chloro-2,4-dinitrobenzene (CDNB) to 
glutathione-S-dinitrobenzene. The working substrate consisted of 0.1 ml of 100 mM CDNB 
added to 0.1 ml of 200 mM glutathione with 9.8 ml Dulbecco’s phosphate buffered saline. 






Figure S1: Evolution of each biomarker’s perfusate concentration in time split into kidneys that developed 
DGF and kidneys with immediate function. Lines are a least square fit to mean biomarker concentrations 
per time point after the initiation of MP, with gray lines drawn for kidneys with immediate function and 
black lines for kidneys that developed DGF. The baseline function used for each least square fit was a typical 
equation for molecular saturation in fluids: y = ax / (x + b), where a and b are determined by the least square 
method. Curves were corrected for outliers using Dixon’s Q test. P-values are the result of Mann-Whitney 
tests which compared the areas-under-the-curve per group.







Figure S2: Evolution of each biomarker’s perfusate concentration in time split into kidneys recovered from 
DBD and kidneys recovered from DCD. Lines are a least square fit to mean biomarker concentrations per 
time point after the initiation of MP, with gray lines drawn for DBD kidneys and black lines for DCD kidneys. 
The baseline function used for each least square fit was a typical equation for molecular saturation in fluids: 
y = ax / (x + b), where a and b are determined by the least square method. Curves were corrected for outliers 
using Dixon’s Q test. P-values are the result of Mann-Whitney tests which compared the areas-under-the-
curve per group.
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 Odds ratio 
Biomarker covariate (95% CI) P-value
Risk of delayed graft function
(biomarker measured in donor plasma)  
Glutathione-S-transferase (U/l) 1.00 (1.00–1.00) 0.22
Heart-type fatty acid binding protein (pg/ml) 1.00 (1.00–1.00) 0.36
Table S2: Multivariate risk analysis (logistic regression model) for delayed graft function testing whether 
GST or H-FABP concentrations in donor plasma just before organ retrieval had any independent prognostic 
value for the risk of developing DGF after transplantation. Other covariates in each model were: Renal 
vascular resistance at the end of MP (mmHg/ml/min), donor age (yr), donor type (DCD vs. DBD), CIT (hr), 
the duration of pre-transplant dialysis (yr), the number of previous transplants of the recipient, recipient 
age (yr), and the number of HLA mismatches. In this table only the adjusted odds ratios and p-values for 
the biomarker of interest are shown.
The final pH of the reaction was set at 6.5. Calibration was performed with GST prepared 
from human placenta tissue (Sigma Aldricht, Zwijndrecht, The Netherlands). H-FABP was 
measured using a commercially available human H-FABP enzyme-linked immuno sorbent 
assay (ELISA) kit (Hycult Biotechnology, Uden, The Netherlands). Activity of Ala-AP and NAG 
were measured using colorimetric assays.187 NAG was measured using a modified enzyme 
assay according to Findlay188 at pH 4.25 using p-nitrophenyl-N-acetyl-β-D-glucosaminide 
as a substrate. Ala-AP was detected with the modified enzymatic assay of Pfleiderer189 using 
alanine-p-nitroanilide as a substrate.
 CIT RR H-FABP NAG Ala-AP GST ASAT
LDH 0.15 0.08 0.39 0.24 0.08 0.45 0.56
ASAT 0.08 0.10 0.29 0.15 0.09 0.44 
GST 0.06 0.05 0.43 0.21 0.15  
Ala-AP 0.11    -0.08 0.16 0.28   
NAG 0.11 0.08 0.32    
H-FABP 0.03    <0.01     
Table S3: Pearson’s correlation coefficients between the six biomarkers at the end of machine perfusion, 
and for each biomarker’s correlation with cold ischemic time (CIT) and renal vascular resistance (RR) at 
the end of machine perfusion. Numbers printed in bold indicate those correlations that were statistically 
significant (p<0.05).







Figure S3: Kaplan-Meier plots of 1-year death censored graft survival split at each biomarker’s median 
value. Logrank tests showed that all p-values for the difference between each pair of survival curves were 
above 0.05. Vertical lines indicate cases that were censored upon death with a functioning graft.
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ABSTRACT
Vascular renal resistance (RR) during hypothermic machine perfusion (MP) is frequently 
used in kidney graft quality assessment. However, the association between RR and outcome 
has never been prospectively validated. Prospectively collected RR values of 302 machine-
perfused deceased donor kidneys of all types (standard and extended criteria donor kidneys 
and kidneys donated after cardiac death), transplanted without prior knowledge of these RR 
values, were studied. In this cohort, we determined the association between RR and delayed 
graft function (DGF) and 1-year graft survival. The RR (mmHg/mL/min) at the end of HMP 
was an independent risk factor for DGF (odds ratio 21.12 [1.03–435.0]; P = 0.048) but the 
predictive value of RR was low, reflected by a c-statistic of the receiver operator characteristic 
curve of 0.58. The RR was also found to be an independent risk factor for 1-year graft failure 
(hazard ratio 12.33 [1.11–136.85]; P = 0.004). Determinants of transplant outcome are 
multifactorial in nature and this study identifies RR as an additional parameter to take into 
account when evaluating graft quality and estimating the likelihood of successful outcome. 
However, RR as a stand-alone quality assessment tool cannot be used to predict outcome 
with sufficient precision.
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INTRODUCTION
Hypothermic machine perfusion (MP) preserves kidney grafts by continuous or pulsatile 
administration of a recirculating cold (1–10°C) preservation solution. The Machine Preservation 
Trial (MP Trial) recently showed that MP decreases the incidence of primary non-function 
(PNF) and delayed graft function (DGF), and increases one-year graft survival compared to 
standard static cold storage.48 In addition, MP offers the unique possibility to assess the graft 
in the interval between procurement and transplantation by monitoring perfusion dynamics 
and/or perfusate biomarkers that possibly correlate with graft outcome.
Since the early days of MP in the 1960s, it has been assumed that perfusion dynamics 
such as perfusion pressure, perfusate flow, and intravascular renal resistance (RR) can reliably 
predict kidney graft outcome. To a certain extent, there is indeed evidence that perfusion 
parameters correlate with kidney graft function. However, this evidence originates almost 
exclusively from retrospective studies in which kidneys were preselected and discarded based 
on empirically defined perfusion parameter thresholds.105 Needless to say, systematically 
discarding kidneys introduced a major bias in these studies. Two of the earliest studies 
addressing the association between perfusion parameters and early graft function did not 
preselect kidneys based on these parameters. Henry et al. showed a correlation between early 
dysfunction and RR at the end of MP.190 However, the group of kidneys with early dysfunction 
was small (n = 10) and only one of those kidneys developed PNF. Sampson et al. found no 
difference in flow rates between immediately functioning kidneys and those that developed 
early graft failure.191 Noteworthy, 12 of the 18 graft failures in this study were related to 
hyperacute or acute rejection, and grafts were removed early after transplantation. The 
changed donor population and improved immunosuppression makes it even more difficult to 
interpret these results leaving the issue of the true prognostic value of perfusion parameters 
unresolved.
With the enduring donor shortage, kidneys of “uncertain” quality originating from 
expanded criteria donors (ECDs) or donated after cardiac death (DCD) are increasingly used. 
As these kidneys have a higher incidence of PNF and DGF compared with standard criteria 
donor (SCD) kidneys,12,40 the need for specific and sensitive surrogates of their viability is 
becoming even more critical. The absence of prospective analyses of the association between 
perfusion parameters and kidney transplant outcomes, and the increasingly urgent need for 
valid predictors of graft outcome led us to analyze the association between prospectively 
collected RR values and kidney graft outcome in a substudy of the MP Trial.
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METHODS
Study design
Study data were prospectively collected in the MP arm of the MP Trial. This randomized 
controlled trial compared MP with static cold storage for the development of DGF in all 
types of deceased donor kidneys within part of Eurotransplant: Belgium, the Netherlands, 
and the federal state of North Rhine-Westphalia in Germany. The MP Trial showed that MP 
significantly reduces the incidence of DGF (adjusted odds ratio (OR) 0.57 (0.36–0.88), P = 
0.01) and increases one-year graft survival (hazard ratio 0.52 (0.29–0.93), P = 0.03).48
Briefly, all kidneys from eligible consecutive deceased donors (SCD, ECD, and DCD) aged 
16 years or older, were included. We defined ECD kidneys according to criteria of the United 
Network for Organ Sharing (UNOS).12 Among the DCD kidneys, only those originating from 
Maastricht category III donors were included.13 One kidney from each donor was assigned to 
MP and the contralateral kidney to static cold storage according to regional and computer 
generated randomization lists. When a reliable connection to the perfusion machine 
was impaired either by an aortic patch that was too small or by too many renal arteries, 
randomization for this kidney pair was changed and the preservation methods switched. 
Kidneys were allocated according to standard Eurotransplant allocation rules without 
revealing the preservation method at the time of organ offer. A strictly paired design was 
maintained, in which both kidneys from one donor needed to be transplanted into different 
recipients. Both kidneys of a pair were excluded when one or both recipients died within 
1 week after transplantation. For this analysis, only the data prospectively collected in the 
MP arm of the MP Trial were used. Informed consent from recipients was not required, as 
kidneys were randomized before organ allocation. Ethical approval was obtained from the 
Eurotransplant Ethical Advisory Committee, the Kidney Advisory Committee, and ethics 
review boards in each trial region.
Preservation method
Kidneys were flushed in situ with the University of Wisconsin solution (64%) or histidine-
tryptophan-ketoglutarate (32%); in 4% of cases the flush solution was not reported. Pulsatile 
MP was provided by LifePort® Kidney Transporter machines (Organ Recovery Systems, 
Itasca, IL, USA). Perfusion was started immediately after organ recovery, and was continued 
until transplantation. All kidneys were perfused with Belzer’s machine perfusion solution, 
available as Kidney Preservation Solution-1® (1–8°C).108 Perfusion was started immediately 
after organ recovery and was continued until transplantation. The systolic perfusion pressure 
was set at 30 mmHg and the machine continuously recorded the perfusion parameters. The 
LifePort® was used as a stand-alone preservation technique: changing the perfusion pressure 
or adding pharmacologic agents to the perfusion solution was not allowed. The MP kidney 
was transported to the recipient hospital without any monitoring. The transplantation team 
was blinded to the perfusion parameters. Because the transplantation team was blinded to 
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the perfusion parameters, the decision to accept or reject a kidney could not be biased by 
these parameters. The RR data were downloaded by the perfusionist at the end of MP, to be 
evaluated at a later time.
Follow-up
Recipients provided follow-up data to a secure online Eurotransplant database and were 
financially compensated to ensure maximal data completeness. No relevant irregularities 
were found during an external audit of a random sample of 10% of all patient follow-up data.
Study endpoints
DGF was defined as the need for dialysis in the first week after transplantation, preceding 
return of graft function. PNF was defined as the permanent lack of graft function. Death 
censored graft survival was the outcome measure for graft performance until 1 year 
posttransplantation. Because the LifePort® software calculates RR every 10 s (mmHg/mL/
min), we chose to analyze RR data at 30 minutes, 1, 2 and 4 h and at the end of MP. These time 
points were chosen before disclosure of RR values.
Statistical methods
We performed univariable logistic regression analysis for DGF and then constructed a 
multivariable logistic regression model to find independent risk factors for DGF. The RR was 
entered as a covariate in these models. Other covariates were prespecified in the protocol 
before the MP Trial started. Because of a limited number of events in this subgroup analysis 
we only included those prespecified factors that were significantly associated with DGF in 
the MP Trial: cold ischemic time, donor type (donation after brain death [DBD] vs. DCD), 
donor age, retransplantation vs. first transplantation, and duration of pretransplant dialysis.48 
A receiver operator characteristic (ROC) curve was constructed to investigate the predictive 
accuracy of RR for DGF. Because the number of PNF was low, an association between PNF and 
RR could not be studied and PNF cases were excluded from further analysis. We performed 
unadjusted and adjusted Cox regression analysis for 1-year graft failure. Because of the low 
number of graft losses, we could only correct for two variables; we therefore chose RR, the 
variable of interest and donor age, the variable that was the strongest independent risk factor 
for graft failure in the MP Trial. To exclude a potential bias introduced by kidneys in which 
randomization needed to be switched, the logistic and Cox regression analyses only included 
kidneys that were randomized to and effectively preserved by MP.
Continuous variables are expressed as median and range, categorical variables as number 
and percentage. Two-sided P-values ≤0.05 were considered to indicate statistical significance. 
Endpoint interim analyses were not performed. All data analyses were performed using SPSS, 
SAS and R software.
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Figure 1: Dot plot representing the individual renal resistance values in function of perfusion time 
during hypothermic machine perfusion and early graft function. PNF: primary non-function defined as 
permanent lack of graft function (n = 6); DGF: delayed graft function defined as dialysis in the first week 
after transplantation, preceding return of graft function (n = 63); IF: immediate function (n = 257); MP: 
hypothermic machine perfusion.
RESULTS
Three hundred thirty-six deceased donor kidneys were preserved by MP between November 1, 
2005 and October 31, 2006. We included 42 DCD kidneys (13%) and 294 DBD kidneys (87%), 
of which 203 were SCD and 91 were ECD. Table 1 shows donor and recipient characteristics, 
early graft function and 1-year graft and patient survival. Overall, 19% of machine perfused 
kidneys developed DGF; PNF occurred in seven cases (2%). The incidence of DGF was highest 
in DCD kidneys; PNF did not differ between SCD, ECD and DCD kidneys. One-year patient and 
death censored graft survival was 97% and 94% and comparable between all donor types. 
The RR data were available in 326 cases (Figure 1 and Table 2). The RR of PNF kidneys were 
intermediate between RR of DGF and immediately functioning kidneys. Because of the low 
number of events, these PNF cases were excluded from further analyses. Randomization was 
switched in 24 donors (7%) because of aberrant vascular anatomy, making the connection 
to the LifePort® difficult. Switching randomization had no significant effect on the incidence 
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of DGF; of these 24 kidneys, 8 developed DGF whereas 16 had immediate graft function (P = 
0.12). To avoid an impact on the outcome of the logistic and Cox regression models, these 24 
kidneys were excluded from the regression analyses.
n(llAelbairaV = 336) = 203) ECD (n = 91) DCD (n = 42) p-Value
Donor characteristics
Age1 100.0)06–71(24)18–05(66)95–61(64)18–61(15)raey( 2
Cold ischemic time1 100.0)52–4(61)32–3(31)03–5(51)03–3(51)h( 2
Recipient characteristics
Age1 100.0)96–42(05)97–02(26)67–11(15)97–11(35)raey( 2
Duration pretransplant dialysis1 (year) 4.5 (0.2–18) 4.5 (0.2–14) 4.7 (0.4–11) 4.7 (1.1–18) 0.112
Early graft function, n (%)
100.0)84(02)57(86)78(871)97(662noitcnufetaidemmI 2
Primary nonfunction1 7 (2) 3 (1) 23 (3) 1 (2) 0.612
Delayed graft function3 63 (19) 22 (11) 20 (22) 21 (50) 0.0012














Table 1: Population characteristics, early graft function, 1-year patient and graft survival of machine-
perfused kidneys in the Machine Preservation Trial. All values of donor and recipient characteristics are 
median (range). SCD = standard criteria donor; ECD = extended criteria donor as defined by UNOS criteria; 
DCD = donation after cardiac death = Maastricht category III.
1 Primary non function: permanent lack of allograft function.
2 Wald test.
3 Delayed graft function: need for dialysis in the first week after transplantation.
4 Log-rank test.
Univariate analysis showed that RR was a risk factor for the development of DGF at 30 
minutes, 2 and 4 h and at the end of MP (Table 3). In multivariate analysis, only RR at the 
end of MP proved to be an independent risk factor of DGF in addition to donor type (DBD vs. 
DCD), donor age and retransplantation (Table 4). The RR data at 4 h showed a trend towards 
significance in the multivariate analysis for the risk of DGF (OR 9.68 (0.79–118.39); P = 0.076). 
The c-statistic of the ROC curve for RR at the end of MP was 0.58. The RR was also a risk 
factor for 1-year graft failure in both unadjusted and adjusted Cox regression analysis (Tables 
3 and 4).
P-v e
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 Variable RR at 30 min MP RR at 1 h MP RR at 2 h MP RR at 4 h MP RR at end MP
All 0.28 0.22 0.20 0.18 0.17
(0.04–3.83) (0.04–2.70) (0.04–1.97) (0.03–1.58) (0.02–1.10)
n = 325 n = 324 n = 323 n = 302 n = 325
Donor type
SCD 0.25 0.21 0.19 0.18 0.16
(0.05–3.83) (0.04–2.70) (0.04–1.97) (0.03–1.58) (0.02–1.10)
n = 202 n = 202 n = 202 n = 193 n = 202
ECD 0.26 0.23 0.21 0.20 0.18
(0.04–1.47) (0.07–0.79) (0.06–0.66) (0.05–0.57) (0.03–0.51)
n = 82 n = 81 n = 80 n = 69 n = 82
DCD 0.29 0.23 0.21 0.20 0.18
(0.08–3.4) (0.09–2.62) (0.09–1.72) (0.08–0.79) (0.07–0.88)
n = 41 n = 41 n = 41 n = 40 n = 41
Early graft function
IF 0.24 0.21 0.19 0.17 0.16
(0.05–2.08) (0.04–2.7) (0.04–0.99) (0.03–0.84) (0.02–0.64)
n = 257 n = 256 n = 254 n = 234 n = 256
DGF 0.28 0.23 0.21 0.20 0.18
(0.04–3.83) (0.08–2.58) (0.07–1.97) (0.08–1.58) (0.07–1.10)
n = 62 n = 62 n = 63 n = 62 n = 63
PNF 0.25 0.22 0.21 0.21 0.20
(0.12–0.68) (0.17–0.47) (0.14–0.43) (0.11–0.35) (0.12–0.31)
n = 6 n = 6 n = 6 n = 6 n = 6
Table 2: Renal resistance of machine-perfused kidneys in function of donor type and early graft function
All values are median (range). RR = renal resistance in mm Hg/mL/min; SCD = standard criteria donor; ECD 
= extended criteria donor as defined by UNOS criteria; DCD = donation after cardiac death = Maastricht 
category III; IF = immediate function; DGF = delayed graft function defined as dialysis in the first week after 
transplantation, preceding the return of graft function; PNF = primary non function defined as permanent 




















Donor age (year) 1.01 (0.98–1.05) 0.5
Table 3: Univariable analysis for delayed graft function and 1-year graft failure in 302 machine-perfused 
kidneys. Logistic regression model for delayed graft function and Cox regression model for graft failure. 
CI = confidence interval; RR = renal resistance expressed in mm Hg/mL/min; MP = hypothermic machine 
perfusion.





















Donor age (year) 1.01 (0.98–1.05) 0.5
Table 4: Multivariable risk analysis for delayed graft function and 1-year graft failure in 302 machine-
perfused kidneys.  Logistic regression model for delayed graft function and Cox regression model for graft 
failure. CI = confidence interval; RR = renal resistance; MP = hypothermic machine perfusion. 
1   Donor type was stratified to either donation after brain death (standard criteria donors and extended 
criteria donors) or donation after cardiac death.
DISCUSSION
This analysis of prospectively collected RR values of kidneys stored by MP showed that RR is 
an independent risk factor for both DGF and 1-year graft failure. These findings suggest that 
RR is an important additional objective tool to be used in kidney graft quality assessment. 
Nevertheless, our analysis also indicates that RR, given its low predictive accuracy, cannot be 
used as a stand-alone viability parameter to accept or discard a given kidney, unlike current 
practice in some centers.
We showed that RR at the end of MP was an independent risk factor for the later 
development of DGF. A potentially important benefit of RR could therefore be the ability to 
estimate the risk of a particular kidney to develop DGF. This information may help clinicians 
in the postoperative management of their patients (e.g. delaying or lowering exposure to 
calcineurin inhibitors, additional information to institute dialysis, etc.). The RR at the end of 
MP is not a fixed point in time but depends on the duration of MP. Knowing the risk profile 
of a particular kidney earlier in the preservation process might be of greater benefit, because 
it would provide a time window necessary for selecting a particular recipient for a particular 
kidney. In fact, RR data at 4 h showed a trend towards significance in the multivariable analysis 
for the risk of DGF and RR values remained stable after 4 h until the end of MP.
Although it would be appealing to use the RR value as a stand-alone parameter to assess 
the risk of DGF, we found that the c-statistic of the ROC curve of RR for predicting DGF was 
0.58. This c-statistic implies that any determined RR threshold would result in a relatively 
poor predictive capacity for DGF. To illustrate this, we attempted a post hoc analysis to define 
a RR threshold value in our data set. The calculated discriminative capacity of this threshold 
(RR = 0.28 mmHg/mL/min) was weak (specificity 93%, sensitivity 17%, positive predictive 
value 40% and negative predictive value 81%). These results are not surprising given the 
multifactorial nature of the pathogenesis of DGF. Several donor, procurement and recipient-
related risk factors (age, donor type, warm and cold ischemic time, inotropy, hypertension, 
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hypovolemia, number of previous transplants, etc.) influence DGF31 and it would be too 
simplistic to believe that one single new risk factor, RR, would replace all the others.
Our observations are in concordance with previous reports that recommend caution in 
using RR in the assessment of kidney quality. Indeed, Sonnenday et al. stressed the importance 
of considering not only the perfusion parameters but all donor factors when assessing 
graft quality. These authors could successfully transplant 11 of 14 kidneys with favorable 
donor characteristics that had been turned down by other centers due to “poor” perfusion 
parameters.192 Mozes et al. analyzed 336 consecutive machine-perfused ECD kidneys and 
showed that the outcome of kidneys with “poor” perfusion parameters (0.40 mmHg/mL/min 
< RR < 0.60 mmHg/mL/min) was similar to the kidneys with “good” perfusion parameters.193 
More recently, Guarrera et al. reported acceptable short- and long-term results in a small 
series of deceased donor kidneys with “poor” perfusion parameters (flow <80 mL/min/100g 
and RR >0.40 mmHg/mL/min/100g) but no other high donor risk factors.194
The necessity to cautiously interpret RR data is also illustrated by the unexpected finding 
that all the PNF cases in our cohort had RR values intermediate between functioning and DGF 
kidneys. Because only seven cases of PNF were encountered, statistically sound conclusions 
regarding a possible association between RR and PNF could not be drawn. However, it is 
remarkable that when RR criteria, commonly used to discard kidneys likely to fail (RR >0.40 
mmHg/mL/min),193 were to be applied in our study population, no single PNF case would 
have been prevented, but eight viable kidneys (2.5%) would have been erroneously discarded 
(four kidneys with immediate function, four with DGF).
Importantly, we also found that RR is a risk factor for 1-year graft failure. As there were 
only 18 graft losses, we could only correct for one additional factor, donor age. Nevertheless, 
our observation is in line with a recent retrospective analysis of 454 preselected MP kidneys in 
the donor service area of New York showing that a RR >0.3 mmHg/mL/min at 3 and 5 h of MP 
is a significant predictor of 1-year graft survival in Cox regression analysis.195 In analogy with 
the carotid intima–media thickness that reflects a person’s cardiovascular risk profile,196 we 
hypothesize that RR of perfused kidneys may reflect their intrinsic morphological “quality” 
and subsequent likelihood of successful outcome after kidney transplantation. Correlation 
studies between RR and renal histology parameters are warranted to determine which 
particular morphological features of the kidney graft are mirrored by RR. In comparison to 
single biopsies, that are subject to sampling error and interobserver variability, RR may reflect 
the overall quality of a given kidney better.
Although our study clearly shows that RR is an independent risk factor for both DGF and 
graft failure, the determinants of transplant outcome are multifactorial and it remains elusive 
to predict outcome based on RR data (or other parameters) alone. Numerous risk scores, 
implementing several independent donor, procurement and recipient risk factors have already 
been proposed. For example, Irish et al. have constructed a “composite DGF score” that has 
a moderate predictive power for DGF (c-statistic 0.70).197,198 Rao et al. recently developed 
the kidney donor risk index to estimate the risk of graft failure.182 Adding RR to such risk 
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scores will likely increase their predictive accuracy and provide better tools to evaluate kidney 
quality. Another parameter that may also improve the predictive value of these multifactorial 
scoring systems is the concentration of certain biomarkers in the perfusate because, like the 
RR, they have been shown to independently correlate with DGF.199
The aforementioned data on the impact of RR on transplant outcome apply to all 
deceased donors with the exception of uncontrolled DCD donors (Maastricht category I, II). 
Such donors were not included in our trial. In most centers within Eurotransplant, kidneys 
recovered from uncontrolled DCD donors are already routinely preserved by MP and when 
designing the study, it was felt unethical to randomize these kidneys to static cold storage 
because of their particularly high risk of PNF (up to 13.5% for category II kidneys).200 The 
exclusion of uncontrolled DCD donors may account, at least in part, for the low incidence of 
PNF in our study.
A potential bias in our study is the change of randomization in 25 cases because 
of vascular anomalies of a right or left kidney that prevented connection to the machine 
perfusion device. In these cases, the other kidney was machine perfused. This could have led 
to the exclusion of kidneys with a higher risk of DGF. Vascular anomalies had no significant 
effect on the development of DGF in our trial. However, to minimize a possible bias, we 
performed the logistic and Cox regression analyses only with kidneys that were allocated to 
and effectively underwent MP.
An important technical point for the interpretation of our data and their possible 
application in the clinics is that all kidneys were perfused with LifePort® machines, whereas 
many previously reported studies used different systems, among which the RM3 machine 
(Waters Medical Systems, Rochester, MN, USA). This is noteworthy because the LifePort® 
uses a pressure controlled roller pump to deliver the perfusate, creating sinusoidal flow curves, 
whereas the RM3 has a flow controlled pumping system. This gives rise to different wave 
pressure forms and different calculated RR values. Although absolute RR values calculated 
by the two devices cannot be compared directly, the association of RR and DGF/1-year graft 
failure found in our analysis remains valid since only one pump type was used. We believe 
that similar conclusions would have been reached if another system had been used, albeit 
probably with different RR values.
In conclusion, this study shows that RR during MP of all common types of deceased 
donor kidneys is an independent risk factor for the development of DGF and for 1-year graft 
failure. Therefore, RR represents an additional and objective source of information that 
can assist clinicians in their decision making process. However, DGF and graft failure have 
a complex pathogenesis and cannot be predicted with precision based on RR as a stand-
alone assessment tool. More accurate prediction of graft outcome will require integration of 
perfusion parameters into multifactorial graft quality scoring systems.
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The vast majority of scientific research in the field of kidney transplantation tends to be 
focused on the recipient. A quick PubMed search on February 8, 2011 yielded approximately 
87,000 articles on the topic “kidney transplantation”, of which almost 40,000 include the 
word “immunosuppression”, or “immunosuppressive” in the abstract. Only 2,300 papers 
(2.6%) deal with donor management, and organ preservation is the topic of no more than 
3,600 studies in kidney transplantation (4.1%). The same pattern can be observed at the 
average organ transplantation conference, where donor management and organ preservation 
related sessions are usually scarce, attended by few people, and situated in a small room at 
the far end of the convention center. Immunosuppression and -modulation, as well as other 
aspects of recipient management offer practically unlimited clinical and pre-clinical research 
opportunities. Without modern pharmacologic recipient management, kidney transplantation 
outcome as we know it would not be possible. Hence, it remains important to continuously 
seek for improvement of posttransplant protocols, with a main focus on new drugs, novel 
combinations of pharmacologic regimens, and other interventions that will modulate the 
host immune response in order to prevent acute rejection and chronic allograft nephropathy. 
However, the studies in this thesis illustrate that various donor, donor management, and organ 
preservation related factors have a profound impact on outcome after renal transplantation. 
Many of these factors can be influenced in such a way that posttransplant results will improve 
significantly. Apart from the interventions that are studied in this thesis, one very important 
factor is cold ischemic time. The multivariate models in chapters 3 and 5 show that increased 
cold ischemic time is significantly and independently associated with an elevated risk of 
delayed graft function and graft failure. The American Organ Procurement and Transplantation 
Network (OPTN) database can be utilized to obtain additional detailed information on the 
association beween cold ischemic time and posttransplant outcome. When the cohort of 
deceased donor single kidney recipients between 1994 and 2007 (n=99,860) is studied, all 
important end points after transplantation, including acute rejection and graft survival, are 
strongly influenced by a few hours rise in cold ischemic time above 8 hours (Figure 1a-e). 
These figures show that the usual assumption that a deceased donor kidney is safe as long 
as cold ischemic time stays below 18-24 hours is incorrect. Deceased donor kidneys should 
always be transplanted as soon as possible, for a few hours reduction in cold ischemic time 
will result in a significant and clinically relevant improvement in outcome. In the following 
section a reference example is outlined:  
In 2007 the large (n=1,645) prospective multicenter Symphony study compared various 
posttransplant immunosuppressive protocols, among which a regimen consisting of low-
dose ciclosporin combined with daclizumab (an anti-CD25 antibody) induction therapy, 
and a regimen with standard-dose ciclosporin without daclizumab. Recipients in the low-
dose tacrolimus + daclizumab group had a 3.8% better 1-year graft survival, a 1.8% lower 
incidence of acute rejection, and a creatinine clearance at 1 year which was 2.3 ml/min higher 
(relative increase 4%) compared to patients in the standard-dose ciclosporin group without 
daclizumab.201 The aforementioned data in the OPTN database suggest that reduction 
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of the average cold ischemic time with just a few hours is likely to result in an improved 
postttansplant outcome which is in the same order as the effect that low-dose ciclosporin 
+ daclizumab had versus standard-dose ciclosporin. A standard induction regimen with 
daclizumab will cost approximately E 5,000 extra per patient. This example illustrates that 
slightly speeding up organ transport, crossmatch, and operating room logistics might result 
in a similar improvement in outcome as a costly new immunosuppressive drug will achieve.
The retrospective study presented in chapter 3 shows that donor age has a large impact on 
delayed graft function and graft survival after kidney transplantation. This study, as well as 
multivariate models in chapters 5, 6, and 7 suggest that donor age is probably the strongest 
determinant of posttransplant outcome. The average organ donor today is older than donors 
were a few decades ago. Although donor age itself cannot be influenced, studies within 
Eurotransplant have suggested that the implementation of an old-for-old allocation policy 
could make best use of older donor kidneys, by allocating these grafts to older recipients who 
have a shorter life expectancy. In theory, even a renal graft recovered from an older donor will 
often outlive its senior recipient, thus reducing death censored graft failure in this group of 
aged patients. The papers that report results from this Eurotransplant Senior Program (ESP) 
conclude that graft and patient survival were not negatively affected compared to standard 
allocation and that, therefore, old-for-old allocation is an effective system.78,85 However, it 
can be argued that these reports emphasize the wrong graft survival data. When looking 
at the group of older kidneys, indeed no significantly different 6-year graft and patient 
survival was observed between old-to-old and old-to-any allocation. This is in line with the 
theoretical assumption outlined above. If not the group of older kidneys, but the group of 
older recipients is studied, there appears to be a rather large difference in graft and patient 
survival between old-to-old and any-to-old allocation in favor of the latter policy, both with 
and without censoring for death with a functioning graft. This implies that with regard to 
patient and graft survival, older recipients as a group are far better off with standard allocation 
than with old-for-old allocation. The finding that older kidneys perform equally well in older 
recipients as in a group with recipients of all ages is interesting, but less relevant. Exactly these 
associations were also observed in the old-for-old simulations in chapter 3, along with the 
inevitable effect that younger recipients as a group will do slightly better when old-for-old 
allocation is implemented, since this group will then receive on average younger (i.e. higher 
quality) kidneys. Another important argument in favor of old-for-old allocation is that it will 
reduce waiting time for older transplant candidates. However, it is questionable whether 
this objective justifies the practice of systematically transplanting inferior-quality organs 
into older patients. Indeed, even with the presumably shorter waiting time in old-for-old 
allocation, patient survival was inferior compared to older recipients who received standard 
allocation (any-to-old). The shorter waiting time in the ESP and the associated shorter time 
on dialysis did apparently not outweigh the negative effect that the on average lower-quality 
kidney grafts had on patient survival. Therefore, old-for-old allocation seems to be much 
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effort for a net effect which is likely to be close to zero. In addition, serious ethical concerns 
apply to the deliberate shifting of graft and life years from one group of recipients to another.





























































































































Figure 1: Delayed graft function (a), primary non-function (b), acute rejection (c), serum creatinine at 
discharge (d), and graft survival at 10 years posttransplant (e) as a function of cold ischemic time. In 
panel (e), cold ischemic time varies between 1 and 36 h and each curve below another curve represents a 
subsequent 4 h wide cold ischemic time category. Retrospective data derived from the Organ Procurement 
and Transplatation Network database, cohort 1994-2006, recipients of deceased donor single kidneys 
(n=99,860).
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Normothermic recirculation of the donor’s body before cold organ preservation is instituted 
has briefly appeared in the transplantation literature approximately 10 years ago.39,93,98 But 
after these publications, no other reports on results of the method have been published. 
In 2010, the group from the Hospital Clínic in Barcelona, who have developed the method, 
published an article in which an update was given on normothermic recirculation results in the 
last decade. Their data show a 60% graft survival and a 77% patient survival at 3 years after 
liver transplantation. Recent figures with regard to kidney transplantation after normothermic 
recirculation are not shown. In addition, the group reports a high incidence of ischemic biliary 
tract complications, and a very high liver discard rate of 75% after uncontrolled Maastricht 
category II donation after cardiac death.92 The authors conclude that not normothermic 
recirculation, but normothermic machine perfusion during the whole interval between organ 
procurement and transplantation is likely to be the most promising method for the future 
of kidney and liver transplantation from uncontrolled donors after cardiac death. Indeed, 
normothermic machine perfusion of kidney and liver grafts has been shown to be superior 
to hypothermic machine perfusion and static cold storage in preclinical studies.202-204 
Theoretically, the superiority of normothermia over hypothermia as the main principle in 
organ preservation is not surprising. Mimicking human physiology and continuously providing 
an organ with its metabolic needs is likely to result in a better preserved graft than the usual 
cascade which consists of warm ischemia, followed by cold ischemia, followed by warm 
reperfusion in the recipient. However, the equipment needed for normothermic machine 
perfusion is complex and requires intensive monitoring, which makes transport logistics 
rather cumbersome.38 Moreover, equipment failure is an emergency situation which results 
in warm ischemia of the graft and requires direct intervention. Unaccompanied transport 
of a normothermic machine perfusion device will never be a realistic option. In contrast, 
when hypothermic machine perfusion fails, the kidney remains safely cold stored inside the 
perfusion machine. Hence, the latter method is more suitable for stand-alone operation and 
travel.
A brief period of normothermic recirculation before organ recovery would theoretically 
combine the beneficial effect of physiological oxygenized perfusion directly after warm 
ischemia with the logistically more feasible method of hypothermia during organ transport. 
The animal study presented in chapter 4 revisits normothermic recirculation in kidney 
transplantation and addresses the question whether the method can indeed mitigate warm 
ischemic injury. Unfortunately, no such effect was found. Despite various relevant limitations 
of this preclinical study, the data do not encourage a prospective study of normothermic 
recirculation in human donors after cardiac death. The total silence in the published literature 
on the topic of normothermic recirculation in clinical renal transplantation that now lasts 
for more than a decade perhaps reflects the fact that, so far, no consistently beneficial effect 
of the method has been shown for kidneys. Positive experiences in the clinic are repeatedly 
reported at conferences by the Barcelona, Madrid, and St. Petersburg groups, but so far 
no comparative clinical study has been conducted to test the presumed positive effect of 
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normothermic recirculation on kidneys. A sufficiently powered prospective clinical study will 
be the only way to answer the question whether normothermic recirculation should have any 
role in management of kidney donors after cardiac death.
Hypothermic machine perfusion is by no means a novel kidney preservation method. In fact, 
some of the first kidney transplants ever were performed after the organ had been machine 
perfused.91,205 Static cold storage was widely adopted in the 1980s, when improved synthetic 
organ preservation fluids such as the University of Wisconsin solution became available and 
Opelz and Terasaki published a retrospective report which suggested that cold storage was 
superior to machine perfusion.103,132 Until one decade ago, only a few centers persisted to 
use machine perfusion for selected marginal donor kidneys. Several retrospective analyses 
published shortly after the 1990s suggested that, with the average donor kidney being more 
marginal than back in the 1980s, hypothermic machine perfusion may nowadays be superior 
to cold storage of deceased donor kidneys.105,106 However, an adequately powered RCT was 
needed to resolve the controversy and show whether machine perfusion has any advantage 
over static storage. The Machine Preservation Trial, the results of which are reported in 
chapters 5 through 11, showed that machine perfusion should be the method of choice for the 
preservation of all common types of deceased donor kidneys. The formal subgroup analyses 
in chapter 5 demonstrated that the magnitude of the beneficial effect of machine perfusion 
in terms of delayed graft function reduction is similar for kidneys recovered from standard 
criteria donors, expanded criteria donors, and donors after cardiac death. These findings are 
reinforced by the two separate pre-specified sub-studies in chapters 6 and 7, which focused 
in detail on the effect of machine perfusion versus cold storage in kidneys derived from brain 
dead expanded criteria donors and donors after cardiac death.
Our 3-year follow-up analysis confirms that machine perfusion will lead to a superior 
graft survival for kidneys donated after brain death, especially in those renal grafts recovered 
from expanded criteria donors. In addition, this analysis shows that kidneys procured from 
donors after cardiocirculatory death do not benefit from machine perfusion in terms of a better 
3-year graft survival. Machine perfusion will lead to a substantial reduction in delayed graft 
function for such kidneys, and therefore sufficient rationale remains for machine perfusing 
kidneys from donors after cardiocirculatory death. Several studies in this thesis have shown 
that delayed graft function could be an important risk factor for graft failure, but our data 
also suggest that this association does not apply to kidneys donated after cardiocirculatory 
death in the same magnitude as it does to kidneys recovered from brain dead donors. The 
substantial reduction in delayed graft function due to machine perfusion does apparently not 
lead to a lower risk of graft failure for this subgroup of renal grafts. Mechanistic studies into 
the precise nature of delayed graft function are needed to determine whether kidneys derived 
from donation after cardiocirculatory death exhibit a different, perhaps less detrimental, type 
of delayed graft function compared to grafts recovered from donation after brain death. Part 
of the explanation of this phenomenon may be that, in a brain dead donor, renal grafts are 
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subjected to the detrimental pro-inflammatory and pro-coagulatory effects of brain stem 
death.11,206 Hence, delayed graft function in these kidneys may have a more immunologic 
cause, in contrast to kidneys procured from donors after cardiocirculatory death. In the 
latter group, delayed graft function could be primarily a symptom of tubular necrosis due to 
ischemic injury, from which a kidney will be more likely to make a good recovery.
A parallel British RCT, the PPART study, failed to show superiority of machine perfusion 
over cold storage for the preservation of kidneys donated after cardiac death and reported 
no difference in delayed graft function between machine perfused and cold stored kidneys. 
However, this study had a rather uncommon sequential design, in which the chances of 
obtaining statistically significant results were determined at regular intervals during the 
enrollment period. After inclusion of no more than 45 kidney pairs, the study was stopped 
prematurely. Statistical models had indicated that further inclusion was unlikely to result in 
a significantly different incidence of delayed graft function between the machine perfusion 
and the cold storage arm.138 Differences between the British and our study may explain the 
discrepancy in results. Of 25 centers, only five participated in the UK trial and most kidneys 
were transplanted locally. In contrast, our study on kidneys donated after cardiac death 
was fully integrated in everyday practice of an international organ sharing organization. 
Centers were blinded at organ offer, which might not have been the case in the British trial 
as the same unit often performed organ recovery and transplantation. We started machine 
perfusion immediately after procurement, whereas this was frequently delayed in the British 
trial. It may be that pumping kidneys throughout the entire preservation period is necessary 
for kidneys to fully benefit from machine perfusion.207 Finally, the novel methodology that 
was utilized in the British study has never before been tested in a similar RCT setting. It 
remains unclear whether the stopping rules that were enforced by this complex method truly 
reflect that finding statistically significant differences cannot be expected, had a sufficiently 
powered complete data set been obtained.
In addition to the favorable clinical results that the Machine Preservation Trial found, the 
cost-effectiveness analysis in chapter 9 confirms that machine perfusion should be adopted 
for all types of deceased donor kidneys. Its implementation would result in less delayed 
graft function, an improved 1-year graft survival, and lower overall costs compared to cold 
storage. With this robust evidence in place, there can be no reason but political issues to 
refrain from broad implementation of hypothermic machine perfusion in Eurotransplant and 
other organ exchange organizations. Unfortunately, an important appraisal of the clinical 
utility and cost-effectiveness of machine perfusion versus cold storage by the British National 
Institute for Health and Clinical Excellence (NICE) had a rigid closing date a few months 
before the final results of the Machine Preservation Trial became available.208 NICE based 
its recommendations in part on a very detailed cost-effectiveness study by Bond et al, which 
was also conducted too early to take the final results of our studies into account.47 Both 
the NICE report and the publication by Bond et al, which are largely based on retrospective 
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evidence and on the prematurely stopped PPART study, suggest that insufficient evidence 
is available to recommend machine perfusion as the standard method for deceased donor 
kidney preservation. Although these reports are comprehensive and well nuanced, the 
structural omission of final data from our studies has rendered them outdated directly after 
their publication.
How exactly the logistics of machine perfusion should be organized remains to be determined. 
In contrast to the situation in the United States, where organ exchange is centralized 
around organ procurement organizations and most kidneys stay in the region of origin, in 
Eurotransplant long-distance international exchange is common and therefore renal machine 
perfusion has to be organized with stand-alone machines that can be transported in the 
same fashion as the traditional cold storage ice box. A realistic scenario could be as follows: 
Connection of kidneys to the machine, as well as retrieval of organs from the machine is an easy 
task and is probably best executed by the procurement / transplant surgeon at the instruction 
of a trained transplant coordinator. In The Netherlands, each of the four procurement regions 
should have 4-6 perfusion machines, which the transplant coordinator can bring to the donor 
hospital. The recipient center will clean and keep the empty perfusion machine in its own 
stock. It can be expected that the number of machines per region will stay in equilibrium 
most of the time. In case of shortage, machines can be transported by courier between two 
regions. Alternative scenarios, including the establishment of independent perfusion centers 
which stock all machines and provide procurement regions with their services could also 
be feasible, depending on the available manpower among transplant coordinators and the 
reimbursement structure chosen.
Apart from its clinical effectiveness on posttransplant outcome, machine perfusion is 
often advocated for its presumed diagnostic potential. Numerous retrospective analyses 
have addressed the prognostic value of renal intravascular resistance and flow rates 
during machine perfusion, as well as measurement of biomarkers in machine perfusion 
perfusate.105,106,152,153,173,191,193,209 All such retrospective analyses suffer from a certain 
amount of selection bias, since kidneys are discarded based on presumably unfavorable pump 
characteristics and/or biomarker concentrations. In addition, most kidneys have undergone a 
usually subjective selection process to determine which organ should be pumped. Therefore, 
only a prospective study in an unselected data set can give insight into the true prognostic 
potential of perfusate biomarkers and pump parameters. The studies in chapters 10 and 
11 are based on such prospective and unselected data. Although our data did show some 
independent predictive value of renal resistance and three perfusate markers, the most 
important conclusion that can be drawn from these studies is that perfusate biomarkers 
and pump parameters should never be utilized as a sole trigger to accept or discard a donor 
kidney. Their only justified application seems to be to consider each marker as one of the 
many factors that determine posttransplant outcome, and to adjust recipient management 
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accordingly. It can be argued that the impact of biomarker measurement is only marginal and 
may not be worth the additional expense. Renal resistance can be determined without extra 
costs, and is therefore a more realistic predictive variable to be considered during machine 
perfusion.
In conclusion, the results brought forward by the studies in this thesis once again emphasize 
that improving kidney transplant outcome starts in the donor. Better methods for deceased 
donor management, as well as superior organ preservation techniques are likely to make a 
relevant difference for the recipient. Normothermic recirculation will have to be tested in a 
randomized clinical study before it can be implemented in everyday practise. Hypothermic 
machine perfusion has been proven superior to static cold storage and should be utilized 
for most types of deceased donor kidneys. Anticipating outcome by means of perfusate 
biomarkers and machine perfusion characteristics has to be be done with caution. However, 
when more physiological, normothermic preservation methods become available, viability 
assessment before transplantation could become a useful tool to predict posttransplant 
organ performance. This thesis shows that static cold storage for marginal donor kidneys 
belongs to the past, and that the present should be dominated by hypothermic machine 
perfusion. Normothermic preservation may have the future, and research in the field of 
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SUMMARY
Chapter 1 provides a brief general introduction to the thesis, in which the various types 
of organ donors are introduced and in chapter 2 the practise of donation after cardiac death 
is discussed in detail. Transplant centers worldwide are revisiting donation after cardiac death 
as a tool to enlarge the deceased donor pool. This chapter reviews mechanisms of warm 
ischemic injury, potential new approaches to improve posttransplant results, and several 
persistently controversial issues that are pertinent to this type of organ donation. In addition, 
it provides an overview of current protocols for donation after cardiac death and up-to-date 
evidence on selection criteria, organ preservation, and clinical outcome after transplantation 
of various types of organs that are recovered from such donors.
Chapter 3 presents the results of a retrospective study in the large database of the 
American Organ Procurement and Transplantation Network, which evaluated the effect of 
deceased donor age on outcome after renal transplantation. Regression models which are 
relevant to guide clinical organ allocation policies were constructed and we simulated the 
effect that old-for-old allocation would have on transplant outcome. The analyses showed 
that donor age strongly influences posttransplant results, not only in the upper extremes, 
but for the whole range of donor ages ≥11. Furthermore, we found that implementation of 
old-for-old kidney allocation is likely to be safe. Such a policy could reduce waiting time for 
aged candidates, but according to our simulation it will not necessarily improve overall kidney 
transplant outcome.
Chapter 4 describes an animal study in which the concept of normothermic recirculation 
is investigated as a potential tool to improve the quality of kidneys that are severely damaged 
by warm ischemia. In this study, we subjected Lewis rat kidneys to various amounts of warm 
ischemia, and subsequently to different time periods of normothermic recirculation. After cold 
storage these kidneys were transplanted into recipient animals and 24 h later we measured the 
percentage of cortical necrosis, and determined the expression of several important genes that 
are involved in renal damage, inflammation, interstitial fibrosis formation, cytoprotection, and 
tissue regeneration. We found that normothermic recirculation had no significant influence on 
any of these markers. Hence, we concluded that these preclinical data by no means support 
the presumed beneficial effect of normothermic recirculation on kidneys that have sustained 
profound warm ischemic injury.
Chapter 5 is the main report of the Machine Preservation Trial. This international 
randomized controlled trial compared hypothermic machine perfusion with static cold storage 
for the preservation of deceased donor kidneys. In The Netherlands, Belgium, and the federal 
state of North-Rhine Westphalia in Germany, kidney pairs from 336 consecutive deceased 
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donors were enrolled. One kidney of each pair was randomly assigned to machine perfusion 
and the other to cold storage. Kidneys could be transplanted in the whole Eurotransplant 
region and recipients were followed up until 1 year after transplantation. We found that 
machine perfusion significantly reduced the risk of delayed graft function in all common types 
of deceased donor kidneys. In addition, machine perfusion was associated with a reduced risk 
of graft failure, and 1-year allograft survival was superior in the machine perfusion group.
Chapter 6 reports the results of a pre-specified sub-study of the Machine Preservation 
Trial. After an extended enrollment period, 82 kidney pairs from consecutive, controlled donors 
after cardiac death were included. One kidney was randomly assigned to machine perfusion, 
and the contralateral organ to static cold storage. As in the main trial, machine perfusion 
significantly reduced the incidence of delayed graft function. However, for kidneys donated 
after cardiac death 1-year graft survival was similar in both treatment groups.
Chapter 7 presents another pre-specified sub-study of the Machine Preservation Trial. 
Ninety-one kidney pairs from consecutive, expanded criteria donors after brain death were 
included and studied as a separate sub-group. One kidney was randomly assigned to machine 
perfusion, the contralateral organ to static cold storage. In these data, machine perfusion 
also significantly reduced the risk of delayed graft function compared with cold storage. The 
incidence of primary non-function in the cold storage group was four times higher than in 
the machine perfusion group, and 1-year graft survival was significantly better in machine 
perfused kidneys. In those patients who developed delayed graft function, 1-year graft survival 
was remarkably superior when their transplanted kidney had been machine perfused (85% vs. 
41%).
Chapter 8 concisely describes the results of our 3-year follow-up analysis of the Machine 
Preservation Trial. As the original study had found an important 1-year graft survival advantage 
for machine perfused kidneys, we decided to investigate whether this advantage would persist 
3 years posttransplant. We found that graft survival of kidneys donated after brain death 
remained significantly better after machine perfusion compared to cold storage, especially in 
kidneys recovered from expanded criteria donors. Delayed graft function was associated with 
a notably lower graft survival of kidneys donated after brain death. Despite the large reduction 
in delayed graft function by machine perfusion in kidneys donated after cardiocirculatory 
death that we showed earlier, there was no positive effect of machine perfusion on graft 
survival in this sub-group.
Chapter 9 is a cost-effectiveness analysis of machine perfusion versus cold storage based 
on data of the Machine Preservation Trial. This economic evaluation combined short term 
results derived from the empirical data in the clinical study with a Markov model that had a 
10-year time horizon. The short-term evaluation showed that machine perfusion reduced the 
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risk of delayed graft function and graft failure at lower costs than cold storage. The Markov 
model revealed that life-years and QALYs can be gained while reducing costs at the same time, 
when kidneys are preserved by machine perfusion instead of cold storage.
Chapter 10 shows an analysis of whether six different biomarkers that were measured 
in the perfusate during machine perfusion have predictive value for outcome after deceased-
donor kidney transplantation. From 306 deceased donor kidneys that were included in the 
Machine Preservation Trial, we tested whether concentrations were independently associated 
with delayed graft function, primary non-function, and graft survival. Three biomarkers proved 
to be independent – albeit mediocre – predictors of delayed graft function, but not of primary 
non-function and graft survival. The other three markers had no independent prognostic 
potential for any of the end points. We concluded that, although elevated concentrations of 
certain biomarkers during machine perfusion may be an indication to adjust posttransplant 
recipient management, the values of these markers alone should not lead to kidney discard.
Chapter 11 is the report of another analysis that evaluated the pre-transplant predictive 
potential of measurements during organ preservation. In this study, we investigated the 
prognostic value of renal intravascular resistance during machine perfusion on delayed graft 
function, primary non-function and graft survival of deceased donor kidneys. This sub-
study of the Machine Preservation Trial showed that primary non-functioning kidneys had 
renal resistances which were comparable to those that showed immediate or delayed graft 
function. Renal resistance at the end of machine perfusion was an independent risk factor 
for delayed graft function. The best threshold value for predicting this end point had a high 
negative predictive value but a poor discriminative capacity. This study demonstrated that 
measurement of renal resistance during machine perfusion can be a valuable additional tool 
to predict aspects of transplant outcome, but renal resistance values alone should not be 
used to discard kidneys for transplantation.
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NEDERLANDSE SAMENVATTING
Niertransplantatie is de beste medische behandeling voor patiënten die lijden aan eind stadium 
nierfalen. De afgelopen decennia is de samenstelling van de overleden donorpool radicaal 
veranderd, zodanig dat er steeds meer organen beschikbaar komen van oudere donoren, 
die vaak al meerdere aandoeningen in de voorgeschiedenis hebben, of van zogenaamde 
non-heart beating donoren bij wie de orgaanuitname pas kan beginnen wanneer het hart al 
enkele minuten stil heeft gestaan. Zulke orgaandonoren worden ook wel marginale donoren 
genoemd, omdat hun organen in het algemeen van minder goede kwaliteit zijn in vergelijking 
met die van jonge, verder gezonde hersendode donoren.
Dit proefschrift beschrijft de resultaten van klinische en pre-klinische studies op het gebied 
van niertransplantatie. In deze studies wordt de invloed die verscheidene karakteristieken van 
overleden orgaandonoren op het transplantatieresultaat hebben gekwantificeerd. Tevens 
wordt het effect onderzocht van interventies vóór of gedurende orgaanpreservatie, die zijn 
gericht op het beter conserveren van de orgaankwaliteit voorafgaand aan de transplantatie. 
Daarnaast beschrijft het proefschrift een studie waarin biomarkers worden gemeten in de 
orgaanpreservatievloeistof en een andere studie waarin de vasculaire weerstand wordt 
bepaald tijdens machinale preservatie van donornieren. Deze beide studies hebben als doel 
het voorspellen van de vitaliteit en de functie van het orgaan na transplantatie. Hoewel 
de resultaten van de studies in dit proefschift betrekking hebben op nieren afkomstig van 
alle typen overleden donoren, zijn ze het meest relevant voor marginale donornieren. 
Aangezien de functie en levensduur van zulke nieren na transplantatie vaak suboptimaal zijn, 
is extra informatie over hun kwaliteit nog vóór transplantatie belangrijk. Tevens zijn nieuwe 
interventies die de orgaanfunctie ná transplantatie verbeteren noodzakelijk.
Hoofdstuk 1 is een beknopte algemene inleiding op dit proefschrift, waarin de 
verschillende typen orgaandonoren worden geïntroduceerd en in hoofdstuk 2 wordt de 
praktijk van orgaandonatie na hartdood (in Nederland meestal non-heart beating donatie 
genoemd) in detail besproken. In veel transplantatiecentra wereldwijd is non-heart beating 
donatie opnieuw ingevoerd in een poging om de overleden donorpool te vergroten. Dit 
hoofdstuk bespreekt de mechanismen van warme ischemieschade, nieuwe methoden om 
het transplantatieresultaat te verbeteren en relevante controverses die direct samenhangen 
met dit type orgaandonatie. Daarnaast wordt er een overzicht gegeven van bestaande 
protocollen voor non-heart beating donatie en van de meest actuele onderzoeksresultaten op 
het gebied van selectiecriteria, orgaanpreservatie en klinische uitkomsten na transplantatie 
van meerdere typen organen die afkomstig zijn van zulke donoren.
Hoofdstuk 3 bespreekt de resultaten van een retrospectieve studie in de grote database 
van het Amerikaanse Organ Procurement and Transplantation Network, waarin de invloed 
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van de leeftijd van overleden donoren op het transplantatieresultaat werd onderzocht. 
Er werden regressiemodellen vervaardigd die kunnen helpen om de orgaan-allocatie te 
sturen en we simuleerden het effect dat old-for-old allocatie zou kunnen hebben op het 
transplantatieresultaat. De analyses toonden aan dat de donorleeftijd een zeer grote invloed 
heeft op het transplantatieresultaat, niet alleen in de extreme leeftijdscategoriën, maar 
voor het hele spectrum van donorleeftijden van 11 jaar en ouder. Voorts berekenden we dat 
de implementatie van old-for-old allocatie waarschijnlijk veilig is. Een dergelijk beleid zou 
mogelijk de wachttijd voor oudere transplantatiekandidaten kunnen verkorten, maar onze 
simulatie liet ook zien dat deze aanpak niet vanzelfsprekend leidt tot een algehele verbetering 
van het transplantatieresultaat voor ontvangers van alle leeftijden samen.
Hoofdstuk 4 beschrijft een dierexperimenteel onderzoek waarin normotherme 
recirculatie werd bestudeerd, een potentieel nieuwe methode om de orgaankwaliteit van 
ernstig ischemisch beschadigde donornieren te verbeteren. In deze studie werden nieren van 
Lewis ratten blootgesteld aan verschillende hoeveelheden warme ischemie en vervolgens aan 
verschillende periodes van normotherme recirculatie. Na koude statische orgaanpreservatie 
werden deze nieren getransplanteerd in ontvangerdieren en na 24 uur overleving maten 
we het percentage corticale necrose in de getransplanteerde nier en werd de expressie 
van verscheidene belangrijke genen bepaald die betrokken zijn bij nierschade, ontsteking, 
vorming van interstitiële fibrose, cytoprotectie en weefselregeneratie. We ontdekten dat 
normotherme recirculatie geen significante invloed heeft op al deze variabelen. Daarom 
concludeerden we dat deze preklinische resultaten op geen enkele manier het vermeende 
positieve effect van normotherme recirculatie op ernstig ischemisch beschadigde 
donornieren bevestigen.
Hoofdstuk 5 rapporteert de belangrijkste bevindingen van de Machine Preservation 
Trial. In deze internationale gerandomiseerde studie werd hypotherme machineperfusie 
vergeleken met statisch koud bewaren (cold storage) voor het preserveren van nieren 
afkomstig van overleden donoren. In Nederland, België en Nordrhein-Westfalen in Duitsland 
werden paren nieren van 336 overleden donoren geïncludeerd. Eén nier van ieder paar werd 
willekeurig toegewezen aan machineperfusie en de andere nier werd statisch koud bewaard. 
Trialnieren konden worden getransplanteerd in de hele Eurotransplant-regio. De ontvangers 
van deze organen werden gedurende 1 jaar gevolgd. Uit de studie bleek dat machineperfusie 
het risico op delayed graft function (het vertraagd op gang komen van een donornier) 
significant vermindert voor alle veel voorkomende typen donornieren. Bovendien was 
machineperfusie geassocieerd met een lager risico op transplantaatfalen en was de 1-jaars 
transplantaatoverleving superieur in de machineperfusie groep.
Hoofdstuk 6  beschrijft de resultaten van een protocollair geplande sub-studie van de 
Machine Preservation Trial. Tijdens een verlengde inclusie-periode werden 82 opeenvolgende 
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paren non-heart beating donornieren gerandomiseerd. Eén nier werd machinaal 
gepreserveerd en de contralaterale nier werd statisch koud bewaard. Machineperfusie 
reduceerde ook bij non-heart beating donornieren de incidentie van delayed graft function. 
In tegenstelling tot de algemene resultaten die worden beschreven in hoofdstuk 5, was de 
1-jaars transplantaatoverleving voor non-heart beating nieren niet verschillend in beide 
studie-armen.
Hoofdstuk 7 rapporteert eveneens resultaten van een protocollair geplande sub-
studie van de Machine Preservation Trial. Eén-en-negentig paren donornieren afkomstig van 
hersendode zogenaamde expanded criteria donoren (donoren van hoge leeftijd en/of met 
significante comorbiditeit) werden geïncludeerd en bestudeerd als een aparte subgroep. Eén 
nier werd willekeurig toegewezen aan machineperfusie, de contralaterale nier werd statisch 
koud bewaard. Ook in deze studie bleek machineperfusie het risico op delayed graft function 
significant te verlagen in vergelijking met statisch koud bewaren. De incidentie van primary 
non-function (het nooit op gang komen van een getransplanteerde nier) was in de cold storage 
groep viermaal hoger dan in de machineperfusie groep en de 1-jaars transplantaatoverleving 
was significant beter voor machinaal gepreserveerde nieren. Bij patiënten die na transplantatie 
delayed graft function ontwikkelden, bleek de 1-jaars transplantaatoverleving opmerkelijk 
veel hoger indien hun donornier machinaal gepreserveerd was (85% vs. 41%).
Hoofdstuk 8 geeft een beknopt verslag van de 3-jaars follow-up van de Machine 
Preservation Trial. Aangezien de studies in hoofdstuk 5 en 7 een belangrijke verbetering in 
1-jaars transplantaatoverleving als gevolg van machineperfusie hadden laten zien, besloten 
we te onderzoeken of dit effect na 3 jaar nog steeds aantoonbaar zou zijn. In deze analyse 
bleek de transplantaatoverleving na machineperfusie in vergelijking met statisch koud 
bewaren ook 3 jaar na transplantatie significant beter voor nieren afkomstig van hersendode 
donoren, met name voor die organen die afkomstig waren van expanded criteria donoren. 
Het ontwikkelen van delayed graft function was geassocieerd met een opvallend slechtere 
3-jaars transplantaatoverleving voor nieren afkomstig van hersendode donoren. Ondanks de 
grote reductie van de kans op delayed graft function die we eerder vonden voor non-heart 
beating nieren, bleek er ook na 3 jaar geen positief effect te zijn van machineperfusie op de 
transplantaatoverlevning van dit type donororganen.
Hoofdstuk 9 is een kosteneffectiviteitsanalyse gebaseerd op data afkomstig van de 
Machine Preservation Trial, waarin machineperfusie werd vergeleken met statisch koud 
bewaren. Deze economische studie combineerde de korte termijn resultaten van de klinische 
trial met een Markov model met een tijdshorizon van 10 jaar na transplantatie. De korte 
termijn evaluatie toonde aan dat machineperfusie het risico op delayed graft function 
en transplantaatfalen reduceert en resulteert in lagere kosten vergeleken met statisch 
koud bewaren. Het Markov model liet zien dat levensjaren en QALY’s toenemen terwijl 
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tegelijkertijd de totale kosten afnemen indien donornieren worden gepreserveerd door 
middel van machineperfusie in plaats van cold storage.
Hoofdstuk 10 beschrijft een studie waarin werd onderzocht of zes verschillende 
biomarkers, gemeten in het perfusaat tijdens machinale preservatie, een voorspellende 
waarde hebben voor klinische uitkomstmaten na transplantatie van nieren afkomstig van 
overleden donoren. Van 306 donornieren die waren geïncludeerd in de Machine Preservation 
Trial onderzochten we of de concentraties in het perfusaat onafhankelijk geassocieerd waren 
met delayed graft function, primary non-function en de transplantaatoverleving. Drie 
biomarkers bleken onafhankelijke, maar zwakke, voorspellers van delayed graft function, 
maar niet van primary non-function en de transplantaatoverleving. De andere drie biomarkers 
hadden geen onafhankelijke voorspellende waarde voor de uitkomstmaten van deze studie. 
We concludeerden dat, hoewel verhoogde perfusaat-concentraties van sommige biomarkers 
tijdens machinale preservatie een indicatie kunnen zijn tot het aanpassen van het vroege 
klinische beleid voor de ontvanger, dergelijke biomarkers nooit mogen worden betrokken bij 
beslissingen over het al dan niet accepteren van een donornier.
Hoofdstuk 11 geeft de bevindingen weer van een tweede analyse waarbij de 
voorspellende waarde van metingen tijdens orgaanpreservatie werd bestudeerd. In deze 
studie onderzochten we de prognostische waarde van de renale vasculaire weerstand 
tijdens machineperfusie voor delayed graft function, primary non-function en de 
transplantaatoverleving bij nieren afkomstig van overleden donoren. Deze sub-studie van de 
Machine Preservation Trial liet zien dat nieren die primary non-function vertonen vasculaire 
weerstanden tijdens machineperfusie hebben die vergelijkbaar zijn met zowel nieren die 
delayed graft function ontwikkelen als nieren die direct functioneren na transplantatie. 
De renale vasculaire weerstand aan het einde van de machinale preservatie bleek een 
onafhankelijke voorspeller voor het ontwikkelen van delayed graft function. De optimale 
drempelwaarde van de vasculaire weerstand voor het voorspellen van delayed graft function 
had weliswaar een hoge negatief voorspellende waarde, maar een slecht onderscheidend 
vermogen. Deze studie toonde aan dat het meten van de renale vasculaire weerstand 
tijdens machinale preservatie een waardevol extra instument kan zijn om aspecten van het 
transplantatieresultaat te voorspellen, maar dat dergelijke weerstandsmetingen op zichzelf 
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